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Abstracts
Macrophages are proposed to play a central role in Maedi-visna virus (MVV)
infection as target cells. However, the level of MVV load in alveolar macrophages
(AMs) and its correlation with pulmonary lesions is unknown. Also it is not yet clear
whether cytokine expression is dysregulated in macrophages infected with MVV. In
addition, the effects of exogenous cytokines on MVV replication in macrophages
have not been documented. The aims of this study were to determine 1. the level of
MVV DNA in AMs compared with blood monocytes in natural infection and assess
the correlation of viral burden and replicative status to the lung lesions related to
MVV infection; 2. the differential expression of cytokine genes in macrophages
infected with MVV in vivo and in vitw, 3. the effect of GM-CSF, TGF-(3 and IFN-y
on MVV replication in macrophage in vitro
Quantitative competitive-PCR for MVV pol was developed to quantify accurately the
level of MVV DNA load in alveolar macrophages (AMs). This first required
constructing a competitive template which bears the same recognition site as target
template to be quantified, but truncated by a 25 bp sequence. The quantitative
evaluation of the PCR signal clearly shows that the overall levels of MVV DNA load
in AMs was significant higher than that in blood monocytes (P<0.05). Changes of
viral load in AMs differed in relation to the histopathological lesions in the lungs.
Relatively high viral load was found in AMs from the lung with histopathological
lesions. Furthermore, MVV replication did not occur in AMs isolated from sheep
without histopathological lesions in the lung, but could stimulated in vitro, suggesting
that the levels of MVV DNA load reflects the pathological manifestation in the site of
disease. In addition, MVV replication in AMs in vivo may require the availability of
certain factors to activate viral replication and these may be important in disease
progression. Such factors could be cytokines produced by macrophages present or
recruited in the site of disease.
Determination of cytokine expression in response to MVV infection in vivo and in
vitro show a significant increase in the expression of IL-6, IL-10, GM-CSF and TGF-
(3 mRNA in AMs isolated from sheep naturally infected with MVV. The level of GM-
CSF mRNA was found to be much higher in AMs isolated from sheep with lung
lesion when compared with those without lung lesions (P<0.05), but the levels of IL-
10 and IL-6 mRNA expression in AMs had no association with histopathological
findings in the lung. TNF-a and TGF-j3 mRNA level were not altered significantly in
AMs. Blood monocytes showed a similar pattern of cytokine transcripts to AMs. In
lymph nodes, the levels of IL-10, IL-2, and IL-6 mRNA were found to be higher than
those in seronegative controls, whereas the levels of GM-SCF mRNA werenot
significantly altered.IFN-y mRNA was undetectable in both groups. Interestingly, IL-
10 mRNA expression in monocyte-derived macrophages (MDMs) was altered in
response to MVV infection in vitro. This result raised a possibility that direct
infection of MDMs with MVV may be not sufficient to stimulate detectable levels of
IL-10 mRNA in these cells. In analysing heterogeneity of cytokine function in MVV
infection increased expression of IL-6 was detected in MDMs exposed to GM-CSF
but not to MVV, suggesting that interaction of MVV with the target cells is not
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essential for the expression of IL-6. In determining the effects of GM-CSF, TGF-P
and IFN-y on the replication of MVV in MDMs, the enhancing effect of GM-CSF
and inhibitory effects of TGF-P on MVV replication in MDMs was observed whereas
IFN-y was unable to demonstrate any apparent enhanced or inhibitory effects of IFN-
y on MVV replication in MDMs. Cytokines modulation of surface antigens
expression on macrophages was also investigated IFN-y had an enhanced effect on
the expression of MHC class I and II on MDMs whereas GM-CSF was showed to
have an enhanced effects on MHC class I but not on MHC class II. Both cytokines
did no significantly increased the expression of CD 14, CD45 and CD 11c, and had no
influence on the expression of CDlb and CDllb on MDMs and MVV-infected
MDMs.
These results may have important implications in understanding of regulation of
MVV in macrophages as target cell for MVV and the balance between stimulatory
and inhibitory cytokines that may play a critical role in controlling MVV replication
and expression and subsequently in the clinical progression of MVV infection.
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Maedi-Visna virus (MVV) is the prototype virus of the retroviral subfamily
Lentivirnae, the members of which include the human, simian, bovine and feline
immunodeficiency virus, caprine arthritis encephalitis virus (CAEV), and equine
infectious anaemia virus (EIVA) and cause a chronic multiorgan disease
characterised by long incubation periods and slowly progressive clinical course.
MVV is widespread in sheep populations. Like other lentiviruses, MVV infects
monocytes/macrophages and causes persistent infection. However, unlike the human
and simian immunodeficiency viruses (HIV and SIV), MVV does not cause immune
deficiency but instead causes chronic mononuclear inflammation of various tissues
(Gendelman et al. 1989, Brodie et al. 1995). The progressive interstitial pneumonia
is the most obvious manifestation of MVV-induced inflammation. The infected
sheep also frequently have indurative mastitis and non-suppurative arthritis and
more rarely wasting and paralysis caused by viral meningo-encephalitis (Sigurdsson
1954, Gudadottir 1974, Cutlip et al. 1977, De Boer et al. 1979, Haase 1986, Narayan
et al. 1988, 1989, Houwers 1989, Simard et al. 1990a, 1990b, Brodie et al. 1992,
1993, 1994, 1995, Kwang et al. 1993). The lesions caused by MVV are characterised
by chronic active inflammatory changes with mononuclear cell infiltration and
proliferation (Lairmore et al. 1986, 1988a, Watt et al. 1994). However, the precise
mechanisms by which MVV causes damage remain to be determined.
1.1.2: Structure of MVV
MVV is an enveloped virus, with an RNA genome, and exhibits typical retrovirus
morphology (Harter 1976). The mature virion has a diameter of approximately 100
nm with a cone-shaped core composed of the viral gag protein p25. Inside this
nucleoid contains a positive sense single-stranded RNA (ssRNA) (Brahic et al.
1977) with which the viral RNA-dependent DNA polymerase (POL, also called a
reverse transcriptase) and nucleoprotein (pi4) are closely associated (Lin & Thormar
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1970). The inner portion of viral membrane is surrounded by gag protein pl6 that
provides the matrix (MA) for the viral structure and is vital for the integrity of the
virions. It has been demonstrated in HIV that MA is required for incorporation of the
Env proteins into mature virions. The viral surface is surrounded by a host-cell-
derived envelope from which project viral glycoprotein spikes composed of gpl35
and gp41 (transmembrane protein, TM). Parts of the central and NH2-terminal
portions of gp41 are expressed on the outside of the virions and the central region of
gp41 binds to the external viral gpl35 in a noncovalent manner. The virion gpl35
located on the viral surface contains the binding site for the cellular receptor (s) and
the major neutralizing domains.
Figure 1.1 A MVV virion with the structural and other proteins identified.
gpl35: envelope surface protein, gp41: envelope transmembrane glycoprotein, p 16:
matrix protein, p25:capsid structural protein
1.1.3: Molecular biology of MVV
The genomes of MVV, like other lentiviruses, are positive-stranded RNA molecules
that is approximately 9.2 kilobases and exists within the virion as a dimer with two
identical RNA molecules (Sonigo et al. 1985, Brawn et al. 1987, Querat et al. 1990,
Sargan et al. 1991, Staskus et al. 1991). The genome of the virus contains the






However, in addition to these genes, MVV genomes encode regulatory genes which
are not found in other non-lentiviruese retroviruses (Carey and Dalziel 1993).
The RNA genomes of MVV contain repeated regions (R) at the 5' and 3' ends and
unique 5' and 3' (U5 and U3) that are important in the process of reverse transcri¬
ption of the genomic RNA into DNA. These regions form the long terminal repeats
(LTR) found in all other retroviruses. The U3 region of LTR contains the
transcription control elements (enhancer and promotor elements) that control the
transcriptional activity (Carruth et al. 1994). The enhancer elements are recognised
by cellular transcription factors that activate basal transcription of viral RNA. The
viral RNA transcripts initiate transcription at the cap site (+1) in the 5' LTR and
terminate in the 3' LTR at the polyadenylation signal. A particular lentivirus uses a
specific cellular transcription factor due to its cellular tropism. Thus, SIV uses NF-
(B, a transcription factor present in activated T cell and macrophages (Carruth et al.
1994, Toohey et al. 1994). In contrast, MVV uses the transcription factor c-Jun and
c-Fos present in macrophages. These factors were found to bind to an AP-1 site in
the MVV LTR (Shih et al. 1992). Recently, a transcription factor related to the
AML/PEBP2/CBF superfamily was found to bind to AML (vis) site in LTR of MVV
EV1 which lack AP-1 site in LTR (Sutton et al. 1997). In addition to the identified
transcription factors, it assumed that there are sites for additional cellular factors in
the U3 region of all lentiviruses. These factors may play an important role in the
virus life cycle by providing the virus with the capacity to be activated at the
transcriptional level in different cellular environments.
1.1.3.1: Structural genes of MVV
The viral gag, env and pol, which lie in the usual order flanked by LTR, encode
proteins required for production of infectious virus particles. The gag (group-specific
antigen) gene encodes a 55 kD non-glycosylated precursor core polypeptide (p55)
which is cleaved after translation to form nucleocapsid p25, pi6 and p 14
(nucleoprotein). The principal gag product p25 noncovalently associates with the
viral genome to form a nucleoid shell (Vigne et al. 1982, Petursson 1990). pol
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encodes enzymatic proteins reverse transcriptase (RT), protease and integrase. There
is a 150 kDa (Prl50) precursor detectable in infected cells (Vigne et al. 1982) which
is believed to be a gag and a pol polyprotein precursor. In common with other
lentiviruses, only the env gene (the envelope gene) of MVV encodes the major
envelope glycoprotein gpl35 (the external envelope glycoprotein) and gp41
(transmembrane protein). Gpl35 is involved in the recognition and binding to the
target cell receptors. It has been identified as an antigenic target during immune
responses to MVV infection and is probably the major viral antigen, which induces
neutralising antibody in infected sheep (Scott et al. 1979). By analogy with HIV,
gp41 appears to be a major serological marker for MVV infection (Kwang et al.
1992) and is involved in membrane fusion. Gpl35 is noncovalently bound to gp41
and can be shed from the surface of virion.
1.1.3.2: Accessory genes of MVV
In addition to three structural genes, a number of regulatory genes (tat, rev and vif)
are present in MVV genomes, which encode regulatory proteins. Although these
regulatory genes have been known to have an important role in the virus life cycle,
the precise roles of these genes remain ill defined. The tat of lentiviruses functions to
activate viral gene expression at both the transcriptional and post-transcriptional
level (Levy 1992). The tat gene encodes a 10 kD protein. In HIV RNAs (as in SIV,
EIAV), the tat (trans-activator of transcription) protein enhances HIV genes
expression by interacting with cellular factors and binding to a stem-loop structure
called tat-activating region (TAR) located at 3 end of viral mRNA (Clements et al.
of 1992). Tat may activate viral gene expression by stabilising mRNA transcripts
and increasing the elongation of RNA (Oliver et al. 1981, Sharma et al. 1992). In
contrast, MVV (as in CAEV) lacks a TAR element, thus the tat protein of MVV acts
in a more indirect fashion (Carruth et al. 1994). MVV Tat protein was reported to be
a transcriptional activator which does not bind directly to viral DNA or RNA. This
behaviour is similar to the transactivator proteins in herpes simplex (VP 16) and
adenovirus (Ela) which interact with cellular factors to activate viral transcription
(Smith et al. 1990, Horikoshi et al. 1991, Ingles et al. 1991, Roberts et al. 1993).
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MVV Tat protein increases viral expression by interacting with the Ap-1 or AML
(vis) sites in LTR, probably by interacting with cellular Jun and Fos proteins
(Gdovin et al. 1992) or AML-1 (Sutton et al. 1997). The rev (regulator of expression
of virion) gene encodes a protein (19 kD) (Mazarin et al. 1990) translated from
multiply-spliced RNA (Sodroski et al. 1986). MVV Rev protein localises in the
nucleolus of infected cells (Schoborg et al. 1994). The functional significance of
Rev protein nucleolar localisation is still unclear. It is possible that the nucleolar
localisation is related to association of Rev with cellular RNA and proteins and the
normal trafficking pattern of those cellular components. The Rev protein functions
to facilitate the export of unspliced viral mRNA from the nucleus and association of
these viral RNAs with polyribosomes (Arrigo et al. 1991). The rev protein binds to
viral RNA in the nulecus through a highly structured RNA element (the Rev-
responsive elements or RRE) located within the env gene (Arrigo et al. 1991) and
facilitates the cytoplasmic accumulation of unspliced and partially spliced viral RNA
(Malim et al. 1989). MVV Rev was found to be present in nucleolus regardless of
whether viral RNA is present in the cells (Schoborg et al. 1994), indicating that the
nucleolar localisation is independent of binding to the RRE in the viral RNA.
Consequently, Rev is required for the expression of unspliced viral RNA that
encodes viral structural protein and indirectly downregulates its own expression, as
well as that of tat. The role of the gene products of other MVV accessory genes in
viral replication remains to be understood. The nef (negative factor) gene is present
in all primate lentiviruses. The mechanism of action of the nef protein has not been
completely defined. It has been shown that the nef protein is not essential for viral
replication in cell culture (Hammers et al. 1989). However, SIV nef protein is
required for in vivo efficient virus replication (Kestler et al. 1991). It has been
reported that the expression of HIV nef protein results in reduction of CD4
expression on the cell surface (Aiken et al. 1994). The nef protein may, therefore, be
associated with membrane structure and may function to downregulate surface
expression of CD4 on infected cells, facilitating the Env protein expression without
interaction with CD4. It is curious that MVV, like other strictly
monocyte/macrophages tropic lentiviruses, lacks a nef gene. It is possible that
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alternative gene products act as an analogue to the nef protein due to different usage
of receptors. The vif (viral infectivity factor) gene encodes a late gene product. Vif
appears to be essential for the infectivity and spread of HIV in infected cells (von
Schwedler et al. 1993). The function of the vif protein in MVV infection is not
completely understood. As the precise role of these accessory genes in virus life
cycle are better defined, insights will be gained into the MVV replication process, in
particular, the interaction with cellular factors.
1.1.3.3: MVV life cycle
The genomes of MVV are single-stranded, positive-sense RNA. The virus
replication is similar to that of other lentiviruses, which involves requirement of RT
enzymatic action and reverse transcription of the viral RNA to produce double-
stranded DNA provirus. Once reverse transcription occurs, viral DNA can be found
in the nucleus. The viral genomes are present for the lifetime of cells. Because
lentiviruses use the normal mechanism of cellular protein synthesis for expression, it
seems likely that, in addition to the viral regulatory proteins already described, the
internal and external cellular environments can have influence on virus expression.
MVV infection is initiated by binding of viral envelope to a cellular receptor. MHC
class II molecule has been identified as a potential cellular receptor for MVV
(Dalziel et al. 1991). There may be other cell surface molecules involved in virus
binding and entry, however, because some cells such as B cells and activated T cells
that do express MHC class II do not confer susceptibility to MVV. In addition, cells
that do not detectably express MHC class II can be infected by MVV in vitro
(Leroux et al. 1995). Antibodies to an unidentified 50 kD protein from sheep
choroid plexus cells can block binding of MVV to these cells in culture (Crane et al.
1991). Thus alternative routes of MVV entry besides MHC class II molecule may be
involved. Once inside the cell, a linear dsDNA copy of the viral genome is produced
by virion-associated RT. Early studies on replication of MVV in vitro had shown
that MVV replicates productively without evidence of integration (Harris et al.
1984). But subsequent molecular cloning of the integrated viral DNA provided
6
definitive evidence that integration is an obligatory step in the MVV life cycle (List
and Haase 1997).
MVV is able to replicate in non-dividing terminally differentiated cells, like other
lentiviruses. This implies that cellular DNA replication may be not required for
integration of the viral DNA into cellular genome, unlike other classes of
retroviruses. It is still an open question whether this may require specific functions,
supplied by the viral accessory genes, to permit translocation of the preintegration
complex and integration into nonreplicating genomic DNA.
1.1,3.4 Restricted replication
MVV infects mainly monocyte/macrophage lineage cells (described in 1.1.4). Unlike
HIV, which replicates to high titres in lymphoid tissues during the early phase of
infection, MVV replicates at a low rate for an indefinite period, and is rarely present
in a cell-free state in tissue during sub-clinical infection (Narayan et al. 1982). This
type of infection with an apparent incomplete virus life cycle continues for years. A
few of these infected sheep eventually develop chronic progressive disease, affecting
specific tissues. In such animals, cell-free virus can usually be recovered from this
affected tissue, however, an incomplete virus life cycle remains operative in
macrophages from other parts of the body (Narayan et al. 1982). Therefore,
expression of the viral RNA and viral proteins in vivo is restricted to a minimal rate
except under certain conditions such as activation of an infected target cell when
replication of virus is stimulated.
Early reports have shown that peripheral blood mononuclear cells (PBMCs) from
persistently infected sheep contain incompletely expressed viral genomes. But in
contrast to the in vivo situation, virus production was observed when these cells were
cultured in vitro which promotes the maturation of monocytes into macrophages
(Narayan et al. 1982, Gendelmam et al. 1989). The molecular mechanisms
regulating this restricted replication and gene expression in vivo and release from the
restrictions in vitro are poorly understood although it seem likely that interaction of
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cellular factor with viral LTR may be involved in the regulation. A recent study
reported that the unexpressed viral genomes were also found in maturing
macrophages (Chebloune et al. 1996). The finding of unexpressed viral genome in
MVV infected macrophages is closely consistent with the observation in HIV
infected subjects who failed to develop evidence of virus replication months after
viral DNA had been detected in PBMC by PCR (Horsburgh et al. 1989). The
findings may in part explain why the actual level of detectable virus antigen is very
low in MVV-infected lung (Gendelman et al. 1985, Lujan et al. 1994). Thus MVV
replication either proceeded to completion, subject to the maturation of monocytes to
macrophages or remained arrested at the DNA stage despite the maturation of
monocytes to macrophages. Although the molecular events controlling restricted
virus replication remains to be determined, it seems likely that, in addition to virus-
defined restriction on MVV replication (described in 1.2.4), there is also cell-
specific restriction. The cellular factors such as MVV-induced cytokines (described
later in this chapter) may play an important role in restricting viral replication in vivo
and in relieving this restriction on the viral replication in vitro or when a persistently
infected cell is activated, possibly through interaction of certain cellular factors with
the virus LTR.
1.1.4: Pathology of MVV infection
MVV infection in sheep causes a wide spectrum of lymphoproliferative and
inflammatory lesions. Respiratory disease (Maedi) including lymphoid interstitial
pneumonia (LIP) and pulmonary lymphoid hyperplasia (Narayan et al. 1985,
Lairmore et al. 1986, Brodie et al. 1993, Watt et al. 1994), nervous system disease
and wasting (Visna) including lymphocytic encephalomyelitis (Narayan et al. 1985,
Nathanson et al. 1985, Georgsson et al. 1989, Watt et al. 1994). lymphocytic
indurative mastitis (Anderson et al. 1985) and non-suppurative lymphocytic
polyarthritis (Narayan et al. 1985) were reported to be infectious sequelae.Maedi is a
classic interstitial pneumonia. Grossly, affected lungs show extensive consolidation
and do not collapse when the thoracic cavity is opened. The lungs may be enlarged
in size 2 to 4 times heavier than normal with decreased elasticity (Sigurdsson et al.
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1954). Histologically, lesions consist of widespread infiltration of mononuclear cells
into the interstitial spaces of the lung and around bronchi. The infiltration of
lymphocytes, monocytes and the formation of lymphoid nodules with germinal
centres in the alveolar parenchyma and around blood vessels and airways leads to a
thickening of alveolar septa (Georgsson & Palsson 1971). The lung of most infected
sheep shows widespread hyperplasia of smooth muscle (Watt et al. 1992). The
regional lymph nodes draining the lung become enlarged consistently with very
prominent cortices (Watt et al. 1994). Macrophages are activated and expressed
MHC class II. Diffuse proliferation of mesenchymal cells including smooth muscle
fibres, accompanies the inflammatory process (Lujan et al. 1994). Lymph nodes
draining the lung undergo massive hyperlasia.
MVV infection of CNS (visna) induces demyelination and destruction of white
matter in the cerebellum and spinal cord (Sigurdsson et al. 1957). Histologically,
visna is characterised by chronic-active meningoencephalomyelitis and choroiditis
with massive infiltrations of mononuclear cells (mainly lymphocytes with some
plasma cells and macrophages) around blood vessels in the neuropil, development of
microgial nodules in which macrophages are activated and expressed MHC class II,
and generalised astrogliosis (Watt et al. 1994). There is perivascular cuffing,
neuronal necrosis, malacia, and demyelination scattered patchily throughout the CNS
(Wzttetal. 1994).
In the mammary gland, infection induces chronic indurative mastitis (Van der Molen
et al. 1985) which is characterised by marked lymphoid hyperplasia and fibrosis as
observed in the affected lung. Non-suppurative lymphocytic polyarthritis/synovitis
has been observed in most MVV infected sheep (Oliver et al. 1981) with swelling
and calcification of soft tissue, fibrosis of the joint capsule and synovium and
perivascular lymphocytic infiltration which is similar to CAEV induced arthritis in
the goat (Wilkerson et al. 1995).
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1.1.5: Immunopathology of MVV infection
There is now evidence suggesting that an important event in the initial establishment
of lentivirus infection is localisation of the viruses in lymphoid organs that serve as
major reservoir and as primary sites for infection (Bird et al. 1993, Pantaleo et al.
1993). Bird et al. (1993) performed lymphatic cannulation on sheep to monitor virus
at different-time points after infection. Detection of MVV in lymph nodes was
observed as early as day 9. At this time, numerous individual cells expressing MVV
were detected in efferent lymph, which is consistent with the study of Pantaleo et al.
(1993) showing SIV replication was observed in lymph node biopsies as early as day
7 post-infection. These results demonstrate that MVV, SIV and likely HIV, localise
very early in lymphoid organs and support the concept that lymphoid tissues may
represent a primary sites for the initial establishment of infection and be important in
determining viral persistence. However, it dose not exclude the possibility that other
anatomical sites may be of importance in pathogenesis. Although sheep mount an
anti-viral immune response, viral replication and dissemination occur (Bird et al.
1993). Therefore, the immune response during MVV infection is more complex and
more ambiguous. As has been demonstrated in HIV, the ability of MVV to replicate
depends in part upon the state of the target cells. Different types of effector cells
become activated during the generation of a specific immune response. This process
of activation may have a stimulating effect on MVV infection by way of generation
of activated target cells for MVV replication and production of cytokines which may
exert stimulating effects on MVV infection such as induction of viral expression or
modulation of certain viral component synthesis in infected cells (Poli et al. 1992a,
Del Prete et al. 1993, Ellis et al. 1994).
The interaction of MVV with the immune system may contribute to the propagation
of MVV infection and the appearance of certain immunopathological lesions during
the course of MVV infection. Induction of cytokine expression in the site of disease
in particular merits consideration but the precise roles of MVV and immune effector
cells which induce chronic inflammation remain to be determined. Interaction of T
cells with infected macrophages has been shown to result in the production of certain
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cytokines with interferon-like activity (Lairmore et al. 1988a). This interferon-like
molecule was discovered in cell culture, but has also been seen in synovial fluid of
arthritis in CAEV-infected goats (Kennedy-Stoskopf et al. 1989) and in culture
supematants of lymphocytes from the lung of MVV-infected sheep (Lairmore et al.
1988a). It is not known whether the release of this cytokine had a role in the
pathogenesis of the lesions. However, secretion of the cytokine may explain the
activation of macrophages as well as the occurrence of free virus in the affected
sites. Lymphocytes from these lesions failed to produce virus, whereas macrophages
cultured from the affected tissues was able to produce cell-free virus. Thus,
productive virus replication in local tissue macrophages contributed to lesions in
vivo, pneumonia being associated with virus production in alveolar macrophages and
encephalitis lesions associated with vims production in microglia.
The presence of high level of antibodies to viral glycoprotein at the sites is another
feature of the lentiviruses infection-related lesions. A large number of plasma cells
were observed in progressive pneumonia (Kennedy et al. 1985) and the antibody to
viral glycoprotein was found in CAEV related lesions (Johnson et al. 1983). Studies
by Nathanson et al. (1981) and McGuire et al. (1986) extended these observations,
showing that immunisation of infected sheep and goats with the viral antigens led to
an increased severity of lesions. These studies suggest that immunoglobins could be
produced locally at these sites and play a critical role in the pathogenesis of the
lesions. Taken together, the immunopathological characteristic of MVV-induced
local tissue lesions is productive virus replication in macrophages, activated
macrophages, release of cytokines and high level of anti-viral antibodies. All of
these factors are also observed in HIV-induced lesions.
1.1.6: Identification of MVV infection
Infection after exposure to MVV is not inevitable. Following viral entry, there is an
initial period of virus replication during which antibody is undetectable, i.e.
detection of antibodies specific for a variety of MVV proteins. In addition, in a small
minority of animals, the seronegative phase may persist for months. Therefore the
identification of virological, immunological and clinical events at this stage of
infection are difficult and their diagnosis relies upon the detection of viral genome.
1.1.6.1: Detection of antibody
Antibody can be detected by a number of methods including the Agar gel immuno¬
diffusion (AGID) test, ELISA and Western Blot. The AGED test for detection of
group-specific antibody to MVV first described by Cutlip et al. (1977) has been used
widely. It is based on the availability of a semi-purified soluble antigen prepared
from MVV infected cells and a positive control serum produced by hyper-
immunisation of sheep. Although the AGID test is simple to perform and rapid, it is
not highly sensitive and quantitative (Houwers et al. 1989, Zanoni et al. 1989,
Torfason et al. 1992). This lack of sensitivity is a consequence of poorly defined
viral antigens and reagents that contains cellular proteins from the tissue culture in
conjunction with the inherent insensitivity of the AGID test compared with that of
other serological tests. Generally, MVV antibodies as measured by the AGED test
appear at the third week after infection when inoculated by the intratrachael route
(Simard et al. 1990). The AGID test may not be adequent to monitor samples for an
eradication scheme.
Several ELISA assays have been evaluated as alternatives to the AGID. Initially
indirect (I) ELISA with higher sensitivity, but modest specificity due to the use of
semi-purified antigen prepared from the infected cells was described (Houwers et al.
1982). In order to reduce the amount of cellular proteins interfering with the test and
to increase the specificity of I-ELISA, Vitu et al. (1982) used sucrose density
purified the viral antigen to obtain good discrimination between the positive and
negative serum samples. Later, Simard et al. (1990a, 1990b) applied an anionic
detergent SDS for preparation of MVV antigen to obtain an ELISA with a specificity
of at least 98.8 % and an increased relative sensitivity of 15.5% compared to the
AGED test and with an average ability to detect MVV antibodies 2-6 weeks prior to
the AGID test. In 1987, Houwers et al. (1987) described a complex trapping
blocking ELISA (CIB-ELISA) in which two monoclonal antibodies with different
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epitopes specificity were involved in a modified double antibody sandwich blocking
procedure. CIB-ELISA was found to be more sensitive than I-ELISA and AGID for
detecting anti-bodies to MVV. Unlike the AGID test, CIB-ELISA was highly
specific and resulted in low false reaction due to two epitopes instead of one, and
resulted in a widening of the antigenic window.
Recently, recombinant gene expression products have been used and well
documented in anti-viral antibody detection. Zanoni et al. (1991) reported that deve¬
lopment and application of gag-derived recombinant antigen in I-ELISA for the
detection of antibodies to ovine and caprine lentiviruses. It was found that the
recombinant antigen was superior to antigen prepared from the whole virus antigen.
A similar recombinant ELISA was also described by Kwang et al. (1992) who
developed and used a recombinant protein corresponding to the NH2-terminal
hydrophilic region of gp41 of MVV in I-ELISA. It was shown that a single
recombinant gp41 can be used successfully for the generation of specific ELISA for
the detection of most MVV infected animals, which suggested that like HIV, gp41
appeared to be a major serological marker for MVV infection. The oligopetides-
based ELISA where the synthesised oligopetides represent regions encoded by the
portion of the env gene proved it further. However, a single recombinant protein in
ELISA may cause a false negative due to an individual sheep lacking antibody to
that antigen of MVV. Therefore to compensate for the loss of antibody reactivity
with one gene derived protein during the course of infection or early stages of
infection, as seen often in HIV infection, so the use of more than one recombinant
proteins in ELISA may be necessary for the detection of all potentially infected
animals. Western blot allows the detection of antibody to specific viral proteins and
it therefore is widely used to analyse the antibody response to MVV infection
(Houwers et al. 1989, Zanoni et al. 1989, Torfason et al. 1992). In MVV infection,
Western blot demonstrated that, generally, antibodies against Gag proteins and the
major env glycoprotein appeared early while the response to gp41 appeared later.
However, these were found in specimens with no antibodies to gpl35 (Houwers et
al. 1989). The possible reason for this is that the Western blot is less sensitive in
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detecting glycosylated proteins. This has been also found in HIV (Saah et al. 1987).
Due to loss of polysaccharides during preparation, this has led to some early
difficulties in the diagnosis of MVV infection, so further refinement of MVV
Western blot assay may solve this problem (Torfason et al. 1992). The results of
Western blotting showed the persistence and predominance of p25 antibodies in
serum of infected sheep, which were strongly supported by the p25 specific ELISA
(Houwers and Schaake 1987). The analysis of antibody recognition patterns in sheep
with or without lesions demonstrated a reduction in antibody during advanced stages
of clinical disease (Torfason et al. 1992). The cause of this declining antibody
activity remains to be elucidated. One possible explanation of this phenomenon is
that at the advanced stage of disease the animal had high titres of cell-free virus and
that causes the formation of antibody-viral antigen complexes.
As noted above, the use of recombinant antigens has produced assays of greater
specificity. However, it is clear that the assay with narrow specificity may give a
false negative result. The ELISA employing recombinant gp41 failed to identify
sheep at an early stage of infection although increased specificity was produced
compared with the AGID test (Kwang 1994). Consequently it is necessary to use
more than one recombinant protein antigens in ELISA and Western blot to detect all
the potentially infected sheep. Furthermore, at the early stage of infection, immune
responses to virus may either be absent or too weak to be detected. Thus it is for this
reason that inconlusive sera must be further investigated carefully.
1.1.6.2: MVV antigen detection
ELISA is presently the predominant antigen assay for MVV used for clinical
investigation (Marcom et al. 1992, Brodie et al. 1995). The MVV p25, which occurs
in relatively high abundance in virions and infected cells (Reyburn et al. 1992), is
generally the target of this assay. By using this assay, as little as 3.2ng of viral p25
antigen per ml can be detected (Marcome/ al. 1992). Immunohistochemical assay is
also useful as a means of detecting MVV antigens in tissue section or cells. By use
of this method, MVV antigens could be detected in cells morphologically and
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histochemically compatible with cells of macrophage lineage which are usually
located within or adjacent to areas of lymphocyte aggregation or lymphoid
proliferation in brain, cervical spinal, cord, distal trachea, lung, mammary gland,
spleen, synovium and node associated with drainage of such tissue (Brodie et al.
1995).
1.1.6.3: MVV nucleic acid detection method: Polymerase Chain Reaction (PCR)
The diagnosis of the MVV infection has routinely relied on demonstrating the
presence of MVV antibody (Houwers et al. 1982, 1989, Simard et al. 1990, Zanoni
et al. 1989, 1991a, Kwang et al. 1992, Torfeson et al. 1992). However, these
antibody assays do not detect virus during the period between infection and
seroconversion and do not give a quantitative measurement of virus load in infected
hosts. They are therefore not useful to study the initial events following viral
infection, the relationship between virus load and pathogenesis and the dynamics of
viral infection.
Recently, the PCR has been used extensively in the study of MVV, especially in
rapid diagnosis and pathogenesis (Haase et al. 1990, Zanino et al. 1991, 1992,
Johnson et al. 1992, Reyburn et al. 1992, Ding and Xiang 1994, Woodall et
al. 1994a). The PCR can amplify genetic material from a single cell or tissue samples
by approximately 106 fold in a matter of hours and it is more rapid, sensitive and
less labour intensive than the nucleic acid hybridisation and virus isolation for
detection and identification of MVV. Because of this extreme sensitivity, the PCR is
able to detect the MVV at the time of the early infection "Diagnostic Window" or
during periods of viral latency (Johnson et al. 1992). This concept is further
supported by a recent study that the presence of MVV DNA was detected in PBMC
from infected sheep but neither viral particle nor protein could be detected in some
of these cells (Chebloune et al. 1996) although the significance of PCR positive in
seronegative individuals remains to be further elucidated.
In PCR assays, it is important and necessary that the methods used to isolate nucleic
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acid be as simple and efficient as possible. PBMCs are the cells most often used for
PCR detection of MVV. Sometimes, the cells are treated with stimulators of RNA
expression to decrease false negative in PCR. For example, low viral burden in cells
is main cause of failure for detection of HIV by PCR (Zazzi et al. 1995).
PCR for MVV is performed mainly on cDNA (RT-PCR). Compared to HIV, there
are fewer PCR primer sets published for MVV. Zanoni et al. (1992) used a set of
three primer pairs derived from MVV gag, LTR and pol genes for the amplification
of the corresponding sequences of six virus isolates. Only with LTR derived primers,
could the corresponding sequences for all strains be detected. These primer
sequences differ slightly simply due to inter-strain variability, which is usually not a
problem as long as the homology remains sufficiently high to allow specific
hybridisation. Currently, PCR has been used to detect MVV RNA directly in clinical
specimens (Brodie et al. 1993) and infected cell culture (Johnson et al. 1992, Zanoni
et al. 1992). Hasse et al. (1990) developed a PCR combined with in situ
hybridisation and applied it successfully for detection of MVV DNA inside
experimentally infected cells. The above report and others hold promise for rapid
detection of MVV RNA, but standardisation of PCR procedures and extensive
validation with field samples are required before routine application for diagnosis.
Quantitative competitive PCR (QC-PCR) has been developed to investigate the
absolute quantitation of viral nucleic acid in order to address fundamental virological
and molecular aspects in pathobiology of viral infection (Menzo et al. 1992, Pistello
et al. 1994, Zhu et al. 1995). QC-PCR has been shown to be a very sensitive and
reliable method of measuring the viral load in infected hosts, and in general,
detection of viral nucleic acid has become a valuable diagnostic tool. Although PCR
for detecting MVV nucleic acid was reported (Haase et al. 1990, Zanoni et al. 1992,
Reyburn et al. 1992, Johnson et al. 1992, Brodie et al. 1993, Ding and Xiang 1994),
it has been mainly limited to qualitative analysis.
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1.2: Cell biology of MVV infection
1.2.1: Cell tropism of MVV
MVV infects a restricted range of target cells in vivo, principally, monocyte/
macrophages (Narayan et al. 1990). MVV cell tropism may contribute in part to the
capacity of the virus to persist in its host. But multiorgan disease observed during
MVV infection can not be explained solely by the interaction between lentiviruses
and its target cells. Other cells have been directly or indirectly shown to be infected.
Cell studies have shown that the content of infection varies and can depend on the
particular virus strain used. Generally, highly cytopathic stain replicates to a higher
titre (Marcom et al. 1992).
Monocyte/macrophages are the principal cells for MVV infection in vitro and in
vivo. In vitro, MVV can be grown productively and induces a cytopathic effect with
the formation of syncytia in monocytes/macrophages. In vivo, the MVV-infected
monocytes/macrophages are found in peripheral blood, spleen, lung, brain, spinal
cord, lymphoid node, mammary gland, bone narrow, synovium (Narayan et al. 1982,
1985, Gendelman et al. 1985, 1986, Gorrel et al. 1992, Brodie et al. 1995). In certain
tissues, notably lung and lymphoid node, the detection of viral proteins or infectious
virus in infected target cells is associated with lymphocyte infiltration (Brodie et al.
1995). Although MVV RNA was detected in a variety of target and non-target
tissues and in several morphologically distinct cells types including monocytes,
macrophages, epithelial cells and in tissues with and without MVV-associated
lesions, only in cells of the macrophage lineage can the MVV capsid proteins be
detected, usually in inflamed tissues or only in target tissues (Brodie et al. 1995). In
infected animals, MVV infection of mononuclear phagocytes occurs predominantly
in terminally differentiated macrophage in tissues such as the lungs and brain.
Alveolar macrophages (AM) bearing MVV capsid protein has been found at the
periphery of such lesions (Brodie et al. 1995), estimates of the proportion of infected
alveolar macrophages range from less than 1% to 12% (Lujan et al. 1994) as
measured by immunohistochemistry. In brain, resident macrophages have been
showed the presence of MVV (Georgsson et al. 1989). Although productive
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infection is found in macrophages, macrophages in some tissues such as Kupffer
cells in liver are not infected with MVV (Brodie et al. 1995). This selectivity of
different macrophage populations for preferentially high level of virus replication
forms the basis of localisation of histological lesions in tissues. It is unclear what
factor or factors allow productive infection of some macrophages but not others
although it may be explained in part by a lack of receptors for the virus because
MVV infection is dependent on virus binding to specific receptors (Gendelman et al.
1986, Kennedy-Stoskopf 1989). Such factors potentially play a critical role on the
tissue distribution of lentivirus and thus potentially in its clinical manifestation.
MVV-infected macrophage precursor cells are present in bone marrow of MVV
infected animals (Gendelman et al. 1985). As macrophages are terminally differen¬
tiated cells with relatively a short life-span, it is likely that these macrophage
precursor cells (long life-span) in bone marrow where infection becomes established
early after infection, act as a viral reservoir for dissemination of MVV.
MVV infects monocytes but viral replication is highly restricted in these cells
(Narayan et al. 1982, Brahic et al. 1981). It is clearly known that susceptibility of
cells to infection as well as the magnitude and rate of viral RNA transcription and
protein synthesis is closely linked to the rate of maturation of monocytes to
macrophages, i.e. the restriction of maturation of the infected cells limits the
replication of virus (Narayan et al. 1985). However, mechanism for the behaviour is
not yet clear. Macrophages play an important role in MVV disease. It has been
suggested that the replication of MVV macrophages in the lung produces a cascade
of molecular and immunological events that lead to chronic inflammatory lesions
(Narayan et al. 1989). The persistent expression of viral antigens on the surface of
these infected cells may be of considerable importance in facilitating these lesions.
In addition, MVV has been detected in vivo in oligodendrocytes, astrocytes and
replicates in vitro fibroblasts (Georgsson et al. 1989). It is unclear whether MVV
may infect and replicate in CD4+ T lymphocytes, as occurs in HIV and SIV (Levy
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1993), although it has been demonstrated that the proportion of CD4+ T
lymphocytes decrease during MVV infection in lungs (Lujan et al. 1993). Early
studies suggested MVV infection in lymphocytes within the CNS, in glial cells and
in the bronchiolar epithelial cells in the lung (Stowring et al. 1985, Georgsson et al.
1989, Staskus et al. 1991). However, these reports have not been supported by other
published data, which failed to find viral replication in lymphocytes from blood,
lymph and lung (Gorrel et al. 1992, Lujan et al. 1994). Lack of productive infection
in lymphocytes may be due to the absence of receptor for MVV.
Gorrell et al. (1992) showed that MVV has a greater tropism for dendritic cells than
monocytes, which is consistent with the previous observation that MVV infection is
greater in lymphoid organs than in liver (Narayan et al. 1985). MVV Infection of
ovine smooth muscle cells in vitro has been demonstrated recently (Leroux et al.
1995), suggesting that the infected smooth muscle cells may act as another reservoir
for virus in addition to myeloid stem cells in bone marrow. This finding probably
helps to explain the induction of pathogenic reaction like myomatosis in the lung of
MVV infected sheep (Georgsson & Palsson 1971). There is a recent report that
human cytomegalovirus stimulates p53 accumulation and that the IE84 CMV
proteins blocks the p53's inhibition of cell cycle progression (Speir et al. 1994). A
similar mechanism could occur during MVV infection. The interaction between
MVV regulatory proteins and cellular genes induces a smooth muscle cell
proliferation.
1.2.2: Phenotypic characteristic of MVV-infected monocytes/macrophages
The expression of surface molecules on monocyte/macrophages is often used as an
indicator of their functional activity. Studies of the expression of the cell surface
molecules on monocytes/macrophages infected with MVV showed the expression of
the cell surface molecules could be affected during the infection (Lujan et al. 1993,
1994, Lee et al. 1996). It had been shown that the AMs of MVV-infected sheep
showed increased expression of major histocompatibility complex (MHC) class II
(Lujan et al. 1993). The same phenomenon was also observed on macrophages from
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synovial fluid of MVV infected sheep (Harkiss et al. 1991). There is no difference in
the expression of LCA between the AMs from MVV-infected sheep and control
animals. AMs of both animals lack the expression of CD4 and CD8 (Lujan et al.
1993). However, The expression of CD4 and CD8 was seen on blood monocyte-
derived macrophages from both MVV-infected and control animals (Lee et al.
1996). Lymphocytes from bronchoalveolar lavage fluid (BALF) of MVV-infected
animals showed increased expression of LFA-1 and LFA-3 compared to that of
control animals (Lujan et al. 1993). In HIV infection, the expression of the cell
surface molecules on macrophages has been studied in more depth (Wright et al.
1988, Rossen et al. 1989, Vermot-Desroches et al. 1990, Pantaleo et al. 1991,
Fecondo et al. 1993, Berman et al. 1994a, Stent et al. 1994). The AMs from HIV-
infected individuals with lymphocytic alveolitis showed elevated MHC class II
antigens HLA-DR, -DQ and -DP expression (Agostini et al. 1993a). This increase
may account for the increase of antigen presenting capacity of AMs from HIV
infected individuals, enabling T cells to recognise alloantigens better (Twigg et al.
1989). AMs from HIV infected individuals also show high-affinity receptors for the
Fc portion of IgG (CD64), IgE (CD23) and complement (CDllb) and increased
expression of other activation markers (CDllc, CD14 and CD71) and adhesion
molecules (CD 11 a/CD 18, CD44, CD54) (Agostini et al. 1993a). A correlation
between histological evidence of AIDS encephalitis and increased expression of
VCAM-1 on parenchmal vessels was observed in the brain tissue of experimentally
infected animals with SIVmac (Sasseville et al. 1992).
The lesions caused by MVV comprise chronic active inflammatory changes with
lymphocyte infiltration and proliferation (Lairmore et al. 1986, 1988b, Watt et al.
1994). Thus alterations in the level of the expression of the surface molecules on
macrophages as a result of infection could play an important role in the pathogenesis
of the lymphoproliferative response and viral persistence. The increased expression
of the MHC class II molecule, a possible component of cellular receptor for MVV
(Dalziel et al. 1991), may favour the spread of the infection to uninfected
macrophages, allowing the virus persistence within the host. The persistent
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expression of these surface molecules may contribute to the accelerated entry and
accumulation of lymphocytes into the lung interstitium as the disease progresses,
mediating local lesion. Furthermore, activation of T lymphocytes (Watt et al. 1992)
and the increased expression of LFA-1 and LFA-3 as well as MHC class II
molecules on the T lymphocytes from MVV infected sheep (Lujan et al. 1993) was
reported. Because LFA-1 and LFA-3 is essential for leukocytes activation and
trafficking (Pardi et al. 1992), the increased expression of these molecules could
contribute to lymphoproliferative response by promoting constant lymphocyte
recruitment into the lung. However, the exact role of these surface molecules in
pathogenesis of lentiviral infection remains to be determined.
Virus regulatory mechanisms responsible for modulation of cell surface molecules of
infected monocytes/macrophages are not fully understood. It has been hypothesised
that the proportion of MVV-infected monocytes in the blood is low (McElrath et al.
1989), therefore it is unlikely that changes in the expression of cell surface
molecules are in part directly related to viral infection of the cells. Increased MHC
class II molecule was expressed on MVV-infected AMs and co-expressed with viral
protein, but, no direct relationship was observed between viral production and the
MHC class II expression (Lujan et al. 1994). Thus mechanisms responsible for
modulation of cell surface molecules on infected monocyte/macrophages may be
that the virus stimulates cells to release various cytokines and other factors which
may in turn alter surface molecule expression. The interaction of lymphocytes with
MVV-infected macrophages leads to the release of lentivirus IFN (Narayan et al.
1985) and it may be through the action of this cytokine that the expression of surface
molecules is increased. Increased expression of MHC class II molecules but
decreased CD5 expression (Lujan et al. 1993) on T lymphocytes suggest that they
are activated and may be producing cytokines which in turn alter the surface
molecule expression on macrophages. Several studies have shown that HIV, by
stimulating the production of IL-1 and TNF, leads to autocrine feedback with
production of other cytokines such as IL-6 and GM-CSF (Merrill et al. 1991, Longo
et al. 1993). In in vitro cell systems, cytokines or combination of cytokines have
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been reported to modulate expression of antigen presenting (MHC class I and class
II) and co-stimulatory molecules on the surface of monocytes and other leukocytes
(Mentzer et al. 1986, Springer et al. 1986, Freyer et al 1988, Te Velde et al. 1988,
Jiang et al. 1992, Nash et al. 1992, Gimcher et al. 1992, Schwartz 1992, Sallusto et
al. 1994, Kruger et al. 1996, Thomssen et al. 1996, Lee et al. 1997). GM-CSF down-
regulates CD 14 expression (Kruger et al. 1996) and induces expression of CD la, b,
c molecules (Kasinrerk et al. 1993) on monocytes. IFN increased surface expression
of MHC class II molecules (Nash et al. 1992), but TGF-(3 suppresses IFN-y
induction of MHC class II gene expression by inhibiting accumulation of class II
transactivator mRNA (Lee et al. 1997). IL-3 in combination with IL-4, induces
expression of CD1 on monocytes and this induction of CD1 by IL-3 can be
suppressed by IL-10 (Thomssen et al. 1996). Thus it is likely that changes on
expression of cell surface molecules on monocytes/macrophages are in part directly
related to cytokines. However, monocytes treated with purified gpl20 in vitro show
increased MHC class II expression (Wahl et al. 1989a, Allen et al. 1990). Thus only
future studies will elucidate this question.
1.2.3: Functional changes in infected monocytes/macrophages
Monocytes/macrophages are capable of eliminating intracellular organisms.
Nevertheless, these cells are excellent reservoirs of MVV infection (Brodie et al.
1995). It is still an open question about the direct effect of MVV infection on the
function of these cells and little is known about their function as effector cells
against MVV. In early studies, a decrease in the delayed type hypersensitivity
response to tuberculin was observed in MVV-infected sheep (Myer et al. 1988),
suggesting that MVV infection could cause macrophage function to be impaired in
vivo. AMs from MVV-infected sheep with interstitial pneumonia showed a
significant increase in fibronectin and neutrophil chemotactic factor release (Cordier
et al. 1990), but not the expected increase in phagocytosis considering the activation
phenotype of the cells (Lee et al. 1996). AMs from MVV infected sheep were
reported to show normal Fc-receptor-mediated (immune system-specific)
phagocytosis (Lee et al. 1996) and monocytes from MVV-infected animals also
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showed no defect in the binding and phagocytic activity for bacteria (Lee et al.
1996). Similar phenomenon also occurs in HIV infection. Monocytes from HIV-
infected individuals showed normal C3-receptor-mediated (nonspecific) or Fc-
receptor-mediated (immune system-specific) phagocytosis (Gersoft et al. 1982,
Estevez et al. 1986, Nielsen et al. 1986, Roux-lombard et al. 1986, Bender et al.
1988), and normal lytic activity (intracellular killing) (Murray et al. 1985, Nielsen et
al. 1985, Mtiller et al. 1990, Bravo-Cuellar et al. 1992). In vitro infected monocyte-
derived macrophages (MDMs) show defective phayocytic activity but the normal
expression of the surface molecules (Lee et al. 1996), suggesting that the phenotypic
alterations observed in vivo (see 1.2.1) may be not directly mediated by MVV but by
inflammatory interactions at local lesions probably involving cytokines. However,
defective chemotaxis also occurred in monocytes from healthy individuals after in
vitro exposure to HIV gp41 or gpl20 (Wahl et al. 1989a).
Monocytes/macrophages are capable of presenting antigen in the context of an MHC
molecule (accessory function). For CD4+ lymphocyte activation, it is required that
antigen be presented in the context of a MHC class II on the surface of macrophages.
HIV chronically infected myeloid cells with normal or decreased MHC class II
expression (Roy et al. 1987, Melendez-Guerro et al. 1992) showed a decreased
ability to stimulate T cells (Foely et al. 1992). A Similar phenomenon may occur in
MVV infection because MVV is genetically and pathogenically similar to HIV.
Infection of monocyte/macrophage may also lead to dysfunction in the secretion of
cytokines which may responsible for the persistent of MVV in these cells.
Study of the state of activation of alveolar lymphocytes from MVV infected sheep
shows an anomalous pattern of T cell activation (Begara et al. 1995). While T cells
from MVV-infected sheep showed increased expression of MHC class II, IL-2
receptor (IL-2R) is lacking, suggesting an impaired alveolar T cells activation during
the course of MVV infection. The decreased response to activation seen in alveolar
T cells from MVV-infected sheep (Begara et al. 1995) could play an important role
in the pathogenesis of MVV infection.
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1.2.4: Virus replication in monocytes/macrophages
MVV replication in monocyte/macrophages is not well understood. In general, these
cells do not divide (Metcalf 1989) but are permissive for MVV replication in vitro
(Gendelman et al. 1986, Georgsson et al. 1992). These cells differ in susceptibility to
MVV infection. It is unclear whether the virus maintained in them is in certain form
of latent state. A recent study showed that blood monocytes are resistant to
productive HIV infection in vitro immediately after isolation, and further
investigation found that replication of HIV was blocked prior to reverse transcription
in fresh isolated monocytes (Sonza et al. 1996), but whether this block is at the level
of binding or entry or following entry remains to be determined. It is not unclear
whether the similar phenomenon occurs in MVV infection of monocytes. But the
question raised is why the viral replication is blocked in these cells (Sonza et al.
1996). It has been shown that MVV infection of monocytes in vitro appears to be
linked to differentiation, and susceptibility of cells to infection as well as the
magnitude and rate of viral RNA transcription and protein synthesis is closely linked
to the rate of maturation of monocytes to macrophages (Brahic et al. 1981, Narayan
et al. 1982, 1985, Harper et al. 1986, Gendelman et al. 1989, 1992, Rich et al.
1992). However, the mechanism for this restriction in monocytes and how this
restriction changes with maturation process remain unclear. A recent study reported
that that ability to produce IFN-oc, an anti-viral cytokine, is lost in response to HIV-1
as monocytes differentiate into macrophages (Francis et al. 1996). This finding may
in part explain that why macrophages are more susceptible to infection. Furthermore,
low levels of IFNs ((3 and y) and/or other negative factors may be induced in
monocytes in response to lentiviral infection (Gendelman et al. 1992, Gessani et al.
1994, Francis et al. 1996). A study extended this hypothesis showing that adherent
cells of PBMCs can produce significantly higher levels of TNF-a than in non¬
adherent cells when stimulated with Sendai virus (Aderka et al. 1986). IFN-(3 is very
effective in inhibiting viral replication in differentiated macrophages but not in
freshly isolated monocytes (Gessani et al. 1994). Moreover, macrophages responded
more effectively than monocytes to the priming effect of EFN-P for 1L-12 production
(Gessani et al. 1997). Thus the difference in response to antigenic stimulation
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between monocytes and macrophages may also play an important role in the
different susceptibility to MVV within these cells.
Although productive infection of MVV is often found in macrophages, little is
known about the characteristics of macrophage infection by MVV in vivo. HIV-1
replication in AMs in vivo in maintained in a latent proviral form without viral
replication, indicating that AMs are latently infected by HIV in vivo but are not a site
for viral replication. In contrast, HIV-1 replication occurs with stimulation in vitro
(Lebargy et al. 1994). Since the pathology of MVV-induced lesions in lung
resembles that of HIV, a similar phenomenon may also occur in MVV infected AMs
in vivo. This could be related to a still unknown mechanism that inhibits replication
of virus in AMs in vivo. Such an inhibition could be related to various cytokines
released by leukocytes present in the lung of infected subjects, such as EFN-y. It has
been demonstrated that IFNs are present in culture fluids from AMs from lambs
experimentally infected with MVV (Lairmore et al., 1988a) and in vitro interaction
between lymphocytes and MVV infected macrophages restricted replication of the
virus in cultured macrophages (Moench et al., 1985). The IFN present in culture
fluids from infected animals with lymphocytic interstitial pneumonia showed to have
moderate inhibitory effects on MVV replication in vitro (Lairmore et al. 1988a).
Since cytokines may be produced and may act locally in tissues without entering the
circulation, their plasma concentration need not be elevated for them to have an
important role in the modulation of the virus expression at tissue level. This
mechanism could be a major negative control of replication in the lung, limiting the
spreading infection. However, there are many other factors involved either directly
or indirectly in regulating virus replication in macrophages in vivo that await
elucidation.
1.3: The role of cytokines in lentiviral infection
1.3.1: Cytokines
Cytokines are consisted of a group of secreted regulatory proteins which act as
intercellular signals in a variety of cellular response including the immune response
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(Paul and Seder 1994). The molecular mass of cytokines ranges between 6 and
70kD, and often contain protective carbohydrates and intramolecular disulphide
bonds. Cytokines are secreted by a variety of cell types such as macrophages and
lymphocytes. Constitutive production of cytokines is usually low or absent and
further expressed to varying degree in immune response to antigen (Paul and Seder
1994). A single cytokine often may have multiple target cells and may both stimulate
and inhibit the production of others (pleiotropy). On the other hand, structurally
dissimilar cytokines may have a similar spectrum of actions (redundancy). This
implies that the loss of one cytokine activity may be compensated by that of others,
and it stresses the vital importance of these interactions.
The pathological manifestation of lentirviral infection is the result of complex
interactions between the direct cytopathic effect of viral infection and local and
system immune response. It is now clear that the immune system is regulated by a
complex network of redundant and pleiotropic cytokines. Cytokines play an
important functional role in maintaining normal immune homeostasis (Paul and
Seder 1994). In addition, cytokines are essential for the interaction between effector
and accessory cells during host defence mechanism in response to infectious agents
and for lymphocyte activation, antibody production and cytotoxic cellular responses.
It is also clear that cytokines secreted either directly by infected cells or indirectly by
lymphocytes and macrophages activated by the immune response to viral proteins
have the key role in the pathological consequences of viral infection and its
virulence (Mosmann and Coffman 1991). Lentivirus infection leads to the
development of antiviral immune responses (Narayan et al. 1985). However, the role
played by the immune response during lentiviruses is not restricted to this anti-viral
immune response. Lentiviruses persistently replicate within cells of the immune
system. This is a persistent source of immune cell activation. This activation is
intimately linked to the expression and production of cytokines (Paul and Seder
1994). Taken together, it has been suggested that cytokines have a variety of roles
during lentiviruse infection, some of which will benefit the host and others the virus.
Some cytokines may contribute to stimulate or inhibit viral replication, but may also
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be in involved in the development of pathological manifestation of the infection.
Therefore, characterisation of the production and the role of cytokines, although
difficult, would be very valuable for understanding that pathogenesis of the viral
infection.
1.3.2: The role of cytokines in modulation of the immune response
Cytokines represent major factors in the development of immune responses. The
different cytokines produced by different antigen-presenting cells and other cell
types in response to infection have an important influence on the type of immune
response that is induced. On the basis of the pattern of cytokines expressed, immune
response can be divided into Thl and Th2. Thl cytokines are EFN-y, IL-2, TNF-a/|3
produced by Thl cells which promote cell-mediated immunity and delayed-type
hyper-sensitivity (DTH) (Mosmann et al. 1986, Romagnani 1994, Mosmann and
Coffman 1991). Th2 cytokines are IL-4, IL-5, IL-6, IL-9, IL-10 and EL-13 secreted
by Th2 cells which favour allergic reactions and provide the most efficient help for
B cells (antibody production) (Mosmann et al. 1986, Romagnani 1994). IL-12,
secreted by macrophages and B cells, has been shown to act directly on CD4+ naive
T cells derived from T receptor transgenic mice to induce EFN-y, production and T
cell differentiation towards Thl development (Seder et al. 1993). In contrast, IL-4
has been shown to drive Th2 cell development and the expression of Th2 cytokines.
Moreover, Th2 cytokines IL-4 and IL-10 has been shown to inhibit IL-12 production
in human macrophages and thereby, the Thl response. As both IL-10 and IL-12 are
macrophage-derived cytokines, these can either stimulate or inhibit Thl response,
depending on the relative production of either cytokines by these cells. IFN-a
stimulates the development of Thl cells and blocks Th2 development (Sher et al.
1992). It has been reported that in certain pathologic conditions different patterns of
cytokine expression may be related to different types of immune response (Mosmann
et al. 1986, Romagnani 1994). In mice, Thl and Th2 responses play a critical role in
viral clearance (Braciale and Braciale 1994). However, In comparison with mouse
and man little information is available regarding the Th! and Th2 cytokine response
in sheep and many other animal species. The existence of a dichotomy in Thl and
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TH2 cytokine response remains ill defined.
The factors responsible for initiating a switch from asymptomatic to symptomatic
disease expression in lentiviral infections have yet to be determined. With regard to
HIV infection, a switch from Th 1 to Th2 cytokine responses has been suggested to
represent a critical step in the disease based on the pattern of cytokines production
from PBMCs from HIV-infected individuals at different stages of disease
progression (Clerici and Shearer, 1993). Patients with Thl-type response,
characterised by production of IL-2 and IFN-y remain as asmptomatic whereas those
that switch from Thl to Th2, as indicated by decreased secretion of EL-12 and
increased production of IL-4, go on to be symptomatic (Clerici and Shearer 1993,
Chehimi et al. 1994). Further-more, recent studies demonstrate that the decreased
percentage of cells expressing EL-2 and IFN-y correlates with an increased
proportion of IL-4 and IL-10-secreting cells on a single cell level among CD4+ T
cells in HIV-1 infected individuals (Klein et al. 1997). In cats, a switch from Thl to
Th2 response has also been suggested as playing a role in FIV infection based the
observation that asmptomatic cat produces high level of EL-2 (a Thl cytokine) and
low level of IL-6 (a Th2 cytokine) (Lawrence et al. 1995).
MVV, like other lentiviruses, persistently infects monocytes/macrophages, which
leads to mononuclear infiltration of various tissues. Thus it has been proposed that a
similar mechanism of immune dysfunction, involving a switch from Thl to Th2
cytokine response may be occurring during MVV infection. In support of this,
Woodall et al. (1997) reported that MVV-infected sheep with lung lesions showed
significantly increased expression of IL-10 mRNA and elevated expression of IL-4
mRNA detected in lung tissues whereas low level of EL-10 and undetectable EL-4
mRNA expression in lung tissue of MVV infected sheep without lung lesions.
Interestingly IFN-y mRNA, marking cytotoxic T lymphocyte activity, and IL-2
receptor, marking T lymphocyte activation, was detected in the lung tissue of MVV-
infected sheep with lung lesions. Very low or undetectable levels of these cytokines
were found in the lung tissue of MVV-infected sheep without either lung lesions or
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clinical signs. It is not clear, however, what type of cell is responsible for the
expression of these cytokines. A study of cytokine expression in CAEV-induced
arthritis (CAEV is closely related to MVV) showed Thl and Th2 cytokine
expression in the same arthritis joints but in different regions (Lechner et al. 1997).
On the basis of this finding, it is hypothesed that both type of cytokine response
could occur concurrently but in different regions of MVV-infected lung tissue.
However, studies monitoring changes in levels of IL-10, EL-4 and IFN-y during
MVV infection are required before a definite role of a shift from Thl to Th2 in the
immunopathology of MVV infection can be determined. Whether or not a Thl/Th2
switch occurs, cytokines are certainly critical in modulating the type and the
effectiveness of the immune response against lentiviral infection.
1.3.3: Cytokines induced during lentiviral infection
1.3.3.1: Cytokine induction by small ruminant lentiviruses
Monocytes/macrophages are the major host for the small ruminant lentiviruses MVV
and CAEV (Bordie et al. 1995). Furthermore, monocytes/macrophages play an
important role in immune regulation, both by acting as antigen-presenting cells and
by producing cytokines and lipid mediators with potent biological activities. Thus
MVV infected monocyte/macrophages play an important role in the pathogenesis of
MVV infection. The precise mechanisms are largely unknown, but dysregulation of
expression of cytokines by infected monocyte/macrophages has been postulated as a
possible mechanism of maintaining or exacerbating inflammation (Lechner et al.
1996, Woodall et al. 1997). Only few studies have investigated cytokine induction
due to MVV infection of host cells. Early studies reported that cytokines, present in
complicated lentiviral pneumonia in sheep (Ellis et al. 1991), might modulate MVV
replication in AMs (Ellis et al. 1994). A recent study extended these observations,
showing that IFN-y, IL-1(3, IL-4, IL-10, IL-2 receptor mRNA was upregulated in
lung tissue of MVV-infected sheep with lung lesions (Woodall et al. 1997). In
particular, hyperelevation of GM-CSF mRNA was found in lung tissue of MVV
infected sheep with lung lesions (Woodall et al. 1997). TNF-a and TGF-(3 mRNA
levels were similar to the lung tissue without lung lesions. By contrast, FIV infected
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PBMCs have shown an increased expression of TNF-a (Kraus et al. 1996) and
CAEV-infected macrophages has shown a decreased expression of TGF-(3 (Lechner
et al. 1997). AMs bearing MVV capsid protein have been found at the periphery of
lung lesions (Brodie et al. 1995). These observations suggest that MVV infection
and replication may directly result in a dysregulated pattern of expression of
cytokines in lung tissues of MVV-infected sheep. However, which type of cell is
responsible for this dysregulation of expression of cytokines by MVV remains
elusive. Currently, studies of the interaction of MVV with AMs showed that EL-8
gene expression is upregulated as a result of MVV in vitro and in vivo infection
(Legastelois et al. 1996). Apart from MVV, two other lentiviruses have also been
shown to increase IL-8 expression in infected cells in vitro, which suggests that this
increase may be a common feature in lentivirus infection. CAEV infection results in
increased expression of IL-8 in macrophages (Lechner et al. 1997) and HIV also
increases the secretion of IL-8 in blood-derived macrophages (MDMs) (Lipschik et
al. 1993). Lentiviruses, however, are not the only viruses capable of augmenting the
expression of EL-8. For example, the retrovirus human T cell leukaemia virus type 1
(HTLV-1) increases IL-8 expression by a NF-KB-dependent mechanism (Baba et al.
1996). It is unclear whether MVV and CAEV induce the expression of EL-8 by a
similar way. Unlike HIV, MVV and CAEV contain neither TAR-like structures nor
NF-kB binding sites in the LTR (Gdovin et al. 1992). Therefore, HIV and MVV and
CAEV may have different effects on expression of cytokines. The fact that the levels
of NF-kB and AP-1 activities was not corrected to the levels of IL-8 expression in
CAEV-infected macrophages (Lechner et al. 1997), suggests that it is most likely
that these cellular factors are not involved in the pathway regulating the increased
expression of IL-8 mRNA in macrophages.
1.3.3.2: Insight from HIV
1.3.3.2a: HIV infection modulates the expression of cytokines
The modulation of cytokine expression in HIV-infected monocytes/macrophages has
been studied in much greater detail than other lentiviruses. A number of cytokines
have been reported to be up- or down-regulated in monocyte/macrophages from
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HIV-infected individuals and after in vitro infection (Wright et al. 1988, Roux-
lombard et al. 1989, Kekow et al. 1990, Vom et al. 1990, Peters et al. 1991, Wahl et
al. 1991, Agostini et al. 1992, Trentin et al. 1992, Twigg et al. 1992, Clerici et al.
1993a, 1993b, Fan et al. 1993, Lipschik et al. 1993, Denis et al. 1994a, 1994b,
Chehimi et al. 1994, Borghi et al. 1995). Increased levels of TNF-a, IL-1, IL-6,
TGF-(3 and IFN-a and IFN-J3 have been found in the sera of HIV infected patients
(Agostini et al. 1992), However, in vitro, no significant difference was observed in
spontaneous and LPS-induced IL-ip, EL-6 and TNF-a secretion in PBMCs from
HIV-infected individuals and those isolated from uninfected controls (Peters et al.
1991,Vom et al. 1990). A rise in the levels of IL-lp, IL-6 and TNF-a mRNA has
also been observed in LPS-stimulated alveolar macrophages isolated from HIV
infected individuals (Sjerra-Madero et al. 1994). In another set of reports,
monocytes/macrophages secrete IL-6 and TNF-a in response to HIV infection
(Merrill et al. 1989, Breen et al. 1990, Biyx et al. 1990, Clouse et al. 1991, Esser et
al. 1991, Mabonndzo et al. 1991, Ameglio et al. 1994, Berman et al. 1994b,
Sandborg et al. 1994, Than et al. 1994). High levels of expression of these cytokines
as well as EFN-y and IL-10 are particularly evident in lymphoid tissue, a major site of
HIV replication throughout the course of disease (Agostini et al. 1992, Emilie et al.
1994, Cheret et al. 1996, Graziosi et al. 1996, Khatissan et al. 1996a). In some
studies, HIV did not appear to stimulate the secretion of EL-6 and TNF-a by
monocytes/macrophages (D'Addario et al. 1990, Molina et al. 1990, Gan et al.
1991, Meltzer et al. 1991, Sperber et al. 1993, Foli et al. 1997). In addition, when
macrophages differentiated from in vitro HIV-infected blood adherent cells are
stimulated with LPS, increased levels of IL-8 gene expression are observed
compared to that in control (Lipschik et al. 1993). These observations show that HIV
infection modulates the expression of cytokines in its host.
A recent study demonstrated that no changes in TNF-a and EL-10 mRNA level were
observed in PBMCs whereas enhanced levels of TNF-a and EL-10 mRNA could be
detected in lymph node mononuclear cell (LNMCs) and mononuclear cells from
brochoalveolar lavages (BALMCs) (Cheret et al. 1996). Moreover, expression of IL-
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2 and IL-4 was generally detected in PBMCs, but rarely found in lymph nodes in a
minority of HIV-infected individuals regardless of the stage of disease (Graziosi et
al. 1994a). These results suggest that the levels of cytokine in sera or other body fluid
may not reflect cytokine expression in tissues. Thus, a comparative analysis of the
expression of cytokines at different tissues is also important for elucidating the
pathological events in affected tissues of lentiviral infection.
1.3.3.2b: Viral gene products modulate the expression of cytokines
Study of interaction of HIV genes products including tat, gpl20, with molecules on
the surface of the target cells showed that the direct infection of monocytes/
macrophages may be not necessary for the expression of some cytokines and that
alternative mechanisms may be involved in this process. Inactivated virus or even
HIV envelope gpl20 at high concentration can induce cytokine production (Clouse
et al. 1991, Mabondao et al. 1991, Oyaizu et al. 1991, Riechmann et al. 1991,
Ameglio et al. 1994). Normal PBMCs produced IL-1, IL-6 and TNF-a on exposure
to HIV gpl20 (Merrill et al. 1989, Wahl et al. 1989b, Molina et al. 1990, Gessani et
al. 1994) and inactivated HIV (Nakajima et al. 1989). Expression of IFN-y can be
induced by inactivated virus and thus is independent of virus replication (Linnavuori
et al. 1987, Capobianchi et al. 1988, 1992a, Gobi et al. 1988, Kikuta et al. 1990,
Szebeni et al. 1991, Gendelman et al. 1992, Francis et al. 1993). Also, EFN-P can be
induced in cultured macrophages by HIV recombinant gpl20 (Gessani et al. 1994),
indicating a role for IFN-p in restriction of virus replication. Yet other studies have
suggested that HIV tat protein may have a role in this process (Buonaguro et al.
1992, Iwamoto et al. 1994, Rautonen et al. 1994, Seal a et al. 1994). Taken together,
cytokine genes may be in part regulated at a transcriptional level through signal
transduction pathways activated by interaction between HIV protein and its receptor
such as CD4. It is unknown, however, whether these effects are of sufficient
magnitude to induce elevated levels of cytokines in vivo. Recently, Foli et al. (1997)
have reported that monocytes/macrophages productively infected by HIV do not
secrete detectable cytokines IL-6 and TNF-a. However GM-CSF, a cytokine that
enhances virus replication in monocytes/macrophages, can induce relatively long-
32
term secretion of cytokines IL-6 and TNF-a by monocytes/macrophages, even in
absence of HIV. Also HIV induces production of IL-6 and TNF-a in monocytes/
macrophages treated with M-CSF. However, whether the MVV gene products have
the similar effect on cytokine expression is still unknown.
It is obvious from these reports that interaction of lentiviruses with host cells
invariably not only results in the release of one or more cytokines but also leads to a
dysregulated pattern of cytokine expression in response to the exogenous
stimulation. Not all cytokine mRNAs are affected similarly, and the actual cytokines
produced depend on the nature of virus and host cell involved or the kind of
stimulus, which suggests that the effects of lentiviruses on the regulation of
cytokines may be well more complex and remains elusive. The fact that infected
macrophages respond differently from uninfected cells to exogenous stimulation is
believed to be of particular significance in the pathogenesis of lentivirus-infected
sites. Priming for a dysregulation of cytokine expression in response to exogenous
stimulation as result of infection may well be a factor in the persistence of
inflammation which ultimately leads to clinical symptoms. Thus elucidation of the
alterations in cytokine expression following lentivirus infection is a crucial step in
determining immunopathological mechanisms involved in lentiviral disease
progression.
1.3.3.3: The expression of cytokines and virus burden
Although lentivirus infection induced the expression of cytokines (Berman et al.
1994b, Legastelois et al. 1996), little is known whether the expression of some
cytokines in vivo are quantitatively related to lentivirus infection, in particular in
MVV infection. Study of the relationship between virus burden in AMs and cytokine
expression shows that the increased level of TNF-a in HIV-infected AMs and
lymphoid tissue did not directly correlate with viral gene expression in these cells or
tissues (Sierra-Madero et al. 1994, Cavert et al. 1997). Similarly in CAEV infection
TNF-a expression did not associate with the degree of viral replication (Lechner et
al. 1996). The lack of relationship between the degree of viral replication and TNF
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mRNA expression, indicates that in vivo TNF-a may not be critical for inducing
viral replication in its hosts. This suggestion is further supported indirectly by the
evidence that the virus in the circulation is mostly produced by continuing cycles of
infection (Ho et al. 1995, Wei et al. 1995, Perelson et al. 1996) rather than by
induction of gene expression in latently infected cells (Cavert et al. 1997). However,
it does not exclude that TNF-a and other cytokines such as IL-2 and IL-6, are
required in earlier stages of infection to activate cells to a permissive state for
replication or to upregulate expression of early viral RNA such as tat and Rev RNA.
By contrast in FIV infection, production of TNF-a has been shown to be related to
the production of FIV p26 in experimentally infected cats (Kraus et al. 1997).
In the case of SIV, expression of cytokines TNF-a/p and IFN-y was correlated with
virus replication in experimentally infected animals (Khatissian et al. 1994, 1996a).
In particular, production of IFN-a was found at higher levels in animals with a high
SIV burden (Khatissian et al. 1996b). IFN-a is virally induced. The anti-viral
activity mediated by IFN-a may, in turn, contribute to the down-regulation of viral
load seen after the acute stage of SIV infection. However, productive SIV infection
persists in spite of the IFN-a response (Khatissian et al. 1996b). The reasons for this
are not clear but could be due to the development of virus resistant to IFN-a during
the course of infection. HIV isolates from HIV infected individuals with AIDS were
found to have various degrees of resistance to IFN-a. This may also occur in MVV
in vivo infection. It has been shown that IFN present in culture fluids from MVV
infected animals with lung lesions has only moderate inhibitory effects on MVV
replication in vitro (Lairmore et al., 1988a). The role of such virus resistance to IFN-
a in immunopathology of the MVV infection remains unclear.
1.3.3.4: Pathological role of virus-induced cytokines
Lentivirus infection invariably results in the release of one or more cytokines
(Legastelois et al. 1996, Poli et al. 1993, 1996, Woodall et al. 1997). It is tempting,
therefore, to hypotheses that lentivirus infection may cause progression of disease
via a profound perturbation of the cytokine network. More precisely, increased
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cytokine release may have more damaging than favourable effects in the infected
microenvironmental sites. The biological significance of increased expression of IL-
8 mRNA in MVV (Lega-stelois et al. 1996), CAEV (Lechner et al. 1997) as well as
HIV-infected (Lipschik et al. 1993) macrophages remains to be determined. EL-8 is a
potent chemotactant for neutrophils. Under certain conditions, IL-8 can also function
as a chemotactant for T lymphocytes (Matsushima et al. 1992). It is tempting,
therefore, to hypothesis that increased expression of this cytokine may contribute to
accumulation of neutrophil and lymphocytes in the alveolar spaces of MVV-
associated interstitial pneumonia (Cadore et al. 1994, Cordier et al. 1992, Lairmore
et al. 1986) and HIV-associated interstitial pneumonia (Joshi et al. 1985).
Hyperevelation of GM-CSF mRNA has been reported in the lung tissue of MVV
infected sheep with chronic lymphocytic interstitial pneumonia (Woodall et al.
1997). Similarly increased expression of GM-CSF was observed in HIV-infected
cells (Agostini et al. 1992, Lipschik et al. 1993). GM-CSF up-regulates antigen-
presenting activity of dendritic cells and recruits these cells to be localised inflamed
regions of the lung, thus promoting lymphoid follicle development. GM-CSF also
mediates abrogation of suppression of T lymphocytes activity in the lung by AMs,
causing T lymphocyte accumulation to occur. Thus it is possible that increased
levels of GM-CSF in the lung may account for development of lymphoid follicles in
the lung (Woodall et al. 1997).
Infection of macrophages with CAEV leads to a decrease in the expression of TGF-P
(Lechner et al. 1997). TGF-P potentially inhibits the proliferation of T and B
lymphocytes and production of cytokines (Lechner et al. 1997). Decreased activity
of TGF-P in the affected sites may therefore result in enhanced proliferation of T and
B lymphocytes. It is unclear whether the reduced expression of TGF-P in CAEV-
infected macrophages also leads to decreased activity of TGF-P in vivo. In MVV
infection, TGF-p mRNA levels in the lung tissues of MVV-infected sheep with
lymphocytic interstitial pneumonia were found to be similar to the lung tissues
without lung lesions (Woodall et al. 1997).
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Like HIV infection, MVV infection in sheep also causes CNS disease such as
encephalomyelitis (Watt et al. 1994). However, events leading to the neurological
disorder are still unclear, but infiltration by monocytes and macrophages is a
consistent finding in the brain of AIDS pateints (Koening et al. 1986). In AIDS
demeatia, the predominant cells in the CNS are macrophages and microglia which
are infected and produce HIV-1. Persistence of BL-1, TNF-a, TGF-P, GM-CSF, M-
CSF and IL-6 expression in these cells was observed. Many of these cytokines are
chemotactic for monocytes and cause death of oligodendrocytes and destruction of
myelin in vitro (Robbins et al. 1987, Whal et al. 1991). In one study, increased level
of IL-1|3 and IL-6 was observed in the cerebrospinal fluid. Therefore cytokines
produced by resident macrophages and microgila cells may contribute to many of
clinical and histological effects of lentiviral infection in the CNS. Undoubtedly,
these findings support the suggestion of a possible pathogenic role for cytokines in
the virus-infected micro-environmental sites.
1.3.4: Role of cytokines in regulation of lentivirus expression
It has been speculated that the interaction of the viral genome with cellular factors
may play a critical role in induction of lentivirus expression (Stanley et al. 1989,
1990, 1996, Ho et al. 1992, Poli et al. 1992a, 1993, O'Brien et al. 1995, Staprans et
al. 1995). In this scenario, the cytokine network has emerged as an important
component of host-mediated control of virus replication (Paul et al. 1994). The
cytokine produced determines the immune response to viral infection, which in turn
regulates virus replication and determines the persistence of virus in vivo. Therefore,
the role of cytokine and cytokine dysregulation in the pathogenesis of lentiviral
infection is under intense investigation. The finding that culture supernatant from
PBMCs stimulates HIV expression in chronically infected cells lines (Folks et al.
1987) led to the identification of numerous individual cytokines that have either
stimulatory or inhibitory effects on lentivirus replication either when manipulated
endogenously or when added to acutely or chronically infected cultures (Vincenzi et
al. 1994).
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1.3.4.1: Stimulatory effects of cytokines on the virus replication
An enhanced effect of TNF-a on MVV expression in AMs has been shown in vitro
(Ellis et al. 1994). Similar effects of TNF-a were also observed on HIV in T
lymphocyes and mononuclear phagocytes (Folks et al. 1989, 1987, Clouse et al.
1989a, Matsuyanma et al. 1989) and SIV in simian AMs (Walsh et al. 1992). It is
obvious from these reports that if this effect occurs in vivo, TNF-a could be an
important mediator of disease in vivo, in particular in the case of complicating
secondary infections (Ellis et al. 1994). It is unclear how TNF-a enhances MVV
replication in infected AMs. Previously, it has been shown that TNF-a activates SIV
expression in rhesus macaques macrophages on a per cell basis (Walsh et al. 1992),
suggesting that cytokine treatment results in an increase in the amount of lentiviruses
produced per infected macrophage. Enhanced effects of TNF on MVV and SIV
expression in AMs may occur through the transcriptional activation of lentiviruses as
a result of TNF-a induction. It has been shown that TNF-a leads to induction of HIV
expression via the activation of the cellular transcription factor NF-kB (Duh et al.
1989, Griffin et al. 1989, Osborn et al. 1989). Activation of NF-kB involves the
phosphorylation and degradation of I-kB (Lenardo et al. 1994), allowing NF-kB to
translocate to the nucleus and bind to promoter region of several cellular genes as
well as consensus sequences present in HIV-LTR. TNF-a receptors are engaged by
TNF-a and TNF-p via sphingomyliase and ceramide (Parrott et al. 1991, Schutze et
al. 1992) which inactivate I-kB. In this regard, TNF can potentially contribute to the
generation of viral quasispecies by rescuing defective viruses otherwise incompetent
for replication. Binding of NF-kB to the HIV LTR leads either to initiation or to
potentiation of viral transcription. However, unlike HIV and SIV, MVV contains
neither TAR-like structures nor NF-kB binding sites in the LTR (Gdovin et al.
1992). Therefore cytokines may regulate HIV MVV in different way. Considering
the fact that there is no difference in the levels of binding activity of NF-kB between
uninfected and CAEV-infected macrophages (Lechner et al. 1997), it is suggested
that TNF enhances MVV replication in infected AMs by a NF-kb-dependent
mechanism. A recent study (Herbein et al. 1996) has demonstrated an additional role
for TNF-a in terms of inhibitory capacity on entry of HIV into primary
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macrophages. This inhibition of HIV entry by TNF-a is independent of CD4
expression level and occurs in tissue culture differentiated macrophages but not in
PHA-activated PBMCs. However, it is unclear which entry step (virus-cell binding,
fusion or uncoating) is inhibited by TNF-a.
IL-1 is a pleiotropic cytokine consisting of two distinct but related proteins, IL-la
and IL-1 (3, and is mainly produced by macrophages (Akira et al. 1990). IL-1 is
involved in regulating the growth and differentiation of lymphocytes and induction
of acute inflammation. IL-1 has been shown to stimulate MVV replication in AMs
(Ellis et al. 1994). Similarly, IL-1 can enhances HIV replication or production in
vitro (Poli et al. 1994, Kinter et al. 1995). Although IL-1 is thought to affect viral
transcription, it is unclear whether the mechanism of IL-1 enhancement of HIV
involves the activation of NF-kB as in TNF stimulation.
Other cytokines have also been shown to have a stimulatory effects on HIV
replication in vitro, including IL-2 (Clouse et al. 1989b, Arai et al. 1990, Smithgall
et al. 1996), EL-6 (Poli et al. 1990), and DL-7 (Smithgall et al. 1996). But the role of
these cytokines in regulating viral replication has not yet been studied for MVV.
1.3.4.2: Inhibitory effects of cytokines on the virus replication
The effects of lentivirus-stimulating cytokines are counterbalanced by those that
down-regulate virus replication. IFN-a/p, as prototypes of cytokines, are naturally
occurring proteins capable of eliciting anti-viral and immunoregulatory activities.
They are produced principally in macrophages, B cells (EFN-a) and fibroblasts (DFN-
P) in response to viral infection. INF-a and INF-p bind to a common ubiquitously
expressed cell surface receptor leading to induction of interferon-stimulated genes,
such as PRK and 2', 5'-oligoadenylate synthetase, for cellular anti-viral and
immunoregulatory activities (Samuel et al. 1993). IFN present in culture fluids of
cells derived from animals with lymphocytic interstitial pneumonia has been shown
to have moderate inhibitory effects on MVV production in vitro (Lairmore et al.
1988a). Furthermore, as in the in vitro study of with 'leukocyte-derived IFN in
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CAEV-infected monocytes (Zink and Narayan 1989), bovine recombinant IFN-a has
an substantially inhibitory effect on MVV replication in macrophages (Ellis et al.
1994).
Similar observations are reported for HIV. In vitro, Both IFN-a and IFN-(3 exert
similar inhibitory effects on HIV replication (Kornbluth et al. 1989, Gendelman et
al. 1990a, 1990b, Shirazi and Pitha 1992, Gessani et al. 1994, Vincenzi and Poli
1994). The mechanism of this inhibition in monocyte/macrophages of lentiviral
production was dependent on the time of exposure to IFNs (a/(3). For example, in
infected primary macrophages, when addition of IFNs and infection occur at the
same time, IFNs interfere with an early step of HIV replication cycle virus by
preventing formation of HIV-1 provirus (Poli et al. 1989, Kornbluth et al. 1990,
Meylan et al. 1993), indicating IFNs may influence virus receptor binding, fusion,
un-coating, or reverse transcription. In contrast, when addition of IFNs occurs after
infection, IFN reduces the relative level of viral RNA without affecting formation of
HIV-1 provirus (Gendelman et al. 1990a, 1990b). It is obvious that the IFN-
mediated inhibition of lentiviral replication occurs at multiple levels, in vivo, and
IFN may have a broad spectrum of anti-cellular and anti-viral activities (Poli et al.
1989, Dubreuil et al. 1990, Gendelman et al. 1990a, 1990b, Kornbluth et al. 1990,
Smith et al. 1991, Shirazi et al. 1992, Meylan et al. 1993).
Recently, another lentivirus inhibiting IL-16 was found in humans and monkeys. IL-
16 is secreted from CD8+ cells and induces a migratory response in lymphocytes,
monocytes and eosinophils expressing CD4 molecules (Laberge et al. 1995). Cloned
African green monkey IL-16 and human IL-16 share 95 % homology (Baier et al.
1995). Either African green monkey IL-16 or human IL-16 has been shown to inhibit
HIV replication in CD8+-depleted PBMCs (Baier et al. 1995) but high
concentrations were required for inhibition. In comparison, the human IL-16 was
less potent than the monkey IL-16. These data in part explains why monkeys do not
succumb to SIV. Sheep EL-16 has been reported yet. It is unclear whether IL-16 has
similar effects on MVV replication.
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1.3.4.3: Bifunctional cytokines
A level of complexity exists in terms of the regulatory effects of cytokines on
lentiviral replication. In some cases, cytokines either induce or inhibit viral
replication in vitro as a function of the model systems. In regard to HIV infection,
IFN-y and TGF-(3 reduce or enhance viral replication depending on the infected cell
type and the culture condition (Koyanagi et al. 1988, Lazdins et al. 1991, Poli et al.
1991, Biswas et al. 1992, Fan et al. 1994, Dhawan et al. 1995). Opposing effects
were also noted in the cases of IL-4 and IL-13 when freshly isolated monocytes or
matured macrophages are exposed to HIV (Kazazi et al. 1992, Schuitemaker et al.
1992, Naif et al. 1997). For example IFN-y treatment prior to infection has a
predominantly stimulatory effect on HIV replication, whereas postinfection
treatment with IFN-y results in decreased virus expression (Koyanagi et al. 1988).
Thus, IFN-y may act as a negative and positive regulator of viral replication as a
function of variables which remain unclear, but appear to be linked to experimental
conditions, in particular the time of IFN-y addition and the type of cells infected, the
activational state of the infected macrophages at the time of exposure to EFN. It is
also possible that factors co-expressed together with IFN-y or induced as a
consequence of the production of this cytokine may also account for some of these
discrepant findings. The bifunction of IFN may in part explain the observation that
the level of IFN spontaneously secreted by pulmonary leukocytes was consistent
with increased MVV replication in tissues and more severe lymphocytic interstitial
pneumonia in lambs experimentally infected with MVV (Lairmore et al 1988a).
TGF-[3 is secreted primarily by platelets and macrophages (Massague et al. 1990). It
has a broad range of biological activities which vary depending on cell type, state of
differentiation, and the presence of other cytokines (Massague et al. 1990). Similar
to the effects of IFN-y, TGF-(3 has been shown to regulate bifunctionally viral
replication in vitro (Lazdins et al. 1991, Peterson et al. 1991, Poli et al. 1991).
However, the effects of TGF-(3 in vivo remain unclear. It is possible that the effects
of TGF-(3 in HIV replication in vivo vary with the phase of the infection and the
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context of other cytokines that modulate virus replication. No study of the effect
TGF-P on MVV has been made.
GM-CSF, a member of GSF family, is a key regulator of monocyte-macrophages. It
is required for the survival, proliferation, and differentiation of monocyte-
macrophages and for the function of the mature progeny (Metecalf et al. 1992,
Crowe and Lopez 1997). The ability of monocytes-macrophages to harbour MVV
and to allow its replication suggests that cytokines which affect the production of
monocytes, their differentiation and functional status, may modulate MVV
replication in vivo. In fact, differentiation and activation of these cells is associated
with lentiviral infection and replication, thus suggesting that GM-CSF may affect
viral replication at multiple stage of monocyte-macrophages differentiation (Poli et
al. 1992b). However, little is known about effects of GM-CSF on MVV infection of
monocyte/macrophages.
The effects of this cytokine on HIV replication have been studied in more detail. The
early studies of the effects of GM-CSF on HIV replication have shown that GM-CSF
has a significant increased effect on the expression of HIV-1 (Folks et al. 1987,
Koyanagi et al. 1988, Perno et al. 1989, Shuitemaker et al. 1990, 1992, Perno et al.
1992). The mechanism of enhancement of HIV replication by GM-CSF remains
unclear. The possible ways that GM-CSF may augment expression of HIV in
monocyte-macrophages is through the stimulation of host-cell transcriptional factors
which could bind to the HIV LTR, resulting in increase in HIV replication (Nabel et
al. 1987). The region responsible for GM-CSF activation in these cells is located
slightly upstream of, and partially overlaps, the NF-kB binding region (Zack et al.
1990). In contrast to its stimulatory effects on HIV replication, GM-CSF also has a
negative effect on HIV replication (Hammer et al. 1986). HIV replication in
monocyte-derived macrophages stimulated with GM-CSF is suppressed in contrast
to active production in macrophage induced by M-CSF (Matsuda et al. 1995),
although the expression of CD4 on the surface of M-CSF and GM-CSF stimulated
cells is similar, In GM-CSF-stimulated macrophages the level of proviral DNA is
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much less than that in M-CSF treated macrophages, suggesting that the suppression
of HIV replication in macrophages induced by GM-CSF may be largely due to
disturbance at certain steps of replication after synthesis of proviral DNA. The
reason for this discrepancy could be differences in the cells, the stage of maturation
of monocytes both at the time of cytokine exposure and at the time of infection, virus
strains, and culture conditions (Folks et al. 1987, Hammer et al. 1990, Matsuda et al.
1995, Feng et al. 1996). Considering the facts that GM-CSF has both suppressive or
stimulatory effects on HIV replication in macrophages in vitro and that there is the
increased expression of GM-CSF in the lung tissue of MVV-infected sheep
(Woodall et al. 1997), it is possible that GM-CSF is involved in regulating MVV
replication in vivo. It would be important to know whether GM-CSF has a similar
effect on MVV replication in macrophages as has been demonstrated in HIV. Thus
further study is required to clarify this point.
DL-10 is a pleoiotropic cytokine which is associated with the negative regulation of
IL-12 and IFNy and to development of Th2 type immune response (More et al.
1993). IL-10 has multiple effects on macrophages including inhibition of
cytotoxicity, oxidative burst, nitric oxide and cytokine production (IL-6, TNF-a and
IL-1P) and induction of IL-lra and FcyRl (Moore et al. 1993). That implicates IL-10
as an important factor in the regulation of cell-mediated immune responses to viral
infection (Clerici et al. 1994). It has been demonstrated that IL-10 has dichotomous
effects on HIV replication (Montanier et al. 1994, Weissman et al. 1994, 1995). IL-
10 can markedly inhibit HIV replication in monocyte/macrophages at concentration
that block secretion of endogenous cytokines such as IL-6 and TNF-a which can up-
regulate HIV-1 expression in these cells (Montanier et al. 1994, Weissman et al.
1994). The mechanism of suppression of HIV replication by IL-10 remains unclear
although it is thought to decrease HIV-1 reverse transcription upon macrophage
infection and subsequently mediate viral latency in vitro (Montanier et al. 1994).
The inhibition of HIV replication in monocytes by IL-10 is associated with
inhibition of cell differentiation (Chang et al. 1996). In contrast, IL-10 at
concentrations that do not completely inhibit release of these endogenous cytokines
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actually enhances HIV replication in infected monocyte/macrophages (Weissman et
al. 1995). On the basis of these observations, it is possible that there is a synergistic
effect between the exogenously added EL-10 and endogenously secreted cytokines
(Weissman et al. 1995, Finnegan et al. 1996).
The Th2 cytokines EL-4 (Novak et al. 1990, Schuitemaker et al. 1992, Naif et al.
1997) and EL-13 (Naif et al. 1997), released by activated Th2 lymphocytes (De Waal
Malefyt et al. 1993), also have dichotomous effects on HFV replication.
Interestingly, although IL-4 and TNF-a can up-regulate HEV replication
independently, combination of both cytokines resulted in a partial inhibition of the
maximal effect of TNF-a (Naif et al. 1997). It is possible that EL-4 inhibits TNF-a
enhancement of cytokine gene transcription by macrophages (Essner et al. 1988,
Yanagawa et al. 1991).
1.3.4.4: Interaction between cytokines in lentivirus infection
The effects of a particular cytokine are often greatly influenced by the activity of
other cytokines present in microenviroment. In this regard, certain cytokines have
been shown to act in a synergistic or in an antagonistic manner with other cytokines
in regulating viral replication. It has been reported that IL-6 co-operates with TNF-a
(Poli et al. 1990) or IL-1 (Poli et al. 1994) to induce an increase in HEV replication
greater than either cytokine alone. In addition, synergy for up-regulation of viral
expression can also occur between cytokines and cAMP or glucocorticoids. For
example, TNF-a co-operates with cAMP (Chowdhury et al. 1993) or glucocorticoids
(Bressler et al. 1993) to stimulate HIV expression in latently infected cells of
monocyte-macrophage lineage. Finally, cytokines are pleiotropic and the overall
effects may reflect the balance between lentivirus-inducing and inhibiting-activities.
From these observations, it is obvious that interaction of cytokines with lentivirus
infection is more complex. Thus the stimulatory and/or inhibitory effects of many
cytokines on the viral replication are observed in vitro, but it does not address the
possible role of endogenous cytokines in controlling the viral replication in vivo and
a direct correlation with cytokine effects in vivo remains difficult to establish. The
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important point about these observations is that a group of cytokines is capable of
either regulating the induction of lentiviral expression from the state of latent or
chronic infection to active viral expression or down-regulating lentiviral replication.
In comparison with HIV and SIV, little information is available regarding the
induction of MVV expression by cytokines.
1.4: Aims
Macrophages are the host cells for replication of MVV (Brodie et al. 1992, 1995).
However, the level of viral replication and load in AM and its correlation with
pulmonary lesion is unknown. Also it is not yet clear whether cytokine expression is
dysregulated in macrophages infected with MVV. In addition, the effects of
exogenous cytokine on MVV replication in macrophages have not been
documented.The aims of this study were to determine 1. the level of MVV DNA in
AM compared with blood monocytes in natural infection and assess the correlation
of viral burden and replicative status to the lung lesions related to MVV infection; 2.
the differential expression of cytokine genes in macrophages infected with MVV in
vivo and in vitro\ 3. the effect of GM-CSF, TGF-(3 and IFN-y on MVV replication in
macrophage in vitro. Prior to this a QC-PCR had to be developed for quantitative









2.2.1.1: Cells for propagation of MVV
2.2.1.1a: Sheep epidermal fibroblast cells
Sheep epidermal fibroblast cultures were grown in Dulbeco's modified Eagle's
medium (DMEM) (Gibco) supplemented with 2mM L-glutamine, lOOu/ml penicillin
and 200p.g mg/ml streptomycin and 10% (v/v) foetal calf serum (FCS). When the
monolayer was approximately 90% confluent, medium was removed and cells were
washed with Versene and then treated with 0.05% (w/v) trypsin and 0.02% (w/v)
EDTA in phosphate buffered saline (PBS) (0.8% NaCl, 0.02 % KC1, 27mM Na2P04,
1.5mM KH2PO4, PH7.2) until cells were no longer adherent. 10 ml of fresh medium
was added and cells split 1:3. Cells were routinely grown at 37°C with 5% C02 in
tissue culture flasks. Cells were stored in liquid nitrogen at a concentration of 1 x
106/ml in 90% (v/v) FCS/10% (v/v) DMSO. Cells were resuscitated by thawing
quickly at 37°C and washed twice with 10% (v/v) /DMEM to remove DMSO.
2.2.1.1b: Preparation of virus stocks
All experiments used the EV1 isolate of maedi-visna virus (Sargan et al, 1991). The
virus was passaged in the fibroblast culture maintained in DMEM/8% (v/v) FCS.
Briefly, when the monolayer was approximately 90% confluent, medium was
removed and virus was added. After incubation at 37°C for 1 hour, fresh DMEM/2%
(v/v) FCS was added. Virus containing supernatant was harvested when the culture
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displayed extensive cytopathic effect and clarified by centrifugation at 8 OOOrpm for
10 minutes at 4°C. The supernatants were aliquoted and stored at -70°C until used.
2.2.1.1c: Titration of virus
96 Well flat-bottomed tissue plates were seeded with lx 104 cells per well in lOOpl
of DMEM containing 8% (v/v) FCS and incubated at 37°C overnight. 10-fold virus
dilution was made in DMEM containing 2% FCS (v/v). Medium was removed from
the inside 60 wells of the plate, and virus dilutions were added in columns (e.g. six
wells for each dilution), incubated at 37°C for 1-2 hours. Medium was used as mock
infection control. 50 pi of DMEM containing 2% FCS (v/v) was added into each
well. The cells were fed with another lOOpl of DMEM containing 2% FCS (v/v) 4
days later. After incubation for another 3 days, cells were stained as follows.
After removal of medium, cells were fixed with ice-cold acetone/methanol (1:1),
lOOpl per well for 5 minutes at room temperature. After removal of acetone/
methanol and air dried slightly, cells were then treated with 1% (w/v) potassium
dichromate for 30 minutes, 50 pi per well and re-fixed with acetone/methanol as
before. Cells were stained with Giemsa stain freshly diluted in water (1:1) for 5
minutes, 100 pi per well. Cells were then washed in excess of water and destained in
tap water until the cell nucleus was dark blue and the cytoplasm light blue. The plate
was air dried and examined for presence of syncytia. The 50% tissue culture
infectious dose (TCrD50/ml) was calculated by Reed and Meunch's method.
2.2.1.2: Isolation and culture of macrophages
2.2.1.2a: Animals
Samples including serum, blood, bronchoalveolar lavage fluids were collected from a
heavily infected flock of sheep belonging to the Pathology laboratory under
controlled conditions. All the sheep were Texel breed apart from Shi06 which was a
Bleu de Maine. They were aged between 3 and 10 years of age at the time when the
samples were collected. Previous examination of the source flock revealed no
evidence of interrecurrent respiratory disease that was unassociated with MVV
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infection (Watt et al. 1992). Sheep from flocks not infected with MVV were
purchased locally. Uninfected and infected animals were separately housed but
otherwise managed under similar conditions. Animals were divided into two groups
according to histological lesions in lung: Group A consisted of sheep with lung
lesions and Group B consisted of sheep without lung lesions.
2.2.1.2b: Isolation and culture of alveolar macrophages
Animals were euthanatized by intravenous injection of barbiturate and were
exsanguinated. The lungs and trachea were removed intact. The lung was then
flushed via the trachea with 200 ml of sterile PBS or HBSS in four aliquots of 50 ml
each. A gentle aspiration of the bronchoalveolar lavage fluid (BALF) is carried out
after each infusion and the four recoveries are pooled together in precooled plastic
containers. BALF was filtered through a loose cotton gauze. Cells were recovered by
centrifugation (800g, 4°C, 10-20min depending on the volume of BALF). Cell
pellets are washed twice in RPMI-1640 supplemented with 2 % (v/v) FCS, 2mM L-
glutamine, lOOu/ml penicillin and 200p,g/ml streptomycin. Cells counts and viability
were performed by using trypan blue exclusion and cells were adjusted to 4 x 106
cells/ml in PRM1/10 % (v/v) FCS. 5 ml of cells are seeded in 25 cm tissue culture
flasks at 37°C with 5 % CO2 in air. After lor 2 hr, non-adherent cells and adherent
cells are harvested and the cells are refed with fresh medium. Adherent cells
recovered were used immediately for either cytospin immunostaining or for RNA or
DNA preparation. For culture, one ml of adherent cells at a concentration of 106/ml
was dispensed into the well of 24-well plate prior to treatment. To harvest adherent
cells (MDMs or AMs), cultures were washed with PBS once and 2.5 ml of 5mM
EDTA in PBS is added to the flasks, after 2-5min incubation, the flasks are knocked
to dislodge the cells and a rubber policemen used to scrape off any remaining
adherent cells.
2.2.1,2c: Isolation and culture of macrophages from sheep blood
Blood samples were collected in an EDTA K3 containing vacutainer (Becton
Dicknson) and diluted by addition of an equal volume of sterile physiological saline
47
(0.9% w/v NaCl). The diluted blood was loaded onto the surface of Lymphoprep
(Nycomed, Norway) and centrifuged at 2000rpm at room temperature for 20-40 min,
and then peripheral blood mononuclear lymphocytes (PBMC) were collected and
washed in sterile PBS three times (by centrifugation at 1200 rpm, lOmin). The cell
pellets were re-suspended in RPMI medium supplemented with 10% FCS, 2mM L-
glutamine, 2.5mM HEPES, lOOu/ml penicillin and 200|ig/ml streptomycin at a
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concentration of 2-4 x 10 cells/ml. 5 ml of the cell suspension was added to 25cm
tissue culture flasks and incubated at 37°C for 2 hrs before non-adherent cells were
removed, and then the medium was replaced in adherent flasks.
2.2.2: Preparation and purification of proteins
2.2.2.1: Preparation of recombinant p25
2.2.2.1a: Purification of Ty-p25 from yeast
Ty-p25 was purified from yeast by a modification of the method of Reyburn et
al.(1992). Briefly, yeast cells were harvested and washed once in ice-cold sterile
distilled water (SDW). All subsequent procedures were carried out at 4°C using pre¬
cluded buffers. Cell pellets were re-suspended and washed twice in 20 ml of TNE
buffer (lOmM Tris HC1, pH 7.4, 2mM EDTA, 140mM NaCl), and then cell pellets
were re-suspended in 4 ml of TEN, 5 ml acid-washed and baked glass breads were
added and the yeast cells were disrupted by three rounds of vortexing with glass
breads (during which they were vortexed for lOx 30sec., bursts with 30sec., rest on
ice in-between). After each round of vortexing the suspension was centrifuged
(5000rpm, 4°C, lOmin). The supernatant was collected and kept on ice, the pellets
were re-suspended and washed twice in TEN, More than 90% breakage of yeast cells
was achieved. All supernatants were pooled and clarified by centrifugation (10500
rpm, Beckman SW40, 4°C, 20min) and then concentrated onto a 2 ml 60 % sucrose
cushion (30000 rpm, Beckman SW40, 4°C, 20min). Material on the cushion were
collected and dialysed overnight against a 1L of TEN at 4°C. Ty-p25 fusion proteins
were purified from the dialysate by centrifugation (24000 rpm, Beckman SW40, 4°C,
3 hrs) through sucrose gradient (15%, 25%, 35%, 45% sucrose solution). After
centrifugation, the gradient was fractionated into 2 ml aliquots and fractions
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containing Ty-p25 were identified by analysis on SDS-PAGE. The fractions
containing Ty-p25 were pooled and dialysed against several changes of Factor Xa
buffer (lOOmM Tris HC1, pH 7.4, lOmM CaCl2) over 36 hours at 4°C
2.2.2.1b: Purification of p25
The dialysate was made to 0.05% CHAPS (3-[(-cholamidopropyl) dimethyl-
ammonio]-l -propane sulphonate) and 0.05% DOC (deoxycholic acid) and incubated
with restriction protease Factor Xa (BCL) at a ratio of 50:4 at 22°C overnight. An
aliquot of this digest was analysed by SDS-PAGE to check that the digestion was
complete. The suspension was then centrifuged (31000 rpm, 4°C, 1 hr) to pellet the
Ty-VLPs. The supernatant containing p25 was dialysed against two PBS changes at
4°C and stored in aliquots at -70°C. Purity of antigen was assessed by SDS-PAGE.
2.2.2.2: Purification of monoclonal antibody against recombinant p25
McAb IgG from cell supernatant was purified by using a protein G Sepharose 4 fast
flow column (Pharmacia). A 5 ml protein G Sepharose 4 fast flow column was
equilibrated with five bed volumes of 0.02 M sodium phosphate (pH 7.0) at a flow
rate of 60ml/h. The sample was loaded onto the column and the unbound protein was
washed out with the same buffer as above until no protein was detected in the eluant
by UV at 280nm. The bound protein was eluted with 0.1M glycine-HCl (pH 2.7) and
0.5 ml fractions were collected in tubes containing a sufficient amount of 1.0M Tris-
HC1 (pH9.0) (60pl-100pd per ml fraction). The fractions containing protein were
pooled and dialysed into PBS overnight at 4°C. The protein concentration was
measured by UV at 280nm. The column was washed extensively with PBS between
application of each sample and finally was washed and stored in PBS/20% ethanol.
The protein concentration was measured by UV at 280nm and stored in -20°C
2.2.3: Immunoassays
2.2.3.1: Quantitation of MVV Gag p25
Supernatants from cell culture were assessed for MVV Gag p25 by liquid-phrase
blocking enzyme-linked immunosorbent assay (ELISA) as described in appendix.
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Briefly, ELISA plates were coated with purified recombinant p25. Supernatants were
incubated with a pretitrated, known concentration of recombinant p25, and then
added into the coated plates. The plates were developed with anti-mouse IgG-
alkaline phosphatase. Under these conditions, the assay could detect as little as
500pg to lng of MVV p25 per ml. Spectrophotometric readings were converted into
inhibition (%) which were calculated as follows. Inhibition (%) = (OD value of non-
blocking control - OD value of sample)/OD value of non-blocking control.
Inhibition was then converted into ng/ml p25 antigen from a standard curve derived
from serial titration of known quantities of purified recombinant MVV p25.
2.2.3.2: Immunochemistry staining
The single staining technique was used to detect expression of viral protein or cell
surface marker and performed using commercial streptavidin-biotin kit (Vector
Laboratories). Reagents were made up according to the manufacturer's instruction.
Incubation was performed at room temperature and washes were carried out with
PBS for 10 minutes each. Cytocentrifuge preparation were air-dried and re-hydrated
by incubation for 10 minutes in PBS, and then incubated in a solution of 3% H2O2 in
methanol, to inactivate endogenous peroxidase activity. Smears were rinsed and
incubated with normal rabbit serum for 30 minutes to block nonspecific interaction
of antibodies with samples and then incubated with primary McAb antibody
overnight at 4°C. McAb was diluted in PBS containing 1 % normal serum. After
overnight incubation, smears were re-equilibrated to room temperature and washed
three times with PBS. Biotinylated rabbit anti-mouse IgG, diluted in 1% normal
mouse serum /PBS, was then added to cytocentrifuge preparations and incubated for
30 minutes and washed another three times with PBS. The slides were incubated
with horseradish peroxidase-conjugated streptavidin for 30 minutes and washed
again. HRP substrate solution diaminobenzidine (DAB) chromogen, diluted in PLO
according the manufacturer's protocol, was added to the slides and incubated for 5
minutes. The reaction was stopped by washing with tap water. The slides were
slightly counterstained with Mayer's hematoxylin for 5 minutes and dehydrated
through graded concentrations of ethanol and xylene and then mounted.
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Cytocentrifuge smears from seronegative animals and from seropositive animals
previously tested were used as negative and positive control, respectively, to test the
specificity of the staining. Positive cells were counted in cytocentrifuge preparations
in 20 randomly selected high-power (400 x) and the positive cell mean was obtained.
2.2.3.3: Flow cytometry analysis of cells for expression of surface molecules
The code name, specificity, dilution and source of the panel of antibodies used in this
study are summarised in Table 6.1. All of them are mouse McAbs. The cells were
incubated with McAb on ice for 15 minutes in phosphate-buffered saline (PBS),
which was supplemented with 10 % BSA to block non-specific binding of McAb via
FcR. The cells were washed twice in PBS and incubated with FITC-conjugated anti-
mouse IgG (diluted in PBS/10%BSA/0. l%NaN3) on ice for 15 minutes. The cells
were washed as before and re-suspended in PBS/10% BSA/0. l%NaN3 Fluorescence
intensity was analysed on a FACScan Plus (Becton-Dickinson). Scatter
characteristics was used to gate the monocytes and 5000 cells were analysed. Per
sample data was expressed as a percentage of positive cells or the mean fluorescence
intensity after subtraction of the mean fluorescence intensity of the isotype control
(arbitrary units).
2.2.4: Molecular biology
2.2.4.1: Preparation, purification and analysis of nucleic acid
2.2.4.1 a: Extraction of DNA
AM and PBMC were obtained from MVV infected and control sheep. The DNA was
extracted with a Qiagen kit (Qiagen), according to the manufacturer manual. DNA
quality and amount were determined spectrophotometrically and by agarose gel
electrophoresis. The DNA from each sample was co-amplified in the presence of
competitive template DNA to measure quantitatively MVV DNA present in each
sample described subsequently.
2.2.4.1b: Isolation of RNA
Total RNA extraction was done using RNeasy Total Kit (Qiagen) according to
51
manufacture's instruction. Briefly, cell pellets were mixed with 0.6 or 1.2 ml of lysis
buffer RLT (containing guanidinium isothiocyanate, 2-mercaptoethanol). The
mixture was homogenized using a syringe and sequentially added onto the surface of
RN easy spin column and centrifuged at lOOOOrpm for 15 sec. Next, the column was
washed once with wash buffer RW1 and then twice with another wash buffer RPE.
The total RNA was eluted with 20-40 p.1 of diethylpyrocarbonate (DEPC) treated
water by centrifugation (lOOOOrpm, lmin).
2.2.4.1 c: Preparation of plasmid DNA
Plasmid DNA was prepared by using the Qiagen purification method (Qiagen)
following the manufacturer's instruction. Plasmid mini-preps were prepared by using
Qiagen Plasmid Spin kits (Qiagen), starting with 1 ml of bacterial culture grown for a
single colony overnight as described in appendix.
2.2.4. Id: DNA gel electrophoresis
DNA samples were analyzed on a 2% (w/v)/TAE gel containing 1 fig/ml of ethidium
bromide. DNA samples were mixed with loading buffer in a ratio of 1:5 loading
buffer to sample and then loaded onto the gel, followed by running at a constant
voltage of 80 - 100 mV for 1 to 3 hours. DNA in the gels was visualized on a UV
transilluminator. 1 Kb DNA ladder (Gibco) was run alongside the samples.
2.2.4. le: Recovery of DNA from agarose
DNA was run on a 1 % (w/v) low melting point agarose made up in TAE buffer.
DNA in the gel was visualized by UV illiumination and the predicted size of DNA
fragment cut out of the gel. DNA was extracted and purified by using the Geneclean
II kit (BIO 101 Inc.) as described in appendix.
2.2.4. If: Measurement of DNA and RNA concentration
Concentration and purity of DNA and RNA was determined by measuring the
absorbance at 260nm and 280nm in a spectrophotometer. An absorbance of 1 unit at
260nm is equivalent to 50 jug of double stranded DNA per ml or 40 jig of single
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stranded DNA or RNA per ml. Purity of the DNA or RNA was determined by
calculating the ratio between the absorbance values at 260nm and 280nm, where pure
DNA or RNA has a ratio of 1.7-2.0. For small amount of DNA, estimates were taken
by visualising the intensity of the fluorescence under UV illumination compared to
DNA markers of the known concentration.
2.2.4.2: PCR amplification
2.2.4.2a: Reverse transcription of RNA
In the lid of a 1.5 ml reaction tube, 13.5pl of RNA containing sample was added to
the premix, consisting of 4 pi of 5xRT buffer (250mM Tris HC1, pH 8.8, 375mM
KC1), 2pl of 20mM dNTP mix, 1 pi of random hexamers (lu/pl, Pharmacia). The
tube was closed and was then incubated for 3min at 80°C. Subsequently, the tube
was placed on ice and spun down, and lpl (200 units) of Superscript II Reverse
Transcriptase (Life Technologies) was added. This reaction was incubated for 1 hr at
45°C and then heated to 95°C for 5min. Subsequently, the reaction mixture was
placed on ice and then spun down and, finally, diluted by addition of 20 pi of RNase
free water.
2.2.4.2b: Primers
The oligonucleotide primer sequences were chosen from the highly conserved
regions (POL, LTR, GAG) of MVV genome (Table 2.1). Various considerations
were taken when designing primers. Primers were made between 20-25 long and
contained no palindromic sequences to prevent formation of hairpin structures. The
primers were synthesized by Genosys (Genosys Biotechnologies (Europe) Ltd, UK).
2.2.4.2c: PCR amplification
A 3 pi of cDNA or DNA sample was added to 46 pi of the PCR mixture. The PCR
mixture consisted of lOmM Tris HC1 (pH8.3), 50mM KC1, 2.5mM MgCb, 200pm
each 2'-deoxynucleoside 5'-triphosphate, 0.5pM sense primer and 0.5pM anti-sense
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Table 2.1 Oligonucleotide primers used
Primers Orientation Sequences(5' to 3') Product length Position
POL Sense ATAGTAAATGGCATCAAGATGC 217 4231
Anti-sense TCCCGAATTTGTTTCTACCC 4448
Probe CATTGGCAAGTGGATT
LTR Sense GACTGTCAGGGCAGAGAACAG 156/116 8912
Anti-sense GCATCAGCTCATACATGACT 9068
Probe TGCCCATGATTGAGAATGACTATGTA
GAG Sense TAGAGACATGGCGAAGCAAGGCT 461 496
Anti-sense TCCTGCTTGCAAATTTACAATAGG 960
Probe AATGCCCATAGACAGTTCCCTCTG
primer. The reaction mixture was overlaid with 30 ju.1 of light mineral oil and placed
in a thermal, cycler (Perkin-Elmer Cetus). The reaction mixture was initially
denatured at 95°C for 5 min before 1 p.1 (lunit) of Taq DNA polymerase (Gibco) was
added, followed by 35 cycles of reaction parameters: 50s of denaturation at 95°C,
lmin of primer annealing at 55°C, and 2 min of primer extension at 72°C. The final
cycle extension was done at 72°C for 5 min.
2.2.4.2d: Identification of the PCR products
Following amplification, 10pl of the PCR product was analysed on a 2.5 % agarose
gel in Tris acetate EDTA (TAE) buffer using a 1 Kb ladder (Gibco) as a molecular
weight marker. Amplification products were visualised by ethidium bromide.
Samples amplifying at least one of the two bands (either POL or LTR) were
considered positive for MVV RNA (expected size of product on the gel). The
identities of the PCR products were confirmed by hybridisation with MVV specific
probes.
2.2.4.3: Analysis of DNA by blotting and hybridisation
2.2.4.3a: Southern transfer by alkaline method
After the PCR products were separated on electrophoresis gels, the amplified DNA
54
bands were blotted to membrane (GeneScreen Plus, NEN) by capillary action using
alkaline transfer method performed as described in Appendix. The membrane filters
were air-dried.
2.2.4.3b: Probes labelling systems
Probes labelling with digoxigenin
Two ologonucleotide probes were used to identify PCR-amplified MVV POL and
LTR sequences (Table 2). A digoxigenin (DIG)-based labelling and detection system
was employed (Boehringer Mannheim). Probes were 3'-end labelled with DIG-11-
ddUTP using terminal transferase. Briefly, the reaction mixture consisting of 5pl of
TdT buffer, 3 pi of 5 mM CaCl2, 2 pi of lOOmM dATP, 2 pi DIG-ddUTP
(lnmol/pl), 1 pg of probe, 1 pi of TdT (25u/pl) and 24 pi of H20 was incubated at
37°C for 2hrs, diluted by adding 75 pi of H20 and then 1 pi of Glycogen (20mg/ml)
and 200 pi of ethanol were added and placed on ice for 15 min. Next, the reaction
mixture was spun down at 10000 x g for 15 min at 4°C. The pellet was washed with
75% ethanol and then air dried. Finally, the pellet was dissolved in 20 pi of sterile
H20 to give a concentration of 50 ng/pl and stored at -20°C. Pre-hybridisation (in 5x
SSC, 0.1% w/v N-laurylsarcosine, 0.02% SDS and 1% blocking reagent) was carried
out at 65°C for 1 hr and followed by hybridization in pre-hybridization solution with
2pl (50ng/pl) of labelled probe at 65°C for 2 hrs. Bands were visualised by a
colorimetric method according to the DIG Nucleic Acid Detection standard protocol
(BoehrigerMannheim).
Probe labelling with 32P
32Probes were 5'-end labelled with ~P ATP (Amersham) using polynucleotide kinase.
Briefly, the reaction mixture consisting of 2pl of PNK buffer, 1 pi (60-100ng) of
probe, 2 pi 32P ATP (10 pci/pl), 1 pg of probe, and 14 pi of H20, was incubated at
37°C for 30 minutes and stopped by adding 80 pi of TE buffer (pH 8.0). The reaction
mixture was added to the top of a Nick Column (Pharmacia), which was pre-treated
with 1 ml of TE buffer (pH7.4). After washing with 400pl of TE buffer, the
incorporated 32P-probe was eluted with 400pl of TE buffer. The radioactivity
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incorporation was measured. Pre-hybridization was carried out at 65 °C for 1 hr and
followed by hybridization in pre-hybridization solution with labelled probe, 50 pi of
herring sperm DNA (lOmg/ml) overnight at 65°C. Blots were washed twice with 2x
SSC at room temperature and then washed twice at 60°C (15 minutes/each) with 1%
SDS in 2x SSC, followed by washing with O.lx SSC for 15 minutes. After each
wash, the blot was monitored for background. After the final washing, the blots were
wrapped in plastic wrap and exposed to x-ray film (Kodak).
2.2.4.4: Cloning of MVV POL PCR product
2.2.4.4a: Preparation of PCR product for ligation.
PCR product was gel-purified by excising a band of the predicted size from a low
melting agarose gel following electrophoreis and recovered by Geneclean (BIO 101
Inc) as described in appendix. Briefly, lpl Klenow polymerase (2u/pl,
BoehrigerMannheim) was added into PCR product mixture and incubated at 37°C for
15 minutes and then 100 pi of TEB (pH8.0) and 100 pi of chloroform were added
and mixed gently. After centrifugation (13000 rpm, 1 minute), the liquid phrase
containing PCR product was collected. The PCR product was then gel-purified by
running a 1% low melting agarose gel and recovered by Geneclean II kit (BIO 101
Inc.). Concentrations were estimated by electrophoresis of sample dilution on 1 %
agarose gel containing 0.5 pg/ml ethidium bromide.
2.2.4.4b: Ligation of PCR product into pCR-Script™SK(+) cloning vector
PCR-Script™SK(+) cloning vector (Stratagene) was used to clone the PCR product
according to manufacture's instruction. Ligation reactions were set up at molar ratios
approximately 100:1 (Klenow treated PCR product: cloning vector). 10 ng pCR-
Script™ SK(+) cloning vector was used for each reaction. Ligation reactions were
incubated for 2 hours at room temperature and heated to 65°C for 2 minutes. After
cooling on ice, hall of each ligation was used to transform supercompetent E.coli
cells (Stratagene). Transformants were selected by plating onto LB agar containing
Ampicillin (20pg/ml), Methicillin (80 pg/ ml) and X-gal (Appendix). White colonies
were picked and inoculated into a fresh X-gal/Amp./Meth. plate and placed into
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falcons containing 1 ml LB/20|ig/ml Amp./80 |lg/ ml Meth, and then incubated
overnight at 37°C with shaking (250rmp). Plasmid mini-preps were prepared by
using Qiagen Plasmid Spin kits (Qiagen) according to manufacturer's instructions.




MVV VIRAL BURDEN AND REPLICATIVE STATUS IN ALVEOLAR
MACROPHAGES OF SHEEP NATURALLY INFECTED WITH MAEDI-
VISNA VIURS
3.1: Introduction
Maedi-visna virus (MVV), a lentivirus, is a cause of inexorably progressive chronic
inflammatory disorders in infected sheep including a chronic interstitial lung disease
which is similar to that observed in human immunodeficiency virus type 1 (HIV-1)
infection. Thereby, MVV may be considered to be a useful model system for
studying ADDS pathogenesis (Carey and Dalziel 1993). As with lentiviruses of other
species, MVV infection of sheep is persistent despite the continued maintenance of a
strong immune response by the host (Narayan et al. 1982).
It is clear that chronic lymphocytic interstitial pneumonia (LIP) is the main clinical
and pathological feature of MVV infection in sheep (Narayan et al. 1985, Lairmore et
al. 1986, Brodie et al. 1992). It is believed that MVV-infected AM are involved in the
induction of proliferation of lymphocytes in the lung interstitium giving rise to an
abnormal immune response through the secretion of cytokines (Gendelmam et
al. 1985, Narayan and Clements 1989, Woodall et al. 1997). In vitro, MVV has been
shown to infect alveolar macrophages productively. In vivo, MVV replication is
rarely observed. AM bearing MVV capsid protein have been found at the periphery
of the lesions (Brodie et al. 1995) indicating the replication of MVV in AM may be
major factor contributing to chronic inflammatory lesions in maedi (Lujan et
al. 1994). But, the absolute viral load in AM and its correlation with disease onset
and replicative status is poorly understood, although it is undoubtedly important for
understanding the mechanism involved in the disease process.
The purpose of this study therefore was to determine the load of MVV DNA in AM
compared with blood monocytes using quantitative competitive polymerase chain
reaction (QC-PCR). To evaluate the MVV status in AM collected freshly from
naturally infected sheep with or without histopathological evidence of lesions in the
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lung, viral RNA was detected in these AM by RT-PCR and were compared with
those obtained from short-term culture with stimulation by phorbol-12 myristate 13
acetate (TPA). Furthermore, the relationship between virus burden and replicative
status in AM and the histopathology of the lung was assessed. To estimate MVV
burden in infected cells, a QC-PCR was developed to quantify viral nucleic acid in
the cells of naturally infected sheep. This technique involves co-amplifying a fixed
concentration of sample DNA and graded amount of competitive template bearing
the same primer recognition sequences as target DNA but containing an internal
deletion such that its product is distinguishable in size from the target DNA product
after amplification. The validation of the assay was subsequently accomplished using
DNA isolated from AM and peripheral blood mononuclear cells (PBMCs) obtained





Twelve MVV-infected sheep were studied at postmorten. The diagnosis of MVV
infection was assessed by the agar gel immunodiffusion test (AGID) (Cutlip et
al. 1979) and the histopathological status in lung was determined according to
previously established criteria (Lairmore et al. 1986, Brodie et al. 1992, 1995). Three
uninfected sheep were evaluated as negative controls.
3.2.2: Histopathology
Fresh-frozen lung tissues or formalin-fixed, paraffin-embedded lung tissues were
sectioned (5(1) by routine method and examined after haematoxylin and eosin
staining. The distribution of inflammatory lesions in the lung with lymphocytic
interstitial pneumonia (LIP) was uniform throughout the tissue, therefore, section of
the cranioventral left lung lobe was considered to be representative of the entire
lung.
3.2.3: QC-PCR
3.2.3.1: Competitive template construction
A 217 bp cDNA fragment (nucleotides 4448 to 4231, 217bp) of the pol region of
MVV EV1 strain was amplified with a pair of wild-type primers POL4 and POL5
(see Table3.1) and cloned into a pCR-Script™SK(+) cloning vector (Stratagene)
which was designated pPOL2. Using this wild-type fragment from pPOL2,
amplification with a pair of primers POL4 and POL2DII (see Table3.1) yielded a
shortened competitor fragment containing a deleted version of the original pol
sequence (192 bp against 217bp of the full-length template) which can be amplified
by the wild type primers POL4 and POL5. Primer POL2DII contains a sequence
specific for a target sequence within the original POL4 and POL5 amplification
product, which was synthesised on to the 3' end of the original POL5 primer
sequence. POL2DII therefore acted to shift the POL5 sequence into an internal
region of the original pol product, deleting the intervening region and the original
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POL5 target sequence from the 3' end (Fig 3.1). This product was purified with a
Biogene clean kit (BIO 101 Inc) and ligated in a polylinker of a pCR-Script™SK(+)
cloning vector (Stratagene). The recombinant plasmid DNA (designated pAPOL2)
was purified with Qiaprep Spin plasmid kit (Qiagen) and then sequenced and
quantified by spectrophotometric analysis (Fig3.1).
3.2.3.2: Quantitative competitive PCR
In a typical QC-PCR assay, a graded amount of competitive template DNA was
added to 500ng of sample DNA. Each reaction was carried out in a 50 pi volume
containing 1 U of Taq DNA polymerase (Life Technologies), 20mM (each) dNTP,
25 pmol of each primer (POM and POL5) and 50mM KC1 and 2.5 mM MgCU in
lOmM Tris HC1. The reaction was overlaid with 30pl of mineral oil. 50 cycles of
amplification were carried out in a thermal cycler (Techne PHC-1) under the
following conditions: 95°C for 60s, 55°C for 60s and 72°C for 120s. Plasmid pPOL2
containing pol and DNA from tissue of non-infected sheep were included in each
experiment as positive and negative control, respectively.
3.2.3.3: Detection and quantitation of PCR products
A 10 pi volume of PCR product was separated on a 2.5% agarose gel in TAE buffer.
The gel was stained with ethidium bromide and visualised with UV light, then
transferred to a nylon membrane (Genescreen plus™, NEN). The target DNA was
detected by Southern blotting and probed with P labelled internal DNA probe
which was generated by using internal primers (POL8 and POL9). The radiolabeled
hybrids were detected by autoradiography, and the intensity of each specific band
was determined by densitometric analysis (Image Analyser, Millipore, UK). For each
QC-PCR, a standard curve was obtained by plotting the log of the ratio of the
intensity of amplified products (pAPOL2/pPOL2)(y-axis) against the log of the
pAPOL2 known amount added into the reaction (x-axis). The original amount of
MVV pol gene present in the sample was then calculated by interpolating the log of
the ratio of the intensity of PCR products (pAPOL2/sample) into the standard curve.
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Figure 3.1 Synthesis of the deleted competitor (192 bp) from the full-length
template (217 bp)
A 217 bp cDNA fragment (nucleotides 4448 to 4231, 217bp) of the pol region of
MVV EV1 strain was amplified with a pair of wild-type primers POL4 and POL5
and cloned into a pCR-Script™SK(+) cloning vector (Stratagene) which was
designated pPOL2. Using this wild-type fragment from pPOL2, amplification with a
pair of primers POL4 and POL2DII yielded a shortened competitor fragment
containing a deleted version of the original pol sequence (192 bp against 217bp of
the full-length template) which can be amplified by the wild type primers POM and




3.2.4.1: Study of cell morphology and cytochemistry
The preparation of AM is described as in Chapter 2.
I. Cell morphology. Cell morphology was studied by light microscope on Leishman-
stained smears. 200 cells were examined and classified by their morphological
appearance.
II Cytochemistry, a-naphthyl acetate esterase activity was studied on cytocentrifuge
slides and fixed formol vapor and incubated for 30 min in an a-naphthol AS-D
acetate solution (Sigma).
3.2.4.2: Surface marker analysis of alveolar macrophages
The technique described in Chapter 2 and Index was applied using a ABC
immunoperoxidase staining kit (Vector Laboratories). VPM63, a mouse McAbs anti-
ovine CD32, was used to identify AM.
3.2.4.3: In vitro stimulation of AM with TPA
AM collected from six infected sheep with no histopathological evidence of lesions
in the lung were cultured (106/ml) in RPMI 1640 medium, 10% foetal calf serum,
and antibiotics in the presence of lng/ml TPA for 24hrs and harvested. Their
viability was evaluated by trypan blue dye exclusion.
3.2.5: Detection of viral nucleic acid
3.2.5.1: Quantitative detection of MVV DNA by QC-PCR
Quantitative detection of MVV DNA was performed by QC-PCR, as described in
3.2.3.
3.2.5.2: Detection of MVV RNA by RT-PCR
Total cellular RNA was isolated using RNA easy kit (Qiagen). RNA was reverse
transcribed into complementary DNA (cDNA) using Superscript II Reverse
Transcriptase (Life Technologies) and random primers (Pharmacial). After reverse
transcription, PCR was performed using the primers specific for MVV POL. To
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assess the efficiency of RNA extraction and cDNA synthesis, PCR using ATPase
specific-primers was performed as internal control. For each assay, a negative
control containing only sterile water and a positive control were run in parallel. After
PCR, 8 |il of aliquots of the product were electrophoresed on 2.5% agarose gel
stained with ethidium bromide and photographed under ultraviolet light.
3.2.5.3: Southern blotting and hybridisation
Gels were Southern blotted onto Gene Screen plus membrane (NEN) by alkaline
transfer according to the manufacturer's instructions. After capillary transfer,
membranes were UV-cross linked and hybridised at 65°C overnight with specific
32P-labelled probe for ATPase and POL. Membranes were autoradiographed with
Kodak X-OMAT film.
Table 3.1. Oligonucleotide primers used in OC-PCR for MVV
Primers Sequences (5'to 3') No of bases(position)*





• Nucleotide positions are those from the published sequence of MVV EV-1 strain





AM exhibited irregular surfaces, numerous filopodia and pseudopodia characterised
the cell membrane. The cytoplasm was filled with numbers of vacuoles (Fig3.2).
Most AM obtained displayed esterase positive (Fig3.3A) and VPM63 (CD32)
positive reaction (Fig 3.3 B). AM cultured for up to 3 weeks in RPMI/10%FCS were
analysed for cell number and viability. After the second day, cell numbers decreased
gradually (data not shown).
3.3.2: QC-PCR
3.3.2.1: Competitive template construction
The results for construction of DNA competitor are shown Fig.3.4 and 3.5. A
fragment of 217bp from MVV pol was amplified with primer set POL4 and POL5
and cloned into a pCR-ScriptTMSK. The clone, designated pPOL2 was then
amplified with primer POL4 and POL2DII. The expected 192 bp PCR products
appeared as sharp band after get electrophoresis and ethidium bromide staining
(Fig.3.5) and used as DNA competitor after cloning and purification. The PCR
amplification of the competitor with primer set POL4 and POL5 resulted in a 192bp
product which was distinguishable from the 217 bp of PCR-amplified viral pol DNA
product after separation by agarose gel electrophoresis (Fig.3.5).
To compare the efficiency of amplification for the competitive and analysed
templates, the ratio of the two templates over a wide range of cycles was measured
(Fig.3.6). Copy number is calculated as {the amount of DNA/(molecular weight per
base pair x number of base pair DNA)} x 6.023 x 1024. 104 copies of pPOL2 was
mixed with the same copies of competitive template and co-amplified for an
increased number of cycles. Amplification was exponential for both templates after
35 cycle amplification. When both templates were amplified for 50 cycles, both
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Figure 3.2 Light microscope of morphology of AM in cytocentrifuge preparation
from one-day cell culture in RPMI/10%FCS
Leishmen staining (original magnification 800 x)
Figure 3.3 Cytochemistry of alveolar macrophages
A: Esterase activity of AM in cytocentrifuge preparation.
B: VPM63 McAb staining of AM in cytocentrifuge preparation. Streptavidin biotin




MVV POL 4231 atagtaaatggcatcaagatgctcaatcattgcatctagaatttgacataccaagaacag 290
Competitor 1 atagtaaatggcatcaagatgcagtgtcattgcatctggaatttgggataccaagaatgg 60
MVV POL 4291 cggctcaagatatagtgcaacaatgtgaaatatgtcaagaaaataaaatgcctaatacaa 4350
Competitor 61 cagctgaagacatagtgcaacaatgtgaagtatgtcaaggaaataaactacccagcacaa 120
MVV POL 4351 tgagaggaagtaacaagaggggaatagatcattggcaagtggattacactca 4402
Competitor 121 agaggggaagtaataaaagaggaatagatcatgggcaagtggattacactca 172
MVV POL 4429 gggtagaaacaaattcggga 4448
Competitor 173 gggtagaaacaaattcggga 192
Figure 3.4 Sequence of competitive template
Nucleotide positions are those from the published sequence of MVV EV-1 strain
(Sargan et al., 1991). A bold letter is shown where nucleotide is different from the
wild-type template.
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Figure 3.5 Amplification of the competitive template with primer set POL4 and
POL5
Amplification of the competitive template with primer set POL4 and POL5 resulted
in a 192bp product which was distinguishable from the 217 bp of QC-PCR-
amplified viral DNA product after separation by 2% agarose gel electrophoresis.
Lane 1: Wild-type/competitor PCR products
Lane 2: Competitor PCR product
Lane 3: Wild-type PCR products
Figure3.6 The effect of the number of PCR cycles on competitive amplification
A mixture of pPOL2 DNA (104 copies) and competitive template pAPOL2 (104
copies) was co-amplified for varying cycle numbers of PCR, as indicated. The PCR
amplified products were probed with ~P labelled probes. Copy number = {the
amount of DNA/(molecular weight per base pair x number of base pair DNA)} x
6.023 x 1024.
A: 2 % agarose gel stained with ethidium bromide.
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molecules gave approximately the same amount of products when the band intensity
following probing and the autoradiography was analysed by the densitometry (data
not shown), indicating competitive template DNA is amplified with the same
efficiency as wild type template. The optimal QC-PCR cycle was then 50 cycles.
Previously, it had been reported that addition of cellular DNA in each of the PCR
reactions that contained two recombinant templates resulted in a decrease in
amplification efficiency (Boivin et al. 1995). Therefore, when construction standard
curve were made, all plasmids used were amplified in the presence of 500 ng cellular
DNA in order to made the condition close as possible as in vivo condition.
3.3.2.2: Construction of standard curve
To obtain the standard curve, a single concentration of pPOL2 (105 copies) was co-
amplified with a four-fold dilution of a known concentration of competitive template
starting at 3xl06 copies (pAPOL2). There was a progressive competition between the
competitor (192 bp) and MVV cDNA (217 bp). By incorporating various amount of
serially diluted competitor in PCR and measuring the corrected densitometry values,
a standard curve was generated. As showed in Fig.3.7, a representative standard
curve was established by plotting on a graph the logio of ratio of amplified products
(y-axis) against the logioof the number of pAPOL2 copies added into the reaction (x-
axis) (Fig.3.7). A linear relationship was obtained between the log of the ratio of
amplified products (pAPOL2/pPOL2) and the log of the pAPOL2 known copy
numbers added into the reaction over the range of 102 to 3 xlO6 (Fig.3.7C). The
original amount of MVV pol gene present in the sample was then calculated by
interpolating the log of the ratio of PCR products into the standard curve.
The lower limit for competitive quantitation with the assay has been determined as
■y
10" copies per 500 ng of total cellular DNA. Serial dilutions of DNA of plasmid
pPOL2 were made in AM lysates down to the equivalent of 102 /500 ng of total
DNA. The density of the specific band (217 bp) was significantly above the
■y
background level given by negative samples. The 10" copies were set as the lower
limit because it is technically impractical to assay accurately the numerous runs
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required to quantify below the 10 copies in order to take account into the stochastic
partitioning of low amount of DNA in a sample and that control experiment with
known copy number of pPOL2 and varying pAPOL2 fitted a standard curve well. In
order to demonstrate that 102 copies were achieved, the 102 copies were diluted 10-
fold into AM to 101 per 500ng total DNA and run five times in duplicate. The 101
copy per 500ng DNA was found positive 4 times out of 5. Furthermore, in the
positive sample lanes, a 217 bp MVV band was present after 3 hours of
autoradiography, whereas in the negative sample lanes, no MVV band could be
detected even after 24 hours of autoradiography. The amount of MVV pol gene
present in samples which were outside the range of the standard curve were reported
as either < 102 or >3x106 copies per 500ng of DNA.
3.3.2.3: Reproducibility of the QC-PCR
As shown in Fig.3.8, when the same preparation of standard DNA was run on
different days, the slopes of the linear standard curves of three separate and
consecutive experiments were equivalent (correlation of SCI and SC2 = 0.996,
correlation of SC2 and SC3 = 0.993, correlation of SCI and SC3= 0.999). This
reproducibility in the slopes of standard curve is an important factor to achieve
accurate quantification. Furthermore, the intra-assay variability of the procedure is
low as shown by the high reproducibility of the duplicate samples (Table 3.2).
3.3 3: Viral burden in alveolar macrophages of sheep naturally infected with
MVV
3.3.3.1: Serology and histopathology
All of 12 infected sheep studied had serum antibodies against the MVV by AGED
test. Of seropositive animals, 6 of 12 animals had histopathological evidence of
lymphoid interstitial proliferation in the lung (Fig.3.9A, B). 6 of 12 animals and 3
seronegative controls had no histopatholoical evidence of lymphocytic interstitial
pneumonia or opportunistic infection in the lung (Fig.3.9C).
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Figure 3.7 Construction of a standard curve
A: 2 % agarose gel stained with ethidium bromide.
Lanes 1-2: DNA positive control obtained from plasmids pPOL2 and pAPOL2
respectively.
Lanes 3-9: Four-fold dilution (starting at 3xl06) of competitive template respectively
(192-bp band) co-amplified with 10s of wild-type template (217-bp band).
B: Corresponding autoradiogram. Probed with 32P labelled probe.
C: Construction of a standard curve following densitometric analysis of specific
band on the autoradiogram shown in B.
Copy number = (the amount of DNA/(molecular weight per base pair x number of
base pair DNA)} x 6.023 x 1024.
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Fig.3.7
Table 3.2 Intra-assav variability
Sample Nos. 1 2 3 4 Mean SD
A188 0.985 0.605 0.720 1.120 0.875 0.236
A115 3.451 2.620 4.149 3.80 3.510 0.655
A011 3.400 1.921 2.330 2.750 2.725 0.63
A006 1.507 1.477 1.430 1.690 1.517 0.266
A163 <0.041 <0.041 <0.041 <0.041 <0.041
Five samples were run four times with different labelled probes and standard DNA.
The means were calculated on five samples. The samples A163 had amount of viral
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Figure 3.8 Three different Standard curves (SC) from three consecutive experiments
were graphed together
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Figure 3.9 Histologic sections of the cranioventral left lung lobe from sheep
naturally infected with MVV
Typical histological lesions of lymphoid interstitial pneumonia in a sheep naturally
infected with MVV.
A: interstitial fibromuscular proliferation.
B: follicular proliferation.
C: histologic section of lung without histopathological evidence of lesions (hema¬
toxylin and eosin stain, original magnification 800x).
73
Fig.3.9
3.3.3.2: Virus load in AM and monocytes from lung and blood
3.3.3.2a: Detection of viral DNA
To assess whether viral DNA is detectable in AM and monocytes isolated from
infected sheep with or without histopathological lesions in the lung, amplification of
MVV DNA was performed using a pair of primers that corresponds to a conserved
region of MVV POL gene. MVV DNA was detected in 12 out of 12 samples in AM,
in 11 out of 12 sample in blood monocytes collected from sheep naturally infected
with MVV with or without histopathological lesions in the lung. No viral DNA was
detected in AM from two MVV seronegative and one SPF lambs. Representative
analysis of amplified pol sequences by PCR is shown in Fig.3.10.
3.3.3.2b: Virus burden in AM and blood monocytes
Viral DNA load in AM and PBM was assessed by QC-PCR. A representative animal
sample is shown in Fig 3 11. Virus DNA was detected in AM from all animals (n=9)
with a median copy 319430 per 500ng cellular DNA (range from <1195 to
1032600). In PBM, infected animals (n=9) with median 36195 per 500ng cellular
DNA, range from 1195 to 11956). Over the range of results obtained (102 to 106
copies per 500ng), the QC-PCR has an intra-assay variability 23% and interassay
variability of 48%. The MVV DNA copy number per 500ng cellular DNA was
higher in AM than PBM (Fig 3.12A). There is significant difference in viral DNA
load between AM and PBM when the animals were compared overall (P<0 05,
Mann-Whitney nonparametric statistics). Since the complexity of the diploid sheep
genome is 3.0x109 bp, one cell contains approx.3pg DNA, therefore, 500ng of DNA
could represent 160,000 cells.
3.3.3.2c: The levels of viral DNA load in AM was compared to the histological
lesions in lung
To determine whether viral load changes differed in relation to the histological
lesions in the lungs, twelve sheep naturally infected with MVV were divided into
two groups according to histologic findings in the lungs. The viral DNA load in AM
from both
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Figure 3.10 Representative analysis of amplified pol sequences by PCR
Cells were isolated as described in Material and Methods. Cell lysates were analysed
by PCR. The nitrocellulose filter was hybridised with 32P labelled internal probe.
Lane 1: Positive control (DNA from plasmid containing pol sequences).
Lane2: Negative control (DNA from uninfected sheep).
Lane 3 through5: DNA from AM of MVV infected sheep with lesions in the lung.
Lanes 6and 7: DNA from AM of MVV infected sheep without lesions in the lung.
Figure 3.11 Representative quantitative analysis of viral DNA from AM by QC-
PCR
AM were isolated as described in Material and Methods. Cell lysates were analysed
by QC-PCR. 2xl06 cell equivalents were used in each reaction. PCR products were
separated in 2% agarose and detected by Southern hybridisation.
A: AM obtained from MVV infected sheep with lesions in the lung.
B: AM obtained from MVV infected sheep without histological lesions in the lung.
Lanel: 500ng of sample DNA.
Lane 2: pAPOL2 control.









Figure 3.12 Virus load in AM and peripheral blood monocytes
A: Quantification of MVV pol DNA copy number in AM and PBMC from MVV-
infected sheep.
Paired results of pol DNA copy number per 500 ng cellular DNA of alveolar
macrophages (AM) and peripheral blood monocytes (PBM) from each animal.
Horizontal bars indicate median copy number. Since the complexity of the diploid
sheep genome is 3.0x109 bp, one cell contains approx.3pg DNA, therefore, 500ng of
DNA could represent 160000 cells. There is significant difference in viral load
between two groups (P<0.05, Mann-Whitney nonparametric statistics).
B: Quantification of MVV pol DNA copy number in AM from MVV-infected
sheep.
Paired results of pol DNA copy number per 500 ng cellular DNA of AM obtained
from MVV-infected sheep either with (n=6) or without (n=6) pulmonary lesions
associated with MMV infection. Horizontal bars indicate median copy number.




group animals is recorded in Fig.3.12B. Among these MVV infected animals used in
the experiment, lung lesions were observed in the cases showing higher level of viral
DNA load in AM whereas no lung lesions were noted in the cases showing lower
level of viral DNA load in AM. As shown in Fig.3.12B, in AM of animals with
histopathological lesions in the lung the median MVV DNA load was 620120 per
500ng cellular DNA (range 38293 to 103260). Conversely, in AM of animals
without histopathological lesions in the lung the median MVV DNA load was 65755
per 500ng cellular DNA (range <1195 to 25594). There is significant difference in
viral load between two groups (P<0.05, Mann-Whitney nonparametric statistics).
3.3.4: Relationship between virus replicative status in AM and histopathology
of the lung
To determine the relationship between MVV replicative status and the histological
lesions in the lungs, nine sheep naturally infected with MVV were divided into two
groups according to histologic findings in the lungs. To detect viral RNA in AM,
RT-PCR was performed using a primer corresponding to a conserved region of pol
gene. PCR products were hybridised with 32P-labeled internal probes. To assess the
efficiency of RNA extraction and cDNA synthesis, PCR using ATPase specific-
primers was performed as internal control. The procedure was performed twice to
test the reproducibility of the assay.
3.3.4.1: Detection of MVV RNA in AM by RT-PCR
To detect viral RNA in AM, amplification of MVV cDNA was performed using a
pair of primers that corresponds to a conserved region of POL gene. MVV RNA
sequences were detected in 6 of 6 AM samples collected from MVV-infected sheep
with histopathological lesions in the lung. Representative analysis of amplified pol
sequences by RT-PCR. is shown in Fig.3.13. In contrast, viral RNA was not detected
in fresh AM collected from three sheep naturally infected with MVV without
histopathological lesions, and no samples from two MVV seronegative sheep and
one SPF lambs. Therefore, it can be considered that MVV is not in active replication
in AM from lungs without histological evidence of lesions, indicating that detectable
viral replication is a factor in the progression of lymphocytic interstitial pneumonia.
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Interestingly, it was found that MVV RNA was undetectable in AM freshly isolated
from infected sheep without lung histological lesions whereas viral RNA could be
detected in lymph node and spleen from the same animals. Fig. 3.14 and 3.15 show
the results of amplification of viral RNA from AM and lymphoid node chorio-
mediastinal lymph node (CMLN) of two naturally infected animals without
histopathological lesions in the lung using pol primers, respectively. MVV RNA is
undetectable in AM from the lung without histopathological lesions but detectable in
lymphoid nodes (Fig.3.14). Results were similar when another primer pair
gagl/gag2, which amplifies a conserved region of the gag gene, was used (Fig.3.15).
These findings indicate that lymphoid tissue is important reservoir of virus in MVV
infection. Results in spleen were similar to lymph nodes when primer pair pol used
(Fig.3.16).
3.3.4.2: In vitro stimulation of AM
To determine whether MVV RNA could become detectable in AM isolated from
sheep without histological lesion in the lung, AM were cultured in vitro with
stimulation with TPA (RNA expression stimulator). Initially various concentrations
of TPA were investigated to optimise the stimulating effect on viral RNA
expression. After removal of non-adherent cells from PBMC preparations, the
adherent cells (monocytes) were treated with TPA at four different concentrations,
cultured at 37°C for 48 hrs and then analysed by RT-PCR using pol and LTR
primers. Results presented in Fig.3.17 indicated that TPA at a concentration of
lng/ml or more appeared to be very effective in stimulating viral RNA expression in
adherent cells. Verification of identity was initially made by radioactive Southern
blotting using a POL probe. With respect to TPA cytotoxicity, TPA at a
concentration of lng/ml was chosen for use through the experiment. To determine
the minimum time required for effective stimulation, adherent cells, derived from
PBMC from MVV infected sheep were treated separately with TPA at a
concentration of lng/ml for different times during period from 0 to 72 hrs. Results
shown in Fig 3.18 indicated that a minimum of 48 hrs of treatment with TPA is
enough to stimulate viral DNA expression in adherent cells to a much greater extent.
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In TPA treated cells, viral RNA was expressed at a more rapid rate and higher level
that in non-treated cells on the basis of electrophoretic band density on gels stained
by ethidium bromide.
AM were then cultured in vitro with stimulation with TPA (1 ng/ml) for 48 hour and
immunocytochemistry using anti-p25 McAb and RT-PCR using POL primers were
performed on AM before and after stimulation with TPA to identify MVV
replication. The results are shown in Fig3.19 and Fig3.20, before culture and
stimulation with TPA, viral p25 antigens and RNA were not detected. However,
after short-term culture of these AM and in vitro stimulation with TPA, Viral RNA
became detectable in these AM and p25 positive cells were found. These results
show TPA stimulation activated MVV RNA expression in AM from sheep without
lung lesions indicating MVV is latent in these AM but replicates after in vitro
stimulation.
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Figure 3.13 Representative analysis of amplified pol sequences in freshly isolated




Lane 1: Positive control.
Lane 2: Negative control.
Lanes 3 -4: AM obtained from MVV infected sheep with lung lesions.
Lanes 5-6: AM obtained from MVV infected sheep without lung lesions.
Figure 3.14 The results of amplification of viral RNA from AM and lymph node
(CMLN) of two naturally infected animals without histopathological lesions in the
lung using POL primers and ATPase primers in the same tube
Lane 1: positive control.
Lanes 2 and 3: lymph nodes.
Lanes 4 and 5: AM.
Lane 6: negative control.





Figure 3.15 The results of amplification of viral RNA from AM and lymphoid node
(CMLN) of two naturally infected animals without histopathological lesions in the
lung using gag primers
Lane 1: positive control.
Lanes 2 and 3: lymphoid nodes.
Lanes 4 and 5: AM.
Lane 6: negative control.
Lane 7: lkb ladder marker.
Figure 3.16 The results of amplification of viral RNA from AM and spleen of two
naturally infected animals without histopathological lesions in the lung using POL
primers and ATPase primers
Lanes 1 and 2: spleen.
Lanes 3 and 4: AM.
N: negative control.
P: positive control.
MW: lkb ladder marker
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Fig.3.15
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Fig.3.16
Figure 3.17 Establishment of a minimum concentration of TPA giving the greatest
stimulating effect on viral RNA expression in adherent cells
Blood monocytes isolated from MVV-infected sheep were exposed to TPA at
concentration of 100, 10, 1, O.lng/ml on the day 0 (day of isolation) harvested at 48
hours after infection. Lysates were analysed by RT-PCR with primers LTR (which
amplifies a 156/116 bp region of LTR), and pol (which amplifies 217 bp region of
pol) lxlO6 cells were used in each reaction. PCR products were separated in 2%
agarose and stained with ethidium bromide.
A: POL primers. B: LTR primers.
Lanes 1: lkb DNA ladder.
Lane 2: Purified MVV DNA.
Lane 3: negative control.
Lanes 4-7: 100, 10, 1, O.lng/ml of TPA, respectively.
Lane 8: non-TPA treated cells.
Figure 3.18 Comparison of treatment time with TPA
Blood monocytes isolated from MVV-infected sheep were incubated with TPA at
concentration of lng/ml and harvested at 0, 24, 48 and 72 hours after incubation
with TPA. Lysates were analysed by RT-PCR with primers pol (which amplifies 217
bp region of pol). lxl06 cell were used in each reaction. PCR products were
separated in 2% agarose and stained with ethidium bromide.
A: POL primers. B :ATPase primers:
Lanes 1: lkb DNA ladder,
Lane 2: purified MVV DNA,
Lane 3: negative control,






Figure 3.19 Representative analysis of induction of MVV replication in AM from
infected sheep without histological lesions in the lung. Probed with 32P labelled
internal probe
A: Detection of MVV pol gene by RT-PCR.
B: ATPase
Lanes 1, 3, 5: AM treated with TPA (1 ng/ml).
Lane 2, 4, 6: freshly isolated AM.
Lane 7: Negative.
Lane 8: Positive control.
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Fig.3.19
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Figure 3.20 Evaluation of p25 production in AM by immunochemistry staining
using ABC complex method
A: before culture and stimulation with TPA, viral p25 antigens were not detected.
(Original magnification x 200 hematoxylin counterstain).
B: after short-term culture of these AM and in vitro stimulation with TPA (1 ng/ml),





3.4.1: Quantitative competitive PCR
In this study, QC-PCR was developed for the amplification and quantification of
MVV pol sequence in macrophages. The strategy for generation of the competitor
construct was based of the exponential nature of PCR amplification small change in
overall efficiency may be reflected in dramatic changes in the yield of PCR product
which makes inter-sample comparison and quantification unreliable. It has been
described that equal amplification efficiency required the competitive template to
share the same primer recognition site as the target sequences to be quantified, have
similar internal sequence and similar size, if the diversity in both templates length is
higher that 15% (Clementi et al. 1994), significant differences in amplification
efficiencies would occur. For this reason, internal deletion has to be reduced to the
minimum necessary for obtaining discrete bands by gel electrophoresis. Based on
this general concept, The QC-PCR developed here uses an internal standard DNA
bearing a 25 bp internal deletion (11.5% diversity in length) which is derived from a
conserved region pol of MVV The competitor template amplicans can be readily
distinguished from that of wild-type template by gel electrophoresis. The two
different templates were co-amplified in the same reaction mixture, competing for
the same primers. The result shows that the internal standard DNA template was
amplified with the nearly same efficiency as that of wild-type template when both
the wild-type and competitive templates were co-amplified in the same reaction
mixture, competing for the same primers. The relative ratio between competitor
product and wild-type template product remains constant throughout amplification.
The viral load in samples can be calculated by determining the initial concentration
of the competitive template. When the QC-PCR developed was used to quantify
viral DNA load in AM and PBM obtained from MVV serological-positive sheep, it
was found to be reproducible and sensitive over range of 102 to 105 copies per 500ng
of DNA. Within these limits, the intra-assay and inter-assay variabilities found to
low which is sufficient to discriminate low, intermediate, and high values. Taken
together, the QC-PCR described here allows not only the verification of the presence
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of MVV, but also provides information about precise quantification of MVV DNA
in infected hosts. This assay will be useful in studying the pathogenesis of MVV
infection, and monitoring the dynamics of MVV replication in vivo at the molecular
level.
3.4.2: Viral burden and replicative status in alveolar macrophages of sheep
naturally infected with MVV
The load of MVV in AM and PBM and virus replicative status in AM from MVV
infected sheep was examined. The level of viral load in AM from sheep with lung
lesions associated with MVV infection was higher than that from sheep without lung
lesions as determined by QC-PCR. Therefore the absolute viral load in AM may
reflect the pathologic manifestation in the lung. In this study, the PCR used detects
all replicate competents of the virus and dose not distinguish between replicate-
competent (integrated) and unintegrated viral DNA. The latter may be present in the
cytoplasm of infected cells and may constitute a labile inducible reservoir
(Bukrinsky et al 1991). As suggested by Bukrinsky et al (1991), most of the viral
DNA detected by PCR is likely to unintegrated reservoir. Therefore the viral load
detected in this study can not directly reflect the frequency of latently infected AM.
It is clear that integration of MVV DNA is necessary for productive infection (List et
al. 1997).
The results in this study showed that increased level of viral DNA correlated with
the ability to amplify viral RNA by RT-PCR and lung lesions. In this study using
RT-PCR, viral RNA was found in freshly isolated AM from sheep with histological
lesions in the lung, In contrast no viral RNA was detected in freshly isolated AM
from infected sheep without lung lesions, but after in vitro stimulation, MVV RNA
was observed in these AM (Fig.3.13 and 3.14). These results may explain the
reasons why no viral antigens p25 could be detected in AM (Fig3.20). Therefore, it
can be considered that MVV is not in active replication in AM in vivo, collected
from infected sheep without histological evidence of lesions in the lung. AM are
latently infected by MVV in vivo, and at resting conditions are not a site for viral
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replication, therefore AM may act ac a latent reservoir for the virus. This leads to
hypothesis that MVV may reside within AM in a latent state or restricted replication
as a provirus integrated within host genomic DNA and the replication of MVV in
AM in vivo may require factors which are able to activate viral replication. This
could be related to still unknown mechanisms that inhibit replication of MVV in AM
in vivo and can be removed after in vitro incubation. It has been shown that any
differentiation stimuli can regulate viral replication and control of viral persistence
in macrophages (O'Brien et al. 1994) and that cellular factors influence
permissiveness of macrophages to productive infection (Gendelman et al. 1990c) and
underscore differences between macrophages. Of these factors, cytokines produced
during host immune response to viral infection particular merits consideration. For
example, in the case of HIV, low level of interferons or other negative regulatory
factors may be induced in response to HIV infection in monocytes (Gessani et al.
1991). In vitro systems in which HIV-1 infected macrophages are maintained in
culture and exposed to different stimuli have demonstrated that HIV-1 re-enters the
replicative cycle after exposure of infected cells to a number of cytokines including
IL-1, IL-6, GM-CSF (for review, see Chapter 1). As a result, cytokines may have a
similar crucial role, at least in part, in controlling MVV replication in infected cells.
However, no clear explanations can be forwarded for the difference in the viral
replicative status in macrophages in this compared with previous studies. The
comprehension of the regulatory network between MVV and cytokines represents a
basic question that awaits elucidation.
In this study, when detection of viral RNA was compared in AM, spleen and CMLN
obtained from animals without evidence of pulmonary lesions in lung using RT-
PCR, it was found that viral RNA was undetectable in AM but detected in spleen
and lymph nodes. Thus MVV appears to actively replicate in lymphoid tissue but not
in lung although activatable virus is present in lung. The difference may be due to
the cell type being infected in these tissues or by the presence of local factors such as
cytokines which exert a profound effect on MVV replication. In the lymphoid organs
throughout the body, target cells together (with immune complex formation by
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accessory cells) constitute the ideal milieu for active viral replication This finding
promotes a consideration that lymphoid tissues may be efficient reservoirs of MVV
and a site for viral replication, where target cells may be infected by MVV and
transmitted to other tissues such as lung of the body. The localised infected target
cells may results in local release various cytokines and other factors which may in
turn recruit mononuclear cells including infected target cells into the inflammatory
area. This dissociation between the viral detection in AM and in lymphoid tissue
emphasises the importance of analysing both compartments when efficiency of any
anti-lentivirus drug is tested.
In this study, the level of viral DNA load in AM from infected sheep was found to be
higher than in PBM, suggesting that AM may be more permissive for MVV
replication than PBM. The previous study demonstrated an increased susceptibility
of in vitro differentiated monocyte to infection with MVV in vitro compared with
that of freshly isolated monocytes (Gorrell et al. 1982, Narayan et al. 1988). Thus,
The increased level of MVV in AM compared with that in monocytes from MVV
infected sheep with lung lesions also may reflect an inherent increased susceptibility
to infection. The mechanism by which differentiated macrophages are more
susceptible to productive infection with MVV in vivo and in vitro is not known.
AM from MVV infected sheep without lung lesions harbour low level of viral DNA.
As suggested by Schnittman et al (1990) using PCR virus production per cell
remains stable while the number of infected cells increase with disease progression.
Thus the low level of viral load may be a reflection of low number of infected AM in
MVV infected sheep without lung lesions. Because of the low proportion of MVV-
infected AM in the lung (in early stage of disease), it is unlikely that chronic active
inflammatory changes with lymphocyte infiltration and proliferation in lung
(Lairmore et al. 1986, 1988b, Watt et al. 1994) are directly related to viral infection
of the cells. It is thought that lentivirus infection results in local release various
cytokines and other factors which may in turn recruit mononuclear cells into the
inflammatory area, thus providing the increased number of susceptible cells for viral
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replication (Lairmore et al. 1986, Zink et al. 1990). The result of this study indicates
that the viral DNA burdens in AM correlated with lung lesions of disease provides
support for such mechanisms.
In conclusion, there was a significantly higher amount of MVV DNA and detectable
viral RNA in AM from sheep with histopathological lesions in the lung compared to
DNA levels and lack of detectable viral RNA in AM from sheep without
histopathological lesions, suggesting that the level of MVV DNA and its replication
status in AM from MVV infected sheep was correlated with histopathological
lesions in the lung. In AM from sheep without histopathological lesions in the lung,




ANALYSIS OF CYTOKINE mRNA EXPRESSION IN MACROPHAGES
INFECTED WITH MVV IN VIVO AND IN VITRO
4.1: Introduction
MVV causes persistent infection in macrophages of sheep, which leads to
mononuclear infiltration of various tissues. The precise mechanisms by which MVV
causes damage are largely unknown, but dysregulation of expression of cytokines
has been postulated as a possible mechanism of maintaining or exacerbating
inflammation (Lechner et al. 1996, Woodall et al. 1997). Early studies showed that
cytokines are likely to be present in complicated lentiviral pneumonia in sheep (Ellis
et al. 1991), modulating MVV replication in AM (Ellis et al. 1994). A recent study
extended these observations, showing that IFN-y, IL-10, IL-1 (3, IL-4, IL-2 receptor
mRNA was upregulated in lung tissue of MVV-infected sheep with lung lesions
(Woodall et al. 1997). In particular, hyper-elevation of GM-CSF mRNA was found
in lung tissue of MVV infected sheep with lung lesions (Woodall et al. 1997). TNF-
a and TGF-(3 mRNA levels were similar to the lung tissue without lung lesions.
These observations provide support for the concept that the viral infection results in
the local release of various cytokines and other factors which may in turn recruit
mononuclear cells into the inflammatory area, thus providing the increased number
of susceptible cells for viral replication or modulate the viral replication (Lairmore et
al. 1986, Zink et al. 1990). However, the type of cell (s) responsible for this
dysregulation of expression of cytokines by MVV remains unknown. Furthermore,
as demonstrated in Chapter 3, AM from MVV infected sheep without lung lesions
harbour low level of viral DNA and the number of infected AM is low (Brodie et al.
1992). Therefore, it is unclear whether the low proportion of infected cells
contributes to the dysregulation of cytokine expression observed in infected sheep
(Woodall et al. 1997). In this context, the expression of cytokine genes was
investigated in macrophages infected with MVV in vitro and in vivo. In vitro the





4.2.1: Detection of cytokines mRNA by relative RT-PCR
4.2.1.1: Cytokine primers
PCR primers (Table 4.1) were designed from published ovine sequences and
synthesised by "Genosys" (Cambridge, England): ATPase (Shull et al. 1985), IL-4
(Seow et al. 1993), IL-10 (Dutia et al. 1994), TNF-a (Woodall et al. 1997), GM-
CSF (Mclnnes and Haig et al. 1991), EL-6 (Ebrahimi et al. 1995), MHC class II DQa
and MHC class H DRa (Ballingall et al. 1992, Wright et al. 1994), TGF-(3 (Woodall
et al. 1994b).
4.2.1.2: Semi-quantatition of cytokine mRNA by RT-PCR
RNA extraction and cDNA synthesis were performed as described in Chapter 2.
Diluted RT reaction mixture (3 pi) was used as a template in PCR. PCR was
performed in 50 pi PCR reaction mixture as described in Chapter 2 with the two
different pairs of primers in the same tube. One pair of primers was ATPase and the
other for cytokine analysis. The optimal number of PCR cycles was determined by a
variable numbers of cycles to identify a linear range of amplification (i.e. to produce
sub-saturation levels of PCR products) for each transcript. EL-6 was amplified for 32
cycles, IL-10 for 30 cycles, TNF-a for 30 cycles, TGF-p for 32 cycles and GM-CSF
for 29 cycles. Eight microliters of amplification mixtures were separated by agarose
gel electrophoresis. The PCR products were transferred to nylon membrane
(Genescreen plus™, NEN research products, Boston, MA), and probed with 32P-5-
end-labeled probes. Bands were visualised by autoradiography, and band density
quantified by densitometry (Image Analyser, Millipore, UK). Results were presented
as the ratio of the signal from each cytokine mRNA to the signal obtained from
ATPase mRNA. A plasmid containing each cytokine (generous gift of Dr C.
Woodall, Edinburgh University, UK) was used as an internal standard for each
cytokine. All samples were measured for each cytokine in the same batch and all the
cytokine amplification was performed on the same cDNA synthesis.
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Table 4.1 Sequences of PCR primers used to amplify cDNAs of cytokines and
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4.3.1: Standardisation and evaluation of RT-PCR for detection of transcripts of
cytokines
To control the quality of each RNA preparation, cDNA preparation and PCR
procedures, the RT-PCR was performed with primers specific for ATPase sequences
which yield an amplification product of 167 base pairs (bp). The expected band
representing ATPase sequences were obtained from all the samples evaluated. This
approach allowed relative amounts of cytokine mRNA to be estimated using the
ATPase signal as standard. The quantity of the total RNA for cytokine testing was
first evaluated using ATPase and normalised to produce equivalent amounts of PCR
products as ATPase (Fig.4.1). All samples were checked in the same test run for
each cytokine. To examine further the reproducibility of the assay, RT-PCR testing
for TGF-P mRNA and TNF-a mRNA were repeated from LPS-stimulated MDMs
on three different days. The ratio of TGF-p mRNA to ATPase mRNA was 0.78 ±
0.20 and the ratio of TNF-a mRNA to ATPase mRNA was 0.59 ± 0.19.
4.3.2: Cytokine gene expression by AM and blood monocytes from MVV-
infected sheep
Cytokine transcription patterns in AM and PBM from MVV-infected sheep were
investigated. As shown in Fig 4.2. an increase in expression of EL-6, IL-10, GM-CSF
and TGF-P mRNA was observed in AM isolated from naturally infected animal
(n=12) with or without histological lesions of maedi in their lungs when compared
with that in seronegative controls. In PBM isolated from MVV-infected sheep (n=6)
the expression of IL-6 and IL-10 mRNA was noticed and an increased expression of
TGF-P and GM-CSF levels was observed when compared with these of control
animals (Fig.4.3).
In addition to the result in both AM and PBM, choriomediastinal lymph node,
(CMLNs) of MVV-infected sheep (n=6) contained higher level of EL-6, and IL-10
mRNA when compared with those in seronegative controls (n=3, Fig.4.4).
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Figure 4.1 Detection of the housekeeping gene ATPase mRNA by RT-PCR
PCR products were separated in a 2.0% agarose gel and visualised by ethidium
bromide staining (B) and probed with 32P-labelled probe (A). RNA was isolated
from alveolar macrophages (AM), monocyte/macrophages (M) from blood and







IL-10 IL-6 GM-CSF TGF-beta
■ Seropositive
□ Seronegative
Figure 4.2 Cytokine mRNA level changes in AM in MVV infection
AM were isolated from naturally MVV-infeeted sheep (n=12) and control animals
(n=3). Cytokine mRNA was determined by RT-PCR assay. IL-6 was amplified for 32
cycles, IL-10 for 30 cycles, TGF-{3 for 32 cycles, GM-CSF for 29 cycles. Results are
expressed as the mean ± SD. Standard deviations are represented by error bars.
There are significant differences between results with MVV-infected cells and those
with uninfected cells (P < 0.05, Mann-Whitney nonparametric statistics).
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Figure 4.3 The expression of mRNA for IL-6, IL-10, TGF-B and GM-CSF in blood
Monocytes
Blood monocytes were isolated from naturally MVV-infected sheep and control
animals and cytokines mRNA was determined by reverse RT-PCR assay and probed
with 32P-labelled probe. IL-6 was amplified for 32 cycles, IL-10 for 30 cycles, TGF(3
for 32 cycles and GM-CSF for 29 cycles.
Lane 1: a seronegative animal.
Lanes 2, 3, 4: seropositive animals.
Figure 4.4 mRNA levels of IL-2, IL-6, IL-10, IFN-y and GM-CSF from lymph
nodes (LNs)
LNs were collected from naturally MVV-infected sheep and control animals.
Cytokine mRNA was determined by RT-PCR assay (left) and Southern blot (right).
IL-6 was amplified for 32cycles, IL-10 for 30 cycles, TGF(3 for 32 cycles and GM-
CSF for 29 cycles.
Lanes 1, 2, 3: seropositive animals:










The mRNA levels of GM-CSF showed no significant change in this small group.
IFN-y mRNAs were undetectable in both MVV-infected sheep groups and
seronegative controls.
4.3.2.1: Correlation of cytokine mRNA expression to the severity of the
histological lung lesions
The above results show that infection of AM with MVV results in alteration of
cytokines. To determine whether cytokine mRNA level changed in relation to the
severity of histological lesions in the lungs, a retrospective analysis of the quantity of
cytokines mRNA in relation to the severity of the histological lung lesions was
performed. Twelve MVV seropositive sheep were divided into two groups according
to histological score in the lung (Table 4.2) and were tested.
Table 4.2 Pathological findings in sheep with and without lung lesions
Mean Mean Mean Mean Median
Sero status IR score SMH score FH score lesion score Viral load*
Group A
6.5x 105(n = 6) + 2.4±0.34 1.8±0.41 27.5± 10.4 32.5± 10.8
Group B
0.6 xlO5(n = 6) + 0.5±0.09 0.20±0.05 0.00 0.5±0.07
Group A = seropositive sheep with chronic lymphocytic interstitial pneumonia. Group B =
seropositive sheep without chronic lymphocytic interstitial pneumonia. IR = interstitial reaction, SMH
= smooth-muscle hyperplasia, FH = follicular hyperplasia. The severity of histological lesions in lung
were measured by grading three parameters: IR, SMH, FH according to previously established criteria
(Brodie et al. 1992, 1995, Woodall et al. 1997). IR was defined by the thickening and cellular
infiltration of interalveolar septae with lymphocytes (Woodall et«/. 1997). The degree of IR and SMH
observed in sections from each animal was classified using the following scales: 0 = none, + = slight,
++ = moderate, and +++ = severe. A score was given to each category of lesion: 0 = 0, + = 1, ++ = 2,
+++ = 3 and to each intermediate category: 0/+ = 0.5, +/++ = 1.5. ++/+++ = 2.5. The FH was
evaluated by counting the number of lymphoid follicles in the sections and determining the number of
follicles per cm2 of tissue section. The mean surface studied for each animal was 10.2 cm2. A more
detailed description of this process is described elsewhere (Watt et al. 1992, Woodall et al. 1997).
*Viral load is expressed as copy numbers per 500 ng cellular DNA
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The mRNA levels of IL-6, IL-10, TNF-a, TGF-p and GM-CSF in AM of both
groups are shown in Fig 4.5. The most striking differences between group A (with
lung lesion) and group B (without lung lesions) were found for GM-CSF mRNA. In
group A, high levels (0.52 ± 0.48) and group B low level (0.12 ± 0.39, p< 0.05) were
determined (Fig.4.5). IL-10 and IL-6 mRNA expression were detected at similar
levels in AM of both groups. Expression of TNF-a and TGF-P mRNA in AM
showed no significant differences among both groups (Fig.4.5). The mRNA levels of
IL-6, IL-10, TNF-a, TGF-p and GM-CSF in PBM of both groups showed no
significant differences (Fig.4.5, P<0.05).
As demonstrated in Chapter 3, the level of MVV DNA and its replication status in
AM from MVV infected sheep was correlated with histological lesions in the lung.
However, the expression of IL-6, IL-10, TGF-P and TNF-a mRNA in AM showed
no significant correlation to viral DNA load and viral RNA expression. The level of
GM-CSF mRNA was correlated with the level of viral DNA. The association is
particularly evident in some animals with high levels of GM-CSF mRNA and high
levels of viral DNA load. In AM with the high level of GM-CSF mRNA (0.69 ±
0.39), MVV RNA was detectable. In contrast, MVV RNA was undetectable in AM
with the low level of GM-CSF mRNA (0.19 ± 0.17) (Fig.4.6).
4.3.3: The expression of cytokine genes by blood monocyte-derived macro¬
phages infected with MVV in vitro
In order to clarify the influence of MVV in any possible regulation of the
dysreguation of cytokine expression observed in AM of infected sheep, blood
monocyte-derived macrophages were infected with MVV with low TCID50 in order
to mimic in vivo condition.
4.3.3.1: MVV increases the expression of TGF-P, TNF-a and GM-CSF mRNA
in macrophages in vitro
MDM were infected with MVV at 0.02 TCID50 per cell. Mock infection with



































Figure 4.5 Comparison of macrophage cytokine mRNA in sheep with and without
lung lesions
Relative level of cytokine mRNA was determined by RT-PCR as described in
Material and Methods. Results were presented as the ratio of the signal from each
cytokine mRNA to the signal obtained from ATPase mRNA. Bars represent the mean
relative level of cytokine mRNA/ATPase mRNA and error bars are the standard
deviation. Group A: animals with lung lesions (n=6). Group B: animals without lung
lesions (n=4). Results are expressed as the mean ± SD. Standard deviations (SD) are
represented by error bars. Statistically significant differences (P < 0.05, Mann-
Whitney nonparametric statistics) between results with group A and those with group




Figure 4.6 Cytokine mRNA levels in AM from infected sheep with or without
detectable viral RNA
AM from infected sheep with or without detectable viral RNA were subjected to RT-
PCR amplification for detection of cytokine mRNA. PCR products for cytokines
were separated on 2% agarose gel and analysed by autoradiography and
densitometry. The results are shown as the ratio between cytokine mRNA/ATPase
mRNA. Results are expressed as the mean ± SD. Standard deviations (SD) are
represented by error bars. Statistically significant differences (P < 0.05, Mann-
Whitney nonparametric statistics) between results with viral RNA (+) group and
those with viral RNA (-) group are denoted by asterisks.
RNA(+): MVV RNA is detectable in AM(n=3).
RNA(-): MVV RNA is undetectable in AM(n=3).
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to remove the virus inoculum and total RNA was isolated from these cultures at the
indicated time post-infection. Cells infected with MVV for 4 hrs showed an increase
in the expression of the mRNA for TNF-a and TGF-(3 compared with that of
uninfected controls (Fig.4.7 and 4.8). To estimate the relative expression of both
cytokines, a semi-quantitative RT-PCR was used and amplification of cytokine
cDNA was standardised to the housekeeping gene ATPase. As shown in Fig 4.7, the
mean expression of mRNA for TNF-a and TGF-p in MVV infected macrophages
was significantly higher than that of uninfected controls (P < 0.05, Student's t test).
This significant increase was not seen when the cultures were treated with heat-
inactivated MVV. Levels of TGF-(3 and TNF-a mRNA in these MDM were similar
relative to uninfected MDMs but markedly lower than in live MVV-infected MDMs
(Fig 4.7), which suggests that viral replication is required for increased expression of
mRNA for TNF-a and TGF-(3 in macrophages. In contrast, although increased levels
of GM-CSF mRNA were observed in MVV-infected MDMs, these were not
significantly different from the uninfected MDMs (P>0.05, Student's t test). EL-10
and IL-6 mRNA level remained unchanged (Fig.4.7).
To follow the expression of TNF-a mRNA, total RNA was extracted from MDM
lysates collected at different times after infection, the level of the cytokine
expression were detected by relative RT-PCR. The significant expression of TNF-a
mRNA level was detected at 6 hours after infection and its level increased with the
time of postinfection (Fig.4.9 and 4.10, P < 0.05, Mann-Whitney nonparametric
statistics) although the increased level of TNF-a mRNA was detected at 2 hours
after infection (Fig. 4.10, P > 0.05, Mann-Whitney nonparametric statistics).
4.3.3.2: Infection of macrophages with MVV failed to activate expression of IL-
10 and IL-6 mRNA in vitro
The effects on IL-10 expression were investigated during the MVV infection and
viral production. IL-10 mRNA was quantified by using RT-PCR during the first 24
hours after MDM infection with MVV TCID50 ranging from 0.02 to 2 per cell. The
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Figure 4.7 Levels of various cytokines detected in cultures of MDMs infected with
MVV
MDMs were infected with MVV at 0.02 TCID50 per cell. Mock infection with
medium served as a control. After 2 h of incubation at 37°C, the cell were washed to
remove the virus inoculum and total RNA was isolated from these cultures at 4hrs
postinfection. The expression of mRNA for IL-6, IL-10, TNF-a, TGF-f} and GM-
CSF was determined by RT-PCR assay and analysed by autoradiography and
densitometry. IL-6 was amplified for 32cycles, IL-10 for 30 cycles, TNF-a for 30
cycles, TGF-P for 32 cycles, GM-CSF for 29 cycles and ATPase for 35 cycles. The
results are shown as the ratio between cytokine mRNA/ATPase mRNA. Results are
expressed as the mean ± SD. Standard deviations (SD) are represented by error bars.
Statistically significant differences (P < 0.05, Student's t test) between results with
MVV-infected cells and those with uninfected cells are denoted by asterisks.
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Figure 4.8 MVV increases the expression of TGF-(3 and TNF-a mRNA in
macrophages
MDMs were infected with MVV at 0.02 TCID50 per cell. Mock infection with heat-
inactivated MVV served as a control. After 2 h of incubation at 37°C, the cell were
washed to remove the virus inoculum and total RNA was isolated from these
cultures at 4 hrs postinfection. The expression of cytokine mRNA in MDMs infected
with live MVV or heat-inactivated MVV was determined by RT-PCR and Southern
blot analysis as described in Material and Methods of Chapter 4. P: positive control.
N: negative control.
A: The expression of mRNA for TGF-(3 in MDMs.
Lane 1: uninfected.
Lanes 2, 3: heat-inactivated MVV,
Lanes 4, 5, 6: MVV
B: The expression of mRNA for TNF-a in MDMs.
Lanes 1, 2, 3: MVV-infected MDMs.
Lanes 4, 5: uninfected MDMs.
Figure 4.9 Kinetics of expression of TNF-a mRNA in MVV infected MDMs
MDMs were cultured at a concentration of 5x10s per well and infected with MVV at
0.02 TCID50 per cell. Cells were harvested at the indicated time after infection. TNF-
































Figure 4.10 Kinetics of expression of TNF-oc mRNA in MDMs
MDMs were infected with MVV at 0.02 TCID50 per cell. Mock infection with
medium served as a control. After 2 h of incubation at 37°C, the cells were washed to
remove the virus inoculum and total RNA was isolated from these cultures at the
indicated lime post-infection. The level of TNF-a mRNA was determined by RT-
PCR. 27 cycles for TNF-a were carried out. Each point is presented as mean ± SD of
three samples. Results are expressed as the mean ± SD. Standard deviations (SD) are
represented by error bars. Statistically significant differences (P < 0.05, Mann-
Whitney non-parametric statistics) between results with MVV-infected cells and
those with uninfected cells are denoted by asterisks.
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after infection could IL-10 mRNA be detected in MDM although the expression of
TNF-a mRNA was seen (Fig.4.11).
MVV infection did not induce increased expression of IL-10 mRNA in infected
MDMs at the time points up to 24 hours. However, it remained possible that MVV
infection might induce IL-10 during productive infection. To explore this possibility,
The expression of IL-10 mRNA was investigated in MDM 3 days after infection
tested. No increased expression of IL-10 was detected up to 3 days after infection
(Fig.4.12). In lipoplysaccharide (LPS)-stimulated MDM, DL-10 mRNA was detected
(Fig.4.12). Therefore, these findings suggest that MVV infection of MDMs is not
sufficient to induce detectable level of IL-10 in these cells. Neither early virus-cell
contact with low nor high TCID50 induced the expression of IL-10 mRNA in
MDMs. In MVV infected sheep, overexpression of TNF-a in lung was reported
(Woodall et al. 1997). TNF-a has been described as inducing IL-10 expression
(Wanidworanun et al. 1993). However, under our culture conditions, no IL-10
mRNA was observed in uninfected and MVV-infected MDMs whereas TNF-a
mRNA were observed in MVV infected MDM (Fig.4.11).
The above results have shown that infection of macrophages with MVV failed to
activate expression of IL-10 mRNA. In view of the potential influence of the state of
maturation of monocytes into macrophages in response to lentivirus infection
(Kazazl et al. 1992), this result would not exclude that the induction of IL-10
expression by MVV is linked to cell differentiation. To test this possibility,
monocytes were infected with MVV at 0.02 TCID50 per cell ether on the day of
isolation of cells (D.0) or cells cultured for 7 days (D.7). As a control, the same virus
stock was used the same day to stimulate both cells. When compared with
uninfected cells, IL-10 mRNA was detected in monocytes on the day of isolation
(Fig.5.13). In contrast, in macrophages cultured for 7 days, no increased expression
of IL-10 mRNA was detected in response to MVV infection compared to uninfected
cells (Fig.4.13). Because the amount of expression of cytokine mRNA was
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Figure 4.11 Expression of viral DNA, IL-10 and TNF-q mRNA in MDMs
MDMs were infected with three different TCIDso/cell (0.02, 0.2, 2) of MVV EV1.
Mock infection with medium served as a control. After 2 h of incubation at 37°C,
the cells were washed to remove the virus inoculum and total RNA for cytokines and
DNA for virus was isolated from these cultures at 24 hrs postinfection. The
expression of mRNA for IL-10 was determined by RT-PCR assay and analysed by
autoradiography. Viral DNA was detected by PCR using a pair of primers specific

















Medium MVV-infected LPS treated
2.001 1 1
MVV p25 IL-10 MVV p25 IL-10 MVVP25IL-110
Figure 4.12 Cellular viral Load and IL-10 mRNA expression in MDMs
MDMs were infected with 0.02TCID5o/cell of MVV EV1. At 3 day postinfection
total RNA was isolated from these cultures and culture supernatants were collected
for detection of viral p25. The expression of mRNA for IL-10 was determined by
RT-PCR assay and analysed by autoradiography. Viral P25 was detected by
competitive ELISA as described in Chapter 2. The level of IL-10 mRNA is expressed
as the mean of ratio of IL-10 mRNA to ATPase mRNA. Viral p25 level is expressed
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Figure 4.13 Induction of expression of IL-10 mRNA by MVV infection during cell
culture of monocytes
Monocytes were cultured in 24-well plates. At the indicated times, cells were
exposed to MVV at a 0.02 TCID50 per cell or control medium. After 6 hours,
expression of cytokines mRNA was determined by relative RT-PCR. These results
are representative of three other experiments. The data is expressed as the mean of
ratio of IL-10 mRNA to ATPase mRNA. Statistically significant differences (P <
0.05, Mann-Whitney non-parametric statistics) between results with MVV-infected
cells and those with uninfected cells are denoted by asterisks.
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proportional to the numbers of monocytes, macrophages were harvested with
treatment of EDTA/PBS after 7 days of culture and re-cultured at the higher cell
density. They still did not express detectable cytokine mRNA when challenged with
MVV. This excludes the possibility that the lack of IL-10 expression in response to
MVV was not caused by an infection-related-loss of macrophage viability.
Stimulation with LPS led to induction of IL-10 mRNA in both freshly isolated
monocytes and macrophages cultured for 7 days indicating that the loss of ability to
express IL-10 was selective as monocytes differentiate into macrophages (data not
shown). As wtih EL-10, no expression of IL-6 mRNA could be observed in MVV-
infected MDM when compared with those uninfected MDM (medium control)
(Fig.4.14 and 4.15). In certain experiments, the cultures were extended for up to 4
days after infection. Even at these late time points, no significant expression of IL-6
mRNA was found in MVV-infected MDMs.
4.3.3.3: The effect of exogenous cytokine on the expression of cytokine gene in
macrophages
As demonstrated in the above results, lack of EL-10 and IL-6 mRNA expression was
observed in MVV-infected MDM and the increased level of GM-CSF mRNA was
found in AM of MVV infected sheep. It is possible that MVV infection might induce
one cytokine expression which in turn induces the expression of another cytokine.
To explore this possibility, the effects of GM-CSF on the expression of IL-6 mRNA
in MDMs was investigated. As shown in Fig.4.16, when MVV infected-MDMs are
stimulated with GM-CSF the expression of IL-6 mRNA was observed within 24
hours. However, increased expression of EL-6 was detected in MDMs exposed to
GM-CSF and GM-CSF+MVV but not in MVV alone, suggesting that interaction of
MVV with the target cells is not essential for the expression of IL-6.
Similarly, it was found that exogenous IFN-y was able to modulate the TGF-(3
mRNA expression. As shown in Fig.4.17, Levels of TGF-(3 mRNA in MDMs treated
with heat-inactivated EFN-y were similar relative to uninfected MDMs but markedly
lower than in live MVV-infected MDMs.
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Figure 4.14 Lack of the detectable expression of IL-6 mRNA
MDMs were cultured at a concentration of 5x10s per well and infected with MVV at
0.02 TCID50 per cell. Cells were harvested at the indicated time after infection. TNF-






























































Figure 4.15 Lack of IL-6 mRNA detectable in MDMs infected by MVV in vitro
MDMs were infected with 0.02TCID5o/cell of MVV EV1. Medium served as a
control. After 2 h of incubation at 37°C, the cells were washed to remove the virus
inoculum. Total RNA and DNA were isolated from these cultures at 2, 6, 12, 24
hours post-infection, and culture supernatants were collected for detection of viral
p25. The expression of mRNA for IL-6 was determined by RT-PCR assay and
analysed by autoradiography. Viral DNA was detected by QC-PCR as described in
Chapter 3. The level of IL-6 mRNA is expressed as the mean of ratio of IL-6 mRNA
to ATPase mRNA. Results shown are the mean (± SD) of three separate
experiments. Standard deviations (SD) are represented by error bars. Statistically
significant differences (P < 0.05, Mann-Whitney non-parametric statistics) between
results with MVV infected cells and those with uninfected cells are denoted by
asterisks.
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Figure 4.16 Effects of GM-CSF on IL-6 mRNA expression by MVV-infected
macrophages
MDMs were exposed to GM-CSF (10 ng/ml) and challenged with 0.02TCID50/cell of
MVV EV1. Cells treated with GM-CSF alone, medium alone and MVV alone were
served as controls. After 2 h of incubation at 37°C, the cells were washed to remove
the virus inoculum. Total RNA was isolated from these cultures at 6, 12, 18, 24
hours post-infection. The expression of mRNA for IL-6 was determined by RT-PCR
assay and analysed by autoradiography. The level of IL-6 mRNA is expressed as the
mean of ratio of IL-6 mRNA to ATPase mRNA. Each point represented mean + SD
of three experiments.
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Figure 4.17 Comparison of TGF-f3 mRNA expression in MDMs treated with IFN-y
or heat-inactivated IFN-y
PCR products were separated in a 2.0% agarose gel and analysed by autoradiography
and densitometry.
Lane 1: IFN-y (10ng/ml)+MVV.
Lane 2: MVV.






The levels of expression of EL-10, IL-6, TGF-(3, TNF-a and GM-CSF mRNA
expression were semi-quantified by measuring the level of mRNA using semi-
quantaitve RT-PCR in AM, blood monocytes after infection in vivo and in vitro.
The increased expression of GM-CSF mRNA was observed in AM of MVV infected
sheep. However, in vitro studies with MDM at low of TCID50 showed that no
significant increase in the GM-CSF mRNA expression of MDM was found after
infection. It is possible that this expression may be restricted to infected cells
because MDM were infected with MVV at low TCID50 and harvested at the time
that only a proportion of the cells were infected. A high level of GM-CSF was
expressed in AM of MVV infected sheep with pathological lung lesions (group A)
where the viral RNA is detectable. This result, together with the previous study that
the number of infected AM increased with the severity of lung lesions (Brodie et al
1992), indicate that the level of GM-CSF expression is related to viral replication.
This response of elevated expression of GM-CSF may, in part, responsible for
driving active replication of the virus in AM in the later stage of disease. It is well
known that GM-CSF up-regulates antigen-presenting activity of dentritic cells and
recruits these cell to localised inflamed regions of the lung, thus promoting lymphoid
follicles development. GM-CSF also mediates abrogation of suppression of T
lymphocyte activities in the lung by AM, causing T lymphocytes accumulation to
occur. Thus it is possible that increased level of GM-CSF in the lung may account
for development of lymphoid follicles in the lung. It is tempting, therefore, to
hypothize that MVV infection may cause progression of disease via a profound
perturbation of the cytokine network. A recent study of TGF-(3 expression in ovine
lentivirus-induced lymphoid interstitial pneumonia showed the increased level of
TGF-|3 expression in lymphoid follicles (Moreno et al 1998), providing further
evidence of a direct pathogenic consequence of MVV infection via a profound
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perturbation of the cytokine network
The levels of TNF-a and TGF-p mRNA was elevated in macrophages infected with
MYV in vivo and in vitro. TGF-(3 has been shown to be a potent chemoattractant for
monocytes and macrophages. Additionally, TGF-(3 is known to induce monocyte
secretion of cytokines and may be important in augmenting and perpetuating
inflammatory reactions (Wahl et al. 1990). Increased activity of TGF-(3 in the
affected sites may therefore result in enhanced chemoattractant activity for
monocytes and macrophages and augmentation and perpetuation of inflammatory
reactions via cytokine release. In exploring whether MVV itself could be a trigger
for the enhanced expression of TGF-(3 and TNF-a, a significant increase in TGF-(3
and TNF-a was not seen when the cultures were treated with heat-inactivated MVV.
In these cells, levels of TGF|3 and TNF-a were similar to uninfected MDMs but
markedly lower than in live MVV-infected MDMs (Fig 4.8), which suggests that
viral replication is required for increased expression of mRNA for TNF-a and TGF-
(3 in macrophages. However, it is unclear whether this expression is restricted to
infected MDM or even if other uninfected cells have contributed.
The increased expression of IL-6 and IL-10 mRNA was observed in AM from
infected sheep. However, in vitro study showed no detectable expression of IL-10
mRNA and IL-6 mRNA in MDMs in response to MVV infection, indicating that
other factors may be involved in contributing to IL-6 or IL-10 expression in
macrophages in response to MVV in vivo. In HIV infection, IL-6 expression is
generally not elevated in patients during their primary infection with HIV, but then
increases toward the end of the acute phase when viral burden is decreasing (Sinicco
et al. 1993), suggesting that the increase in EL-6 expression is not related with the
virus replication. The results of the study that IL-10 mRNA was detected in freshly
isolated monocytesbut not in cultured macrophages in response to MVV infection,
suggest that the failure to induce IL-10 expression by MVV may be linked to cell
differentiation. Furthermore, GM-CSF was found to stimulate the expression of IL-6
mRNA in MDMs, suggesting the possible mechanism that MVV might induce
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expression of IL-6 in vivo by an indirect process, i.e., MVV may induces the
expression of GM-CSF. This may in turn trigger the expression of IL-6 mRNA in
AM. Thus the interaction among cytokine have, in part, a role in regulation of
cytokine expression in macrophages during viral infection (Foli et al. 1997).
The factors responsible for initiating a switch from asymptomatic to symptomatic
disease expression in lentiviral infections are not yet clear. Thl and Th2 response in
mice play a critical role in viral clearance (Braciale and Braciale 1994). The Th2
cytokine response has been suggested to response for disease progression during
HIV infection (Clerici and Shearer, 1993). Patients with Thl-type response,
characterised by production of IL-2 and IFN-y remain as asymptomatic whereas
those that switch from Thl to Th2, as indicated by decreased secretion of IL-12 and
increased production of IL-4, develop clinical diseases (Clerici and Shearer 1993,
Chehimi et al. 1994). In FIV-infected cat asymptomatic cats produces high level of
IL-2 (a Thl cytokine) and high level of 11-6 (a Th2 cytokine) (Lawrence et al. 1995).
In this study, both Thl and Th2 cytokine expression was seen in LNs. Similarly, a
study of cytokine expression in CAEV-induced arthritis (CAEV is closely related to
MVV) extended these observations showing both Thl and Th2 cytokine expression
in the same arthritis joints but in different regions (Lechner et al. 1997). On the basis
of this finding, it is hypothesed that both types of cytokines could be expressed
concurrently but in different regions of MVV-infected tissue. However, studies
monitoring changes in levels of IL-10, IL-4 and IFN-y during MVV infection are
required before a definite role of a shift from Th 1 to Th2 in the immunopathology of
MVV infection can be determined. Whether or not a Thl/Th2 switch occurs, it is
obvious from these observations that interaction between lentiviruses and host cells
invariably results in modulation of cytokine expression and a possible dysregulated
pattern of cytokine expression in response to the exogenous stimulus.
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CHAPTER 5
EFFECT OF THE CYTOKINE GM-CSF, TGF-(3 AND IFN-y ON MAEDI-
VISNA VIRUS REPLICATION
5.1: Introduction
MVV is genetically and pathogenically similar to HIV. A number of studies have
demonstrated that HIV replication in monocytic cells is particularly sensitive to
modulation by cytokines (see Chapter 1). IL-1, IL-3, IL-6, TNF-a, TNF-(3, EFN-y,
and GM-CSF have been shown to be capable of up-regulating HIV in these
mononuclear phagocytes (Poli et al. 1993, Bornmann et al. 1997). Other cytokines
such as 1L-4 and IL-10 on the other hand, have generally been reported to suppress
HIV replication (Poli et al. 1990, Saville et al. 1994, Weissman et al. 1994).
Furthermore, the results of the studies demonstrated the level of GM-CSF mRNA
expression was correlated with the viral DNA load, indicating that cytokines might
play an important role in regulating MVV replication or that virus replication plays a
role in cytokine expression.
Despite a large number of reports about the role of cytokines in regulating HIV
replication, there are relatively little data concerning the role of cytokines in
modulating MVV replication. Ellis et al. (1994) showed that TNF-a and IL-1 (3
enhance on MVV expression in AMs in vitro. In addition, it has been demonstrated
that bovine recombinant IFN-a has an inhibitory effect on MVV in AM (Ellis et al.
1994). Indeed, like other lentiviruses, it has become apparent that there is a complex
pattern of interaction between the regulation of cytokines and virus replication and
that such interactions may have a critical role in induction of MVV expression and
in the pathogenesis of maedi-visna disease. Thus the elucidation of the effect of
cytokines on MVV expression is a crucial step in the determining immuno-
pathological mechanisms involved in lentiviral disease progression. To address this
question, the effects of recombinant GM-CSF, EFN-y and TGF-(3 on MVV





Recombinant ovine GM-CSF (0.65 mg/ml) was kindly provided by Dr DM Haig
Moredun Research Institute, Scotland. Recombinant bovine interferon gamma (IFN-
y, lmg/ml, 2.5xl06u/mg) was obtained from Ciba Geigy S.A. (Basel, Switzerland).
This has been previously demonstrated to be active on ovine AMs (Nash et al. 1992,
Ellis et al. 1994). Human recombinant TGF-p was obtained from Genosys (UK).
5.2.2: Preparation of viral stocks
MVV EV1 was propagated as described in Chapter 2. Virus containing supernatant
was then filtered though a 0.4 pm filter to remove cell debris, treated with DNase at
37°C for 60 minutes to remove viral DNA and stored at -70°C.
5.2.3: Cytokine treatment and MVV infection of MDMs
Monocyte-derived macrophages (MDM) was isolated and cultured as described in
Chapter 2. Cytokines were added to 5 to 7 day-old macrophage cultures 1 day before
infection. Treated and untreated macrophages were inoculated with cell-free, DNase
treated MVV culture at 0.02 TCID50 per cell and allowed to absorb for 2 hours
before complete aspiration of medium, washing and addition of fresh medium.
Medium containing cytokine was replenished every 3 days. The supernatants were




5.3.1: Morphology of blood monocytes and MDMs
Figure 5.1 shows the morphology of monocytes and MDMs. During differentiation,
monocytes underwent a marked increase in cell size with a concomitant increase of
the nucleus-cytoplasmic ratio (Fig5.1). The nucleus of the monocytes rounded off
after the second day and was located centrally or slightly eccentrically within the
cells. On day 7, the cytoplasm was characterised by numerous vacuoles.
Macrophages, after 7 days culture, exhibited an extremely irregular surface and
numerous pseudopodia on cell membrane (Fig.5.1B). Cell populations exhibited a
certain morphological heterogeneity. This phenomenon may reflect the presence of
different maturation stages of the cells or early acquisition of characteristics of tissue
macrophages by sub-populations of the cultured cells.
5.3.2: Effect of maturation/differentiation of monocytes on MVV replication in
these cells
In view of the potential influence of the state of maturation or duration of adherence
of monocytes on MVV replication, a series of experiments were designed to test this
hypothesis.
5.3.2.1: Reverse transcription in MVV-infected fresh and cultured monocytes
To study the influence of cellular differentiation on the susceptibility of monocytes
/macrophages to MVV infection and virus replication, monocytes were inoculated
with EV1 at 0.02 TCIDso/cell on the day of isolation and day 7 in culture, and then
lysed at 12h, 48h and 7 days after infection. The cell lysates were analysed by PCR
with primers to MVV pol. The pol DNA were detectable within infected MDM after
7 days culture by 12 hours, with the amount of the pol DNA increasing with the time
of infection (Fig5.2). In contrast, freshly isolated monocytes exposed to MVV
generated no detectable viral DNA, even up to 7 days, later. This result supports the
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Figure 5.1 Morphology of monocytes and monocytes-derived macrophages (MDMs)
Monocytes were isolated from peripheral blood mononuclear cells by means of
plastic adherence and cultured in medium containing 10% FCS.
A: monocytes on the day of isolation (light microscope, original magnification x
200).
B: macrophages after 7 day culture (light microscope, original magnification x 200).
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Fig.5.1
Figure 5.2 Effect of culture duration on susceptibility of monocytes to MVV
infection as determined by PCR
Cells (2xl05 cells /well) were exposed to MVV at 0.02 TCIDsoper cell on either day
of isolation (day 0) or day7 in culture and harvested at 12h, 48h and 7 days after
infection. The cell lysates were analysed by PCR for 35 cycles with primers to pol
region, which amplify a 217 bp region of pol gene. PCR products were separated in
2% agarose and detected by Southern hybridisation. The figure is representative of
three replicate experiments. P: positive control. MW: 1 kb DNA ladder.
A: MVV POL. Stained with ethidium bromide
B: Corresponding autoradiogram. Probed with ~"P labelled probe
Figure 5.3 Effect of culture duration on content of viral DNA synthesis in infected
monocyte and MDMs
Cells were exposed to MVV at 0.02 TCID50 per cell on the day 0 (day of isolation)
or 1, 2 and 7 in culture and harvested at 24 hours after infection. Lysates were
analysed with primers LTR (which amplifies a 156/116 bp region of LTR, pol (which
amplifies a 217 bp region of pol) and gag (which amplifies a 461 bp region of gag).
Cell equivalents (2xl05) were used in each reaction. PCR products were separated
by 2% agarose and stained with ethidium bromide. P. positive control, N: negative












concept that the monocyte is not susceptible to productive infection with MVV
(Narayan et al. 1982).
Since viral DNA synthesis could not be detected in fresh monocytes, but was
detectable within 12 hours of infection of MDMs, the next experiment was designed
to investigate whether reverse transcription was initiated in monocytes exposed to
MVV on the day of isolation using PCR with three primer sets. Cell lysates were
analysed with LTR, pol and gag primers pairs to detect viral DNA initiated within
the first 24 hours of infection. In three experiments, no products were detected in day
0 monocytes with any of the three sets of primers, indicating that reverse
transcription had not been initiated in these cells. This result was not due to a lack
of, or difference in amount of amplified DNA within these samples as ATPase
primers gave similar levels of amplification with all samples (data not shown). On
other hand, when cells were maintained for a day or more prior to infection, viral
DNA were clearly detected within 24 hours of infection (Fig 5.3). Increasing time in
culture before infection resulted in increasing amount of transcripts of LTR. pol and
gag detectable at 24 hours.
5.3.2.2: Levels of p25 antigen in MVV-infected fresh and cultured monocytes
Virus replication was next analysed by measuring p25 antigens in culture
supernatants by competitive ELISA at 14 days after infection. Data from three
separate experiments were very similar and summarised in Fig.5.4. The results show
that the levels of p25 antigen detected in monocyte culture increased with time in
culture (Fig.5.4). No p25 antigen was detected in day 0 culture. However, p25
antigen was detectable in monocytes cultured for 1 or 7 days, but 7 day-old cells
show higher virus replication, measured by p25 antigen than cells infected at day 1
(maturing macrophages). The level of p25 antigen increased with time in culture.
This may be a reflection of the increase in cellular gene transcription and protein
synthesis, which characterises the maturation process. The results above suggest that
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Figuree 5.4 Levels of" p25 antigen in MVV-infected O-dav-old. 1-dav-old and 7-dav-
old monocytes, respectively
Cells were exposed to MVV at a 0.02 TCID50 per cell on the day 0 (day of isolation)
or dayl or day 7 in culture. Cell culture supernatants were harvested at 14 days post¬
infection and analysed by measuring p25 antigen in by a competitive ELISA as
described in Materials and Methods (Chapter 2). Data were obtained by comparison
of mean OD values (from triplicate wells) with a standard curve from recombinant
MVVp25.
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kinetics of virus replication depends on the stages of differentiation at the time of
infection.
5.3.2.3: Kinetics of MVV replication in macrophages
The efficiency of replication of MVV EV1 strain was studied in MDMs from MVV
seronegative sheep that were cultured 5 days after isolation, before investigating the
effect of cytokines GM-CSF, TGF-P and IFN-y on MVV replication. As determined
by the p25 levels in culture supernatant, the replication of MVV in this culture
system is easily demonstrated over 14- day time course (Fig.5.5).
5.3.3: Effect of cytokines GM-CSF, TGF-p and IFN-y on MVV replication in
MDMs
In initial experiments, the effect of exogenous cytokines GM-CSF, TGF-p and IFN-y
on MVV replication in MDMs was examined. MDMs were pre-treated with GM-
CSF (lOng/ml), TGF-P (lOng/ml) and IFN-y (20 ng/ml), respectively. The
supernatants were harvested at day 7 post infection for measurement of viral p25.
The cells were washed with PBS and lysed in DNA lysis buffer for quantification of
viral DNA.
5.3.3.1: Enhanced effect of GM-CSF on viral expression
5.3.3.1a: p25 production in GM-CSF treated MDMs
The effect of GM-CSF on MVV p25 production was determined using a competitive
ELISA. The level of viral p25 in culture supernatants of macrophages treated with
GM-CSF (lOng/ml) 1 day before and continuously after MVV infection was
significantly (P< 0.01) higher than those of an equal number of macrophages
cultured in medium alone (Fig.5.6).
In further experiments, the effect of various doses of GM-CSF was examined with
the cytokine level ranging from lOOpg/ml and lOOng/ml. MVV replication was
assessed at viral protein levels using the competitive ELISA. These studies show that
the stimulatory effects of GM-CSF on MVV replication are concentration dependent
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Figure 5.5 Kinetics of MVV replication in MDMs. as reflected by p25 level in
culture supernatant
MDMs were infected with MVV EV1 strain at 0.02TCID50 /cell, and supernatants
were harvested at the indicated time points for p25 determination. Data were
obtained by comparison of mean OD values (from triplicate wells) with a standard
curve from recombinant MVVp25. Data are expressed in ng/ml as the mean ± SD













Figure 5.6 Effect of GM-CSF to stimulate MVV replication in MDMs
MDMs were prepared as described in Materials and Methods (Chapter 2) and
cultured for 5 days, and seeded in 24-well plates (1 xlO5). Cells were incubated with
GM-CSF (10 ng/ml) 1 day before and continuously after infection with MVV EV1
(0.02 TCID50 per cell). Cell-free supernatants were harvested on days 7 for p25
determination by using competitive ELISA. Data were obtained by comparison of
mean OD values (from triplicate wells) with a standard curve from recombinant
MVVp25.
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in MDM (Fig.5.7). Increasing concentration of GM-CSF yielded an increasing
stimulatory effect on MVV p25 expression over the range tested. Maximum
stimulatory concentration was obtained at the concentration of 10 ng/ml (Fig.5.7).
To confirm that the observed stimulation was specifically due to GM-CSF, the GM-
CSF preparation used was heat inactivated for 45 min at 56°C. Use of heat
inactivated GM-CSF resulted in similar amounts of virus p25 production to untreated
MDMs, but significantly less than those of GM-CSF treated MDMs (Fig.5.8), which
confirms the specificity of stimulatory effect of GM-CSF on MVV replication and
excludes non-specific effects.
5.3.3.1b: Effect of GM-CSF on viral DNA expression
Effect of GM-CSF on the replication of MVV in MDM was further examined by
quantification of viral DNA using QC-PCR with a primer pair to the pol region. As
shown in Fig.5.9, MVV replication (when measured 7days after infection) in MDMs
treated with GM-CSF 1 day before and continuously after virus infection was
markedly enhanced when compared to untreated MDMs. All amplification products
were analysed by Southern blot hybridisation (Fig.5.9B) with a radiolabeled DNA
probe specific for a pol sequence internal to the primer pair. Autoradiographs were
analysed by an optical scanning system that assigns optical density values to each
specific band on the autoradiograms. The amount of MVV DNA present in lysate of
MVV infected MDMs was estimated from a standard curve derived from DNA of
plasmid pPOL2 using QC-PCR and then expressed as amount per 500ng DNA. The
quantitative evaluation of the PCR signal clearly shows that the level of viral DNA in
GM-CSF treated MDMs was higher than that in untreated MDMs and increased with
concentration of GM-CSF added (Fig.5.10). Comparable results were obtained in
each of three different experiments.
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Figure 5.7 Dose-dependent stimulation of MVV replication in MDMs cultured in the
presence of GM-CSF
MDMs were prepared as described in Materials and Methods, and seeded in 24-well
plates (1 xlO3). Cells were incubated with GM-CSF (0.1, 1, 10, 100 ng/ml) 1 day
before and continuously after infection with MVV EV1 (0.02 TCID5o per cell).
Culture supernatants were collected at day 7 after infection and assayed lor level of
viral p25 by ELISA. Data were obtained by comparison of mean OD values (from
triplicate wells) with a standard curve from recombinant MVVp25. Each point is




Figure 5.8 Heat inactivation of GM-CSF abrogated GM-CSF-mediated stimulation
of MVV replication in MDMs
MDMs were prepared as described in Materials and Methods, and seeded in 24-well
plates (1 xlO5). Cells were incubated with GM-CSF (10 ng/ml) or heat-inactivated
GM-CSF (lOng/ml) or medium only 1 day before and continuously after infection
with MVV EV1 (0.02 TCID50 per cell) and culture supernatants were collected at the
indicated time after infection. Results are presented means ± SD of three replicates
and representative of three independent experiments. Data were obtained by
comparison of mean OD values (from triplicate wells) with a standard curve from
recombinant MVVp25.
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Figure 5.9 Levels of MVV DNA in lysates of MVV infected MDM treated with
GM-CSF
MDMs were treated with a range (0 to lOOng/ml) of GM-CSF concentration added 1
day prior to virus challenge at 0.02 TCIDso/cell and subsequently maintained with
GM-CSF. At 7 day after infection, 500ng of total DNA purified from cell lysates
was analysed for levels of MVV DNA by PCR using primers specific for MVV pol.
N: negative control. P: positive control. MW: lkb DNA ladder
A: Stained with ethidium bromide










0 0.1 1 10 100
GM-CSF concentration (ng/ml)
Figure 5.10 Levels of MVV DNA in lvsates of MVV infected MDM treated with
GM-CSF
MDMs were treated with a range (0 to lOOng/ml) of GM-CSF concentration added 1
day prior to virus challenge at 0.02 TCID50/cell and subsequently maintained with
GM-CSF. At 7 day after infection, DNA purified from cell lysates was analysed for
levels of MVV DNA using QC-PCR with primers from pol gene. Autoradiographs
were analysed by scanning densitometry. Data are presented in copy number/500ng
total DNA as the mean (± SD) of triplicate assays for each treatment used.
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5.3.3.1c: Kinetics of GM-CSF induced stimulation of viral replication
The kinetics of MVV production induced in MDM treated with GM-CSF is shown
in Fig.5.11. The time-course studies were conducted to follow the observed GM-
CSF induced stimulation of viral replication up to 14 days post-infection. This
shows that enhanced MVV expression induced by GM-CSF was observed as early as
3-days post infection, and was still seen at 14 days post infection.
5.3.3. Id: GM-CSF mediated induction of MVV RNA
As shown in Fig.5.12, GM-CSF up-regulated MVV mRNA expression when GM-
CSF was added 1 day before infection. An increased hybridisation signal for pol was
observed in GM-CSF treated MDMs in comparison to an equal number of untreated
MDM using RT-PCR. Therefore, GM-CSF has effect in stimulating MVV RNA
production
5.3.3.2: Inhibitory effect of TGF-P of on MVV replication in infected MDMs in
vitro
5.3.3.2a: Effect of TGF-P on extracellular MVV production by macrophages
As shown in Fig.5.13 TGF-P significantly decreased the amount of extracellular
MVV p25 produced in MDMs culture compared with that found in untreated-MVV
infected cultures (P<0.05, Student's t test).
5.3.3.2b: Dose-dependent response of TGF-P on MVV expression
In further experiments, the effect of various doses of this cytokine was examined
with cytokine level ranging from lOOpg/ml to lOOng/ml. Viral levels were measured
by RT-PCR (Fig. 14A) and QC-PCR (Fig. 14B). The modulatory effects of TGF-P on
MVV replication are concentration dependent in MDMs and increasing
concentrations of TGF-P yielded increasing inhibition of MMV replication over the
range tested (Fig. 14). TGF-P was consistently active in inducing inhibition of MVV
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Figure 5.11 Kinetics of GM-CSF induced stimulation of viral replication
ELISA values for extracellular p25 antigen levels over 14 days post-infection (MVV
EV1 0.02 TCID50/cell. Cultures treated with GM-CSF (10 ng/ml) for 1 day before
and continuously after MVV infection show a continued stimulation of viral output.
Data are expressed in ng per millililre as the mean + SD from triplicate assays for
each treatment. Statistically significant differences (P < 0.05, Mann-Whitney non-
parametric statistics) between results with treatment of GM-CSF and those without
treatment of GM-CSF are denoted by asterisks.
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Figure 5.12 GM-CSF mediated induction of MVV RNA
Cells were exposed to MVV at 0.02 TCID50 per cell and harvested at 24 hours after
infection. Lysates were analysed with primers POL4 and POL5 (which amplifies 217
bp region of pol) by RT-PCR. Cell equivalents (2xl05) were used in each reaction.
PCR products were separated on 2% agarose and detected by Southern hybridisation.
To control for input RNA in samples analysed for MVV cDNA. PCR with ATPase
primers was performed at 2xl05 cell equivalent. The 167bp amplification was
separated on 2% agarose and stained with ethidium bromide.
A: MVV POL
B: ATPase
Lanes 1 and 2: treatment with GM-CSF.
Lane 3 and 4: medium only.
P: positive control.
N: negative control containing no RNA
MW: lkb DNA ladder
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Figure 5.13 Inhibitory effect of TGF-(3 on MVV replication in MDMs
MDMs were prepared as described in Materials and Methods, and seeded in 24-well
plates (1 xlO6). Cells were incubated with TGF-p (10 ng/ml) 1 day before infection
with MVV EV1 (0.02 TCID50 per cell) and incubated with complete medium
containing TGF-fJ. Cell-free supernatants were harvested on days 6 for p25
determination by using ELISA. Data were obtained by comparison of mean OD
values (from triplicate wells) with a standard curve from recombinant MVVp25.
Results shown are the mean (+ SD) of three separate experiments. Standard
deviations (SD) are represented by error bars. There are statistically significant
differences (P < 0.05, Mann-Whitney non-parametric statistics) between results with




Figure 5.14 Dose-dependent inhibition of MVV replication in MDMs cultured in the
presence of TGF-(3
MDMs were prepared as described in Materials and Methods, and seeded in 24-well
plate (1 xlO6). Cells were incubated with TGF-P (0.1, 1, 10, 40 ng/ml) 1 day before
and continuously after infection with MVV EV1 (0.02 TCID50 per cell). Infected cells
were collected at day 3 after infection. Viral levels were measured by RT-PCR for
viral RNA (A) and by QC-PCR for viral DNA (B). Each point is presented as means
± SD of three replicates and representative of three independent experiments.
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5.3.3.2c: Kinetics of TGF-P- induced inhibition of viral replication
The kinetics of MVV production induced in MDMs pre-treated with the cytokine is
shown in Fig.5.15. The time-course studies were conducted to follow the observed
TGF-P-induced inhibition of viral replication up to 14 post-infection by ELISA.
Detection of p25 antigen in culture supernatant by ELISA showed that inhibition of
MVV expression induced by TGF-P was observed at 7 days after infection and was
still seen at 14 days after infection.
To confirm that the observed inhibitory effect was specifically due to TGF-(3, the
TGF-P preparation used was heat-inactivated for 60 min at 65°C. Use of heat
inactivated TGF-|3 resulted in similar amounts of virus p25 production (Fig.5.15),
viral DNA (Fig.5.16) and RNA level (Fig.5.17) to untreated MDMs, but
significantly higher (P<0.05) than those of TGF-P treated MDMs (Fig.5.15 and
5.16). For comparison, TPA was used as stimulator of virus replication. TPA at a
concentration of lng/ml has been shown to be very effective in stimulating viral
RNA expression in blood monocytes (see Chapter 3). These findings confirm the
specificity of the inhibitory effect on MVV replication and exclude non-specific
effects.
5.3.3.2d: TGF-p delays and inhibits MVV transcription kinetics
In investigating the potential mechanisms of anti-MVV action of TGF-P, the kinetics
of transcription were compared between TGF-p-treated and untreated MDMs by
using PCR amplification of LTR The results show that a 4 to 8 hours delay of
appearance of viral RNA in TGF-P-treated cells in comparison with untreated MDM
(Fig5.18). The MVV LTR RNA was detectable by 4 hours and 8 hours in untreated
and treated MDMs respectively.
5.3.3.2e: TGF-P acts as a modulator in MDM
In investigating the effects of TGF-P (lOng/ml) on infected MDM, the recovery of
virus after removal of cytokine was examined. Cessation of treatment with cytokine
at day 7 after infection was followed by a further 7 days of culture, and then the
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Figure 5.15 Kinetics of TGF-ft induced inhibition of viral replication
MDMs were prepared as described in Materials and Methods, and seeded in 24-well
plate (2 xlO3). Cells were incubated with TGF-P (lOng/ml), heat-inactivated TGF-
P(10ng/ml), TPA (1 ng/ml) medium only 1 day before and continuously after
infection with MVV EV1 (0.02 TCID50 per cell). Culture supernatants were collected
at 3, 7 and 14 days after infection and assayed for the level of viral p25 as described
in Chapter 2. Cultures treated with TGF-p (10 ng/ml) shows a continued inhibition of
viral output. Data are expressed in ng per millilitre as the means ± SD from triplicate
assays for each treatment. Data were obtained by comparison of mean OD values
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Figure 5.16 Heat inaetivation of TGF-ft abrogated TGF-ft-mediated inhibition of
MVV DNA expression in MDMs
MDMs (2 xlO5) were incubated with TGF-{3 (10 ng/ml), heat-inactivated TGF-P
(lOng/ml), TPA (1 ng/ml) and medium only 1 day before and continuously alter
infection with MVV EV1 (0.02 TCID5o per cell). Culture supernatants were collected
at 3 days after infection and assayed for the level of viral DNA by QC-PCR. Results
are presented as means ± SD of three replicates and representative of three
independent experiments. Standard deviations (SD) are represented by error bars.
There are statistically significant differences (P < 0.05, Student's t test) between
results with TGF-p treated MVV-infected cells and those without treatment of TGF-







Figure 5.17 Heat inactivation of TGF-B abrogated TGF-P-mediated inhibition of
MVV replication in MDMs
Cells (2 xlO5 cells/well) were incubated with TGF-(3 (10 ng/ml), heat-inactivated
TGF-P (lOng/ml), TPA (1 ng/ml) and medium only 1 day before and continuously
after infection with MVV EV1 (0.02 TCID50 /cell). Infected cells were collected at 3
days after infection and assayed for the level of viral RNA by RT-PCR.
Lanel: treatment with TGF-P (10 ng/ml).
Lane 2:heat-inactivated TGF-P (lOng/ml).
Lane 3: medium only
Lane 4: TPA (1 ng/ml).
Figure 5.18 TGF-B delays and inhibits MVV transcription
MDMs were prepared as described in Materials and Methods, and seeded in 24-well
plates (2 xlO5 cells/well). MDMs were incubated with TGF-P (10 ng/ml) and
medium only 1 day before and continuously after infection with MVV EV1 (0.02
TCID50 per cell). Cells were collected at the indicated time after infection and
assayed for the level of viral RNA by RT-PCR using the primers specific for LTR
sequence. Results are representative of three independent experiments.
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Figure 5.19 TGF-(3 acts as a modulator in MDMs
MDMs were prepared as described in Materials and Methods, and seeded in 24-well
plates (2 xlO5). Cells were incubated with TGF-[3(10 ng/ml) and medium only 1 day
before and continuously after infection with MVV EV1 (0.02, 0.2 and 2 TCID50 per
cell, respectively). Cessation of treatment with TGF-(3 at the day 7 after infection was
followed by a further7 days of culture and then culture supernatants were harvested,
in which recovery of virus production was measured by an ELISA. Results are
expressed in ng/ml as the mean ± SD from triplicate assays for each treatment.
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culture supernatant was harvested. Viral production was then measured by p25
ELISA. The recovery of virus production was proportional to the initial TCID50 of
MVV used. Infected MDM treated with TGF-p for 7 days and cultured further 7
days without treatment of TGF-P yielded a higher level of virus than those which
had been continuously treated with TGF-P (Fig.5.19, P < 0.05, Mann-Whitney non-
parametric statistics).but lower than those untreated control (data not shown). These
findings suggest that TGF-P may act as a modulator of a latent state after infection.
5.3.3 3: MVV replication in vitro is not affected by IFN-y
The level of MVV replication in MDM treated with IFN-y 1 day before and
continuously after infection was determined at protein and nucleic acid level by
using p25 ELISA and PCR, respectively. There was no significant variation in the
level of p25 expression, compared with that in untreated MDM (Fig.5.20A).
Similarly, the level of viral DNA measured by QC-PCR (Fig.5.20B) and viral RNA
measured by RT-PCR (Fig.5.20C) was unaffected in MDM by IFN-y treatment.
142
Figure 5.20 MVV replication in vitro is not affected by IFN-y
MDMs were prepared as described in Materials and Methods, and seeded in 24-well
plates (2 xlO5 cells/well).
A: IFN-ydoes not affect production of MVV p25 antigen in MDMs.
Cells were incubated with IFN-y (20 ng/ml), GM-CSF (lOng/ml) and medium only 1
day before and continuously after infection with MVV EV1 (0.02 TCJD50 per cell).
Infected cells were collected at 7 days after infection and assayed for the level of
viral antigen p25 by ELISA as described in Chapter2. Results are presented as means
± SD of three replicates and representative of three independent experiments.
B: Effect of IFN-y on expression of MVV DNA in MDMs.
Cells were incubated with IFN-y (20 ng/ml) and medium only 1 day before and
continuously after infection with MVV EV1 (0.02 TCID50 per cell). Culture
supernatants were collected at 7 days after infection and assayed for the level of viral
DNA by QC-PCR as described in Chapter 3. Results are presented as means ± SD of
three replicates.
C: Effect of IFN-y on expression of MVV RNA in MDMs,
Cells (2 xlO5 cells/well) were incubated with IFN-y (0, 0.2, 2, 20, 40 ng/ml) 1 day
before and continuously after infection with MVV EV1 (0.02 TCID50 per cell) and
were collected at 7 days after infection and assayed for the level of viral RNA by
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CHAPTER 5:
Discussion
5.4.1: MVV replication is blocked in freshly isolated peripheral blood
monocytes.
The role of monocyte/macrophages in the pathogenesis of MVV infection is
incompletely understood. MVV virion, viral DNA or RNA and viral protein have
been identified in monocytes/macrophages found in peripheral blood, lung and a
wide variety of tissues (Narayan et al. 1982, 1985, 1985, Gendelman et al. 1985,
1986, Gorrell et al., 1992, Brodie et al. 1995). In lung, the detection of viral proteins
or infectious virus in infected target cells is associated with lymphoid infiltration
(Brodie et al 1995). In view of these data and the tropism of many lentiviruses for
cells of the monocytes/macrophages lineage, it has been proposed that these cell
have the potential to act as a reservoir of MVV and to disseminate virus to other
cells within the infected host. In monocytes, viral replication is highly restricted to a
minimal rate (Narayan et al. 1982), often only small quantities of viral RNA
production occurs and undetectable concentration of capsid protein is synthesised
(Brahic et al. 1981). High rate of viral replication only occurs once these cells
mature to macrophages (Narayan et al. 1985). Infection of monocytes appears to be
linked, at least in part, to differentiation (Narayan et al. 1985), i.e. the restriction of
maturation of the infected cells limits the replication of virus. In this respect, MVV
resembles many lentiviruses viral which RNA transcription and protein synthesis is
closely linked to the rate of maturation of monocytes to macrophages (Kalter et al.
1991).
In this study, it has been demonstrated that monocytes exposed to MVV immediately
upon isolation from peripheral blood do not become productively infected. It was
found that, in fresh monocytes, there was no evidence of viral DNA synthesis
initiated up to 7 days after infection (Fig.5.2).
It was reported previously that viral RNA was detectable soon after isolation of fresh
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monocytes form infected animals but virus replication did not extend beyond low
levels of transcription of viral RNA (Gendelman et al 1986). Although reverse
transcription did not occur after the infection of fresh monocytes with MVV in vitro,
it was found that a short period in culture was sufficient for reverse transcription to
proceed (Fig5.3) and for the cells to be productively infected. In fact, as little as 1
day in culture was sufficient for transcripts to be detected. If the cells were left to
mature for longer periods before infection with MVV, the infection becomes more
efficient, with an increase in viral load in cells according to the intensity of specific
bands on the blot. In MDMs infected with MVV, the transcripts were detected soon
after exposure to MVV. These results agree with the widespread observation that the
macrophage is the principle cell type permissive for MVV replication in tissues
(Gendelman et al. 1985, 1986, Gorrel et al., 1992, Brodie et al. 1995) and also
concur with reports that in human monocytes which have been maintained in culture
for a day or more after isolation and purification from peripheral blood, HIV is able
to bind, enter and reverse-transcribe its RNA in vitro (Kalter et al. 1991).
The result in this study that MVV replication is blocked in freshly isolated peripheral
blood monocytes raises the question of whether monocytes in peripheral blood are
susceptible to MVV infection in vivo. The in vitro finding in the study suggests that
they are not and that examination of this compartment alone may not lead to an
insight into the pathogenesis of MVV infection. This finding further supports the
work of Gorrell et al. (1992) who found that MVV has a greater tropism for
dendritic cells than monocytes.
5.4.2: Effects of cytokines on MVV replication in MDMs
MVV replicates and causes pulmonary disease amidst a cellular milieu that is likely
to be rich in cytokines (Ellis et al. 1988, 1991). Therefore, precise characterisation of
cytokine effects on MVV replication would be valuable in order to delineate the role
of cytokines in lentiviral pathogenesis. In this study, the effect of the recombinant
cytokines GM-CSF, TGF-(3 and IFN-y on the replication of MVV in an in vitro
model system was investigated.
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5.4.2.1: Stimulatory effects of GM-CSF on MVV replication in MDMs
As GM-CSF is a key regulator of monocyte-macrophages and is required for the
survival, proliferation, and differentiation of monocyte-macrophages and for the
function of their mature progeny (Methcalf et al. 1992, Crowe and Lopez 1997).
Furthermore, the ability of monocytes-macrophages to harbour the MVV and to
permit its replication suggests that cytokines which affect production of monocytes,
their differentiation and functional status, may modulate MVV replication. Based on
this concept, the effect of GM-CSF on MVV replication in MDMs in vitro was
explored. The results demonstrate that GM-CSF can up-regulate MVV replication in
primary infected MDMs. To determine the effects of GM-CSF on MVV replication
in macrophages, cells were treated with GM-CSF from 24 hours before infection
with different concentrations of cytokine. The effect of the GM-CSF on viral
replication varies with the cytokine dose. Concentrations higher than 0.1 ng/ml
enhanced MVV replication in macrophages. The specificity of this stimulatory effect
was confirmed by use of heat-inactivated GM-CSF.
The above results demonstrating the enhancing effect of GM-CSF on MVV
replication in MDMs are consistent with those of Perno et al. (1989) with HIV in
monocytes and Koyanagi et al. (1988) with HIV in primary mononuclear
phagocytes. Furthermore, these results parallel those of Folks et al. (1987), who
demonstrated the induction by GM-CSF of HIV-1 replication in chronically infected
immature monocytic cell lines. Collectively these studies are at variance with others
that reported inhibitory effects of GM-CSF on lentivirus expression. Matsuda et al.
(1995) reported an inhibitory effect of GM-CSF on the replication of HIV in human
blood MDMs. Moreover, the studies of Hammer et al. (1986) indicated that GM-
CSF could suppress viral replication in a promonocytic cell line chronically infected
with HIV. The reasons for the discrepancies are not clear, but may relate to the target
cell population used or dose and duration of cytokine treatment or virus strains
studied. Nevertheless, the results in this study support the concept that GM-CSF
could be an important mediator driving the virus replication, thus promoting virus
spread.
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The results in this study demonstrated of GM-CSF up-regulates the expression of
MVV RNA and DNA in MDMs, indicating that this cytokine may exert its effects at
various stages during MVV replication. Increased amount of viral DNA was
observed in MDM pretreated with GM-CSF, suggesting that GM-CSF pretreatment
of MDM stimulates early steps of MVV replication between absorption and reverse
transcription. The effect on viral DNA synthesis may be important enough for
accounting for a part of the increased RNA level. DFN-a has been reported to have
no effects on HIV transcripts that were clearly independently from the effect on viral
DNA in the early steps of the life cycle (Meylan et al 1993). It is also possible that
the level of viral RNA increased in MDM pretreated with GM-CSF, suggesting an
additional effect on transcription. MVV transcription directed by the 5'LTR is
regulated by the interplay of viral proteins such as Tat and host cell factors.
Therefore GM-CSF may augment MVV replication in MDM is through stimulation
of the production host transcription factors, which bond to the MVV LTR, resulting
in transactivation and thus in an increase in MVV transcription. The increase in the
MVV RNA in GM-CSF treated macrophages reflects the effect of GM-CSF on
multiple rounds of MVV infection of macrophages. Further experiments are required
to measure single-step growth curves using the high concentration of MVV as
inoculom to define further the role of GM-CSF in MVV infection. In addition,
differentiation of monocyte/macrophages by GM-CSF may result in the increase
permissiveness to MVV infection. This differentiation-induced susceptibility to
infection is true for MVV, where replication has been found to depend on the state
of maturation and differentiation of the infected cells (Gendelman et al 1986). Viral
gene expression may vary up to more than ten-fold between PBM and AM in MVV
infected sheep (Chapter3). Similarly, even in absence of exogenous cytokines, the
result in the study has demonstrated the relative lack of permissiveness of freshly
isolated monocytes to MVV infection and dramatically increased susceptibility to
MMV infection of MDM (Fig.5.2), further suggesting that cellular permissiveness of
cells of macrophages lineage to infection may alter during the maturation process.
Another possible way that GM-CSF argument the expression of viral RNA and
DNA is that GM-CSF can induce proliferation of monocyte/macrophages
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(Schuitemaker et al 1990). It is conceivable that GM-CSF might increase the amount
of MVV through increased proliferation of the treated, infected cells. This has been
studied carefully in cases of HIV infection. Koyanagi et al. (1988) demonstrated that
exposure to GM-CSF resulted in up to 100-fold enhancement in HIV replication as
assessed by quantification of HIV p24 antigen. Walsh et al. (1992) have also
demonstrated in SIV that in GM-CSF-treated cells there were more cells containing
gag protein than in cells not exposed to GM-CSF, suggesting that cytokine treatment
may cause an increase in the percentage of infected macrophages.
Of note is the fact that it has been found that the level of GM-CSF mRNA was
enhanced in MVV-infected macrophages in vivo (Chapter 4) and hyperevelation of
GM-CSF in MVV-infected lung (Woodall et al. 1997) suggesting that in vivo AM
might a main potential producer of GM-CSF, which stimulates the virus replication.
5.4.2.2: Inhibitory effects of TGF-P on MVV replication in MDMs
TGF-P comprises a group of molecules that are produced during the normal
response to injury (Rappolee et al. 1988). The TGF-P produced locally triggers a
series of events ranging from chemotactic attraction of monocytes to induction of
gene expression for several cytokines including the autocrine regulation of TGF-p
(Wahl et al. 1991). To explore the effects of TGF-P on MVV replication in
macrophages, cells were treated with TGF-P from 24 hours before infection with
decreasing concentrations of cytokine. The inhibitory effect on viral replication was
achieved at concentrations that are comparable to those required to induce other
effects on macrophages (Wahl et al. 1991). This inhibitory effect is specific for
TGF-P, since it was confirmed by use of heat-inactivated TGF-P (Fig5.16). It was
also found to be related to a reduction in the rate of transcription and dependent on
the continued presence of TGF-p as demonstrated by virus recovery experiments
after removal of TGF-p (Fig.5.19). This suggests that pre-treatment of TGF-P
decreased the number of successfully infected MDMs in vitro. These results are
consistent with the observation that in HIV-infected macrophages, TGF-P
suppresses HIV replication
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(Poli et al. 1991). This is in contrast to the work of Lazdins et al. (1991) who found
a stimulatory effect on MVV replication. It is possible that differences in culture
methods and condition, time of treatment with cytokine may explain the discrepancy
between our findings and those of other groups, although which differences
contribute most of these discrepancies in MVV infection is still unclear.
Many steps have been defined in MVV infection and replication, such as binding to
the cell surface, internalisation of the viral core into the cytoplasm, uncoating of
viral RNA, reverse transcription, integration of viral DNA to cellular DNA, viral
DNA transcription and translation, viral components assembly and virus budding. In
this study it was found that that TGF-P delays and inhibits MVV transcription
suggesting a possible mechanism by which TGF-P might inhibit viral replication at
transcriptional level. Further study is required to clarify this point. Another possible
explanation worth investigating could be that TGF-P exerts a negative influence on
the expression of critical cellular proteins involved in the replication of MVV, such
as enzymes of the cell signalling pathway that ultimately impact on nuclear
translocation or other cellular factors which might downregulate other surface
molecules needed for virus binding or inhibit cellular components involved in virus
fusion, uncoating or transcription. This effect is different from that of DL-13 which
inhibits HIV production independently of effects on the total amount of DNA
(Montanier et al. 1993). However, it does not exclude an effect of TGF-P on an
alternative antiviral mechanism. Taken together these findings implicate TGF-p as a
candidate mediator of MVV latency within macrophages in vivo.
The above described effects of TGF-P, taken together with the observations
described in Chapter3 and 4, suggest that TGF-P provides a possible mechanism by
which macrophages can suppress MVV replication in vivo and inhibit the spread of
infection by creating an inhibitory system. Finally, since others cytokines capable of
inducing expression of MVV, such as GM-CSF (Chapter 5) have been found be
increased in AM (Chapter 4) or lung tissue (Woodall et al. 1997), the balance
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between stimulatory and inhibitory cytokines may play a critical role in controlling
MVV replication and expression and subsequently in the clinical progression of
MVV infection.
5.4.2.3: MVV replication in vitro is not affected by IFN-y
Previous work has shown the presence of an interferon species (lentiferon) with
biochemical characteristics of both IFN-a and IFN-y in culture of leukocytes from
the lung of lambs with experimental MVV infection (Lairmore et al. 1988a) or of
macrophages from goat blood cells exposed to CAEV (Narayan et al. 1985). This
IFN present in cultures derived from lambs with lymphocytic interstitial pneumonia
had moderate inhibitory effect on MVV replication in vitro (Lairmore et al. 1988a).
The levels of IFN produced by pulmonary leukocytes correlated with an increase in
virus replication in tissue (Lairmore et al 1988a).
In the present study, it was not possible to demonstrate any apparent enhanced or
inhibitory effects of IFN-y on MVV replication in MDMs. The results demonstrated
that IFN-y does not influence MVV replication in MDMs (Fig.5.20). The same
phenomenon has been observed in other virus infection. For example in hepatitis
delta virus (HDV), the replication of HDV in transfected cell lines has been shown
to be not affected by IFN-y despite intact cellular responses to interferons and
dsRNA (McNair et al. 1994).
The reasons for the discrepancies are not obvious, but may relate to the target cell
population used or dose and duration of cytokine treatment or virus strains studied
and/or the particular origin of IFN may determine what effects the cytokine has on
lentiviral replication. It should be considered that in vitro culture of blood monocytes
results in a time-dependent differentiation into macrophages characterised by an
increased expression of certain surface markers (such as CD11/CD18 and CD14
antigens) (Gessani et al. 1993, Lee et al. 1997). This differentiation process can
result in marked change in cell behaviour such as an increased susceptibility to
MVV itself (Narayan et al. 1982) and loss of ability to expression of IL-10 mRNA in
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response to MVV infection (Chapter 4), which may significantly affect virus
replication. It is reasonable to assume that differences in the these experiment
including the differentiation stage of macrophages on the time of virus infection or
addition of cytokines, can exert marked influence on the results and contribute to
some of these conflicting data available on the role of endogenous cytokines in the
replication of MVV infection in monocytes/macrophages.
5.4.3: Conclusion
The results of the present study showed that GM-CSF and TGF-(3 have contrasting
effects on MVV replication. GM-CSF stimulates and TGF-(3 suppresses the MVV
replication in macrophages. IFN-y exerts no effect on MVV replication. From these
data it is speculated that these cytokines may alter MVV expression in macrophages.
However, because of the complex network of cytokine interactions it is difficult to
draw clear-cut conclusions on the roles of specific cytokines in MVV replication in
macrophages. Further experiments with neutralising antibody to cytokines should be
carried out to understand the role of a given specific cytokine. Further studies are
required to demonstrate conclusively the involvement of cytokines in modulating the
replication of MVV in vivo.
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CHAPTER 6
CYTOKINE MODULATION OF CELL SURFACE MOLECULES ON
MACROPHAGES
6.1: Introduction
The expression of cell surface molecules on macrophages is an important marker of
their functional activity. It has been shown that these molecules on monocytes/
macrophages were modulated during lentiviral infection (Rossen et al. 1989,
Pantaleo et al. 1991, Fecondo et al. 1993, LujD et al. 1993, 1994, Berman et al.
1994a). It has been shown that HIV infection resulted in alterations in the level of
expression of surface molecules of the infected monocyte (Autran et al. 1988,
Davidson et al. 1988, Wright et al. 1988, Twigg et al. 1989, Vermot-Desroches et
al. 1990, Agostini et al. 1992, Stent et al. 1994). In MVV infection, LujD et
al.( 1993) showed that AM in MVV-infected sheep expressed an increased level of
MHC class II. Because MHC class II acts as a component of cellular receptor for
MVV (Dalziel et al. 1991), the increased expression of the cell surface of the
receptor for MVV may favour the infection of AM, thus suggesting that cell surface
molecules might be good candidates to explain the involvement of monocytes/
macrophages in pathogenesis of lentiviral infection. However, the mechanisms
responsible for modulation of cell surface molecules on infected monocytes/
macrophages are poorly understood. It has been hypothesised that changes in the
expression of cell surface molecules may be directly related to viral infection of the
cells. It is also possible that the virus stimulates cells to release various cytokines
and other factors which may in turn alter the expression of molecules. It has been
shown that HIV infection, by stimulating the production of IL-lp and TNF-a, leads
to autocrine feedback with production of other cytokines such as IL-6 and GM-CSF
(Merrill et al. 1991, Longo et al. 1993). In MVV infection, elevated expression of
GM-CSF mRNA was observed in AM of MVV infected sheep (Chapter 4).
Cytokines or combinations of cytokines have been reported to regulate the
expression of cell surface molecules such as MHC class I and class II (Nash et al.
1992, Schwartz 1992, Sallusto et al. 1994, Kruger et al. 1996, Thomssen et al. 1996,
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Lee et al. 1997), CD 14 (Kruger et al. 1996), CD la, b, c molecules (Kasinrerk et al.
1993) on human monocytes and other leukocytes. Taken together, it is likely that
changes on expression of cell adhesion molecules on monocytes are in part directly
related to cytokines. However, there is little information on the effect of cytokines on
modulation of the expression of cell surface molecules on sheep macrophages. There





6.2.1: Assessment of surface antigens on cytokine-stimulated MDM
6.2.1.1: Antibodies
Eight mouse monoclonal antibodies (McAbs) against sheep cell surface molecules
were used for immunolabelling (Table 6.1). The secondary antibody alkaline
phosphatase (AP) or FITC-conjugated goat anti-mouse IgG was purchased from
Sigma.
6.2.1.2: Detection of cell surface molecules on monocyte-derived macrophages
Phenotypic characterisation of membrane antigens expressed on monocyte-derived
macrophages (MDMs) was determined by a indirect immunofluorescence assay
(flow cytometry analysis).
6.2.1.2a: Flow cytometry
MDM cells were pre-treated with cytokines 1 day before infection, leaving an equal
portion uninfected or untreated. McAbs to cell surface CD1 lb, CD 14, CD lb, MHC
class I, MHC class II DR, MHC class II DQ, CD45c, CD1 lc (Table 6.1.2) were used
to evaluate cell surface expression of these antigens by flow cytometry using a
FACScan Cell Analyser (Becton Dickinson, San Jose CA). Cells were washed with
PBS/ 1% BSA and stained with FITC-conjugated goat anti-mouse Ig (Sigma), as
described in Chapter 2.
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Table 6.1 Monoclonal anitbodies used in this study
Clone Specificity Dilution Reference
VPM54 MHC class II (DR gene) 1:2 Dutia et al. 1993
VPM36 MHC class II (DQ gene) 1:2 Dutia et al. 1993
VPM19 MHC class I 1:2 Hopkins et al. 1990
VPM18 CD45 1:2 Hopkins et al. 1990
VPM65 CD14 1:2 Gupta et al 1996
IL-A15 CDllb 1:2 Gupta et al 1995
OMI CDllc 1:2 Gupta et al 1995




6.3.1: Effects of cytokines in MHC antigens expression
In the following experiments the ability of ovine GM-CSF and bovine IFN-y to
modulate MHC antigens expression on ovine macrophages was examined in vitro.
MDMs were recovered 3 days after treatment with the cytokine, stained with McAbs
against MHC class I, MHC class II DQ and DR. Reactivity was assessed by flow
cytometry
GM-CSF-stimulated MDMs were found to be positive for MHC class I antigens, but
negative for MHC class II DR and DQ (Fig 6.1). In comparison with unstimulated
cells, incubation of GM-CSF with MDMs increased the expression of MHC class I
(Fig.6.2).. In contrast, GM-CSF showed no influence on the expression of MHC
class II DR and DQ (Fig.6.1).
To investigate whether GM-CSF synergizes with MVV in induction of MHC class I,
comparison of MHC class expression on GM-CSF-stimulatedAininfected and MVV-
infected MDMs was carried out. As shown in Fig 6.3, the level of expression of
MHC class I by GM-CSF stimulated/infected MDMs was decreased when compared
with GM-CSF stimulated/uninfected MDMs. GM-CSF-stimulated/MVV-infected
cells showed a lower fluorescence intensity when compared with GM-CSF
stimulated/ uninfected MDMs, suggesting GM-CSF does not synergize with MVV
in induction of MHC class I.
IFN-y -stimulated MDMs were found to be positive for MHC class II DR and DQ as
well as MHC class I (Fig 6.4). As shown in Fig.6.5, stimulation of IFN-y did lead to
a significant increase in the level of expression of MHC class II expression on
MDMs when compared with control.
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Figure 6.1 Flow cytometric analysis of MHC molecules on GM-CSF-stimulated
macrophages
MDMs was cultured in the presence of GM-CSF (lOng/ml) for 3 days and then
analysed by flow cytometry. Negative control antibody is shown as the blank. These






Figure 6.2 Flow cytometric analysis of MHC molecules on GM-CSF-stimulated and
unstimulated macrophages (MDMs)
MDMs was cultured in either the presence of or absence of GM-CSF (lOng/ml) for 3
days and then analysed by flow cytometry. These data are representative of
experiments that were repeated three times. A: negative controls, B: unstimulated












Figure 6.3 Flow cytometric analysis of MHC class I molecules on CM-CSF-
stimulated/infected and uninfected macrophages (MDMs) with MVV in vitro (0.05
TCIDsn per cell)
MDMs were cultured in the presence of GM-CSF (lOng/ml) for 3 days after infection
with MVV, then analysed by flow cytometry. These data are representative of
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Figure 6.4 Flow cytometric analysis of MHC class I and II on macrophages
stimulated with IFN-y in vitro
MDMs were cultured in the presence of IFN-y (lOng/ml) for 3 days and then
analysed by flow cytometry as described in materials and methods. Negative control
antibody is shown as the fine line. These data are representative of experiments that
were repeated three times.
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As shown in Fig 6.5, the level of expression of MHC class II DR by IFN-y
stimulated/infected MDMs was decreased with lower fluorescence intensity when
compared with DFN-y stimulated/uninfected MDMs. The level of expression of
MHC class II DQ by IFN-y -stimulated/MVV-infected was similar to that on IFN-y
stimulated/ uninfected MDMs.
6.3.2 The effects of cytokines on CD antigens on macrophages
In the following experiments the ability of ovine GM-CSF and bovine IFN-y to
modulate CD antigens expression on macrophages was examined in vitro. Cells
were recovered 3 days after treatment with the cytokine, stained with McAbs against
CDlb, CDllb, CDllc, CD14 and CD45. Reactivity was assessed by flow
cytometry.
MDMs, treated either GM-CSF (Fig.6.6 and 6.7) or IFN-y (Fig.6.8), were found to
be positive for the surface molecules CD1 lc, CD 14, CD45, but negative for CD1 lb,
CDlb. However, treatment of either GM-CSF or IFN-y did not lead to a significant
increase in the level of expression of CD 14 and CD45 on MDMs when compared
with control. No significant in difference in the percentage of cells CD 14 and CD45
was observed between stimulated and unstimulated cells.
Either GM-CSF (Fig.6.7) or IFN-y (Fig.6.8) in combination with MVV had not any
further enhanced effect on the expression of CD 14 and CD45 on MDMs. Both
cytokines showed no effects on the expression of CDlb and CD1 lb and CD1 lc.
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Figure 6.5 Flow cytometric analysis of MHC class II molecules on MVV-ini'cctcd
and uninfected macrophages (MDMs) stimulated with IFN-y in vitro
MDMs were infected with MVV (0.02 TCID50 per cell) and cultured in the presence
of IFN-y (lOng/ml) for 3 days, then analysed by flow cytometry. These data are
representative of experiments that were repeated three times. A: negative controls. B:
IFN-y stimulated/infected cells. C: IFN-y-stimulated/uninfected cells.
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Figure 6.6 Flow cytometric analysis of the expression of CD14. CDlb. CDllb.
CD1 lc and CD45on macrophages stimulated with or without GM-CSF
MDMs were stimulated with or without GM-CSF (lOng/ml) for 3 days and then
analysed by flow cytometry as described in materials and methods. Negative control
antibody is shown as the blank.
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Uninfected cells Infected cells
Figure 6.7 Comparison of CD 11c. CD 14 and CD45 on uninfected or infected
macrophages stimulated with or without GM-CSF in vitro
MDMs was infected with or without MVV (0.02 TCID50 per cell) and cultured in
either the presence or absence of GM-CSF (lOng/ml) for 3 days, and then analysed
by flow cytometry as described in materials and methods. Data are presented as mean
± SD of the percentages of macrophages expressing CD antigens.
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Figure 6.8 The expression of CDllc. CD14 and CD45 on uninfected or infected
macrophages stimulated with or without IFN-y in vitro
MDMs were infected with or without MVV (0.02 TCID50 per cell) and cultured in
either the presence or absence of IFN-y (lOng/ml) for 3 days, and then analysed by
flow cytometry as described in materials and methods. Data are presented as median




It is unclear what are the precise mechanisms involved in modulation of cell surface
molecules in infected macrophages. It has been hypothesised that the virus might
stimulate cells to release various cytokines and other factors that may in turn alter
surface molecule expression. Several studies have shown in in vitro cell systems,
cytokines or a combination of cytokines to modulate expression of antigen
presenting (MHC class I and II) and co-stimulatory molecules on the surface of
monocytes and other leukocytes (Mentzer et al. 1986, Springer et al. 1986, Te Velde
et al. 1988, Freyer et al. 1988, Gimcher et al. 1992, Jiang et al. 1992, Nash et al. 1992,
Schwartz 1992, Sallusto et al. 1994, Kruger et al. 1996, Thomssen et al. 1996, Lee et
al. 1997). Thus it is likely that changes in the expression of cell surface molecules on
monocytes are in part related to cytokines. To test this hypothesis, MDMs were
treated with either GM-CSF or IFN- y.
Treatment with IFN-y was able to augment the macrophage expression of MHC II. In
human and murine models, IFN-y has been demonstrated to be a potent mediator of
MHC class II antigen expression on macrophages which extended to ovine MDMs in
this study. As T cell sub-populations generally recognise antigen in the context of
MHC class I and II molecules (Townsend and Bodmer 1989), this regulation has
important implications for initiation and development of the immune response.
IFN-y increased the expression of MHC class II on MVV-infected MDMs in vitro. In
contrast, GM-CSF had no enhanced effects on the expression of MHC class II on
infected macrophages. AMs of MVV-infected sheep showed increased expression of
MHC class II (Lujan et al. 1993). IFN-y mRNA was up-regulated in lung tissue of
MVV-infected sheep with lung lesions (Woodall et al. 1997). These results suggest
that IFN-y induced by MVV in vivo may account for the increased expression of
MHC class II on infected cell in vivo. The increased expression of IFN-y induces the
expression of MHC II on macrophages. The continuous expression of these antigens
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might then favour recruitment of lymphocytes into the lung and lead to local
inflammation. Thus increased level of cytokines in vivo may have damaging rather
than favourable effects in the infected microenvironmental sites. Treatment with
GM-CSF was able to augment the expression of MHC class I and but not class II by
the macrophages. MVV-infected MDMs were found to be positive for MHC class I,
GM-CSF in combination with MVV did not show a synergistic effect on induction
of MHC class I, thus promoting the hypothesis that GM-CSF may account for the
increased expression of MHC class I on MVV infected MDMs in vitro.
The continuous expression of CD 14 was observed on ovine MDMs. After treatment
with GM-CSF, there was no significant increase in the expression of CD 14 when
compared with unstimulated cells. This finding is inconsistent with a previous study
in human monocytes which reported that GM-CSF down-regulates the expression of
CD14 on monocytes (Kruger et al. 1996). This result may reflect a difference in
response of different stages of maturation of monocyte to GM-CSF, a cytokine with
differentiation-inducing properties on monocytes. GM-CSF thus may have a role in
controlling the expression of CD 14 and thereby modify certain pathophysological
conditions and clinical pictures. IFN-y was found to exert no influence on the
expression of CD 14 and CD45. This result was in agreement with the previous
report on ovine alveolar macrophages which reported that IFN did not influence that
expression of CD45 on macrophages (Nash et al. 1992). Taken together, the results
reported here further support the concept that the changes on expression of surface




MVV infects monocytes/macrophages and causes persistent infection. However,
unlike the human and simian immunodeficiency viruses (HIV and SIV). MVV does
not cause immune deficiency but instead cause chronic mononuclear inflammation
of various tissues (Gendelman et al. 1989, Brodie et al. 1995). The lesions are
thought to be immune-mediated, but the mechanism involved in their development
is poorly understood.
Macrophages are the host cells for the replication of MVV in the lung and synovium
(Brodie et al. 1992, 1995). MVV-infected macrophages are thought to serve as a
stable reservoir for the dissemination and persistence of MVV in vivo, therefore the
replication of MVV in these cells has been considered as a major factor contributing
to chronic inflammatory lesions in the site of disease during MVV infection (Brodie
etal 1992, 1993, 1995, Lujan et al 1994).
Although viral DNA was detected in AM of all animals, irrespective of the
histological findings in the lung, there were pronounced differences in the levels of
viral burden among animals. Viral load in AM of animal with lung lesions was
higher than that in cells of animals without lung lesions. The absolute viral load in
AM therefore reflects the pathologic manifestation in the lung. These data, together
with the previous studies which reported that animals with moderate or severe
lymphoid interstitial pneumonia have high percentage of MVV positive AM (Brodie
et al 1992; DeMartini et al 1993; Lujan et al 1994), implied that AM as important
target cells in the pathogenesis of pulmonary lesions in MVV infected sheep. Thus
viral load in AM may have predictive value even if the time of seroconversion is
unknown. Serial measurement of viral load over time may provide a therapeutic
guidance. It is conceivable that quantitative analysis of viral activity in vivo is
invaluable in order to understand fully the pathogenic steps of lentiviral infection.
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The findings of lower level of MVV DNA load in blood monocytes, even from the
sheep with severe lung lesions, when compared with that in AM, suggests that AM
may be more susceptible targets than monocytes and represent major focus of MVV
infection. The results of an increased susceptibility of in v/tro-differentiated
monocytes to infection with MVV in vitro, when compared with that of freshly
isolated monocytes provides further support. Thus AM may act as cellular reservoirs
of MVV by the time the infected animals develops maedi. MVV would be released
from infected AM and then be free to infect other cells within the lung. Thus,
increased viral load in AM compared with that in monocytes from sheep with
pulmonary lesions also might reflect an inherent increased susceptibility to infection.
The mechanism by which differentiated monocytes are more susceptible to
productive infection with MVV in vivo and in vitro is not yet clear.
AM from MVV infected sheep without lung lesions harbour low level of viral DNA.
It has been reported that virus production per cell measured by PCR remains stable
while the number of infected cells increase with disease progression (Bukrinsky et al
1991). Thus the low level of viral load may be a reflection of low number of infected
AM in MVV infected sheep without lung lesions. This leads to hypothesis that low
proportion of MVV-infected AM in the lung (at early stage of disease) causes the
chronic active inflammatory changes with lymphocyte infiltration and proliferation
in lung (Lairmore et al. 1986, 1988b, Watt et al. 1994) through local release of
cytokines. It is thought that lentivirus infection results in local release various
cytokines and other factors which may in turn recruit mononuclear cells into the
inflammatory area, thus providing the increased number of susceptible cells for viral
replication (Lairmore et al. 1986, Zink et al. 1990). The result of this study showing
that the viral DNA burden in AM correlated with lung lesions of disease provides
support for such mechanisms.
Although viral DNA was detected in AM of all infected animals, viral RNA was
only detected in AM of sheep with lung lesions. No viral RNA was detected in
freshly isolated AM from infected sheep without lung lesions, but after in vitro
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stimulation with TPA, MVV replication was observed in these AM. This suggests a
loss in restriction of viral gene expression and replication in AM of animals with
prominent lymphoproliferative and inflammatory lesions. It may be considered that
AM are latently infected by MVV in vivo, and at resting conditions are not a site for
viral replication, therefore AM may act ac a latent reservoir for the virus. This leads
to the hypothesis that the presence of MVV in the AM of infected animals is likely
to represent the consequence of the fact that MVV may reside within AM in a latent
state or restricted replication as a provirus integrated within host genomic DNA. The
replication of MVV in AM in vivo may require factors able to activate viral
replication. The result of this study reasserts the importance of the AM as a key cell
in the pathogenesis of MVV induced pulmonary disease. Viral RNA was
undetectable in AM but detected in spleen and lymph nodes. Thus MVV appears to
actively replicate in lymphoid tissue but not in lung although activatable virus is
present in lung. The difference may be due to the cell type being infected in these
tissues or by the presence of local factors such as cytokines which exert a profound
effect on MVV replication. In the lymphoid organs throughout the body, target cells
together (with immune complex formation by accessory cells) constitute the ideal
milieu for active viral replication This finding promotes a consideration that
lymphoid tissues are efficient reservoirs of MVV and a site for viral replication,
where target cells may be infected by MVV and transmitted to other tissues such as
lung of the body. The localised infected target cells may results in local release
various cytokines and other factors which may in turn recruit mononuclear cells
including infected target cells into the inflammatory area.
No clear explanations can be forwarded for the difference in the viral replicative
status in macrophages. Exposure of macrophages to any differentiation stimuli can
regulate viral replication and control of viral persistence (O'Brien et al. 1994). A
variety of reports demonstrate that cellular factors influence permissiveness of
macrophages to productive infection (Gendelman et al. 1990) and underscore
differences between macrophages. For example, in the case of HIV, low level of
interferons or other regulatory factors may be induced in response to HIV infection
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in monocytes (Gessani et al. 1991). These factors may regulate early stages of virus
infection in monocytes/macrophages and may underlie the differences in
susceptibility or permissiveness of monocytes/macrophages. Since macrophages are
terminally differentiated cells (non-dividing), viral nucleic acids must traverse the
nuclear membrane before provirus establishment and viral replication can occur
(Weinberg et al. 1991). In the case of HIV, nucleophilic components related to the
pre-integration complex of HIV-1 facilitate nuclear localisation of viral nucleic acids
in the absence of mitosis (Heinzinger et al. 1994), thus indicating that restriction to
virus replication in macrophages is not at the level of host cell mitosis. The in vitro
system in which HIV-1 infected macrophages are maintained in culture and exposed
to different stimuli has demonstrated that HIV-1 re-enters the replicative cycle in
exposure of infected cells to a number of cytokines including IL-1(3, EL-6, GM-CSF
(for review, see Chapter 1). Thus, another pathway modulating transactivation of
lentivirus in macrophages may be related, at least in part, to cytokines network
produced during host immune response to viral infection. The comprehension of the
regulatory network between MVV and cytokine represent a basic question that
awaits elucidation.
MVV infection results in the release of one or more cytokines. A significant increase
in expression of IL-6, IL-10, GM-CSF and TGF-P mRNA was observed in AM
isolated from naturally infected sheep. TNF-a, IL-6, IL-10 and GM-CSF
enhancement was detected in blood monocytes. In LNs, IL-2 and IL-10 was elevated.
In particular, the findings that the increased expression of GM-CSF mRNA was
observed in AM of MVV infected sheep, may explain, in part, to the previous
observations that increased expression of GM-CSF in the lung tissue of MVV
infected sheep with chronic lymphocytic interstitial pneumonia (Woodall et al.
1997) at cellular level. These results suggest that alterations of cytokine expression
may contribute to MVV pathogenesis by regulation of the virus replication in
macrophages. The finding that the levels of GM-CSF expression in AM differed in
relation to the lung lesions, provides support for such mechanism. It is well known
that GM-CSF up-regulates antigen-presenting activity of dentritic cells and recruits
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these cell to localised inflamed regions of the lung, thus promoting lymphoid
follicles development (Steinman 1991), GM-CSF also mediates abrogation of
suppression of T lymphocytes activity in the lung by AM, causing T lymphocytes
accumulation to occur. Thus it is possible that increased level of GM-CSF in AM
may account for the development of lymphoid follicles in the lung of MVV infected
animals. However, in vitro studies show that MMV infection does not increase GM-
CSF mRNA in macrophages, it is unlikely that the increased expression of GM-CSF
in vivo is, in part, the direct consequence of MVV infection. It should also be noted
that overexpression of cytokines might favour local virus spreading (Agostini et al.
1993b). MVV is pathologically similar to HIV. In HIV, GM-CSF is effective at
driving virus replication in monocytes (Poli et al. 1992b, Crowe and Lopez 1997)
and that differentiation and activation of monocytes was observed to be associated
with the virus infection and replication. These results suggest that GM-CSF may
play a role In driving the HIV replication, thus promoting the spread in vivo (Crowe
and Lopez 1997). Similar mechanism may exit in MVV infection. The suggestion is
supported by that fact that the higher level of GM-CSF mRNA was detected in AM
in which MVV RNA and high level of viral DNA was detected. In contrast, MVV
RNA was undetectable in AM with the lower level of GM-CSF mRNA and viral
DNA level. This response of elevated expression of GM-CSF mRNA may in part
account for the observations that a higher viral load was observed in the AM of
infected animals with lung lesions and responsible for driving actively replication of
the vims in AM. This suggestion is further supported by the in vitro study from GM-
CSF treated MDMs that GM-CSF has stimulatory effects on MVV replication.
The factors responsible for initiating a switch from asymptomatic to symptomatic
disease in lentiviral infections are not yet clear. Th 1 and Th2 response in mice play a
critical role in viral clearance (Braciale and Braciale 1994). Thl cytokines are IFN-y,
IL-2 which promote cell-mediated immunity and delayed-type hyper-sensitivity
(DTH). Th2 cytokines are IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 secreted by Th2
cells which favour allergic reactions and provide the most efficient help for B cells
(antibody production) (Mosmann et al. 1986; Romagnani 1994). Several reports
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have shown that some infectious agents may be controlled by either Thl or Th2
response (Khatissian et al. 1994, Collette Y et al. 1996, Lechner et al. 1997).
Evidence has suggested that switch in Thl cytokine to Th2 cytokines response may
be responsible for disease progression during HIV infection (Clerici and Shearer
1993). Patients with Thl-type responses, characterised by production of IL-2 and
IFN-y remain as asymptomatic whereas those that switch from Thl to Th2, as
indicated by decreased secretion of IL-12 and increased production of IL-4, develops
symptomatic disease (Clerici and Shearer 1993, Chehimi et al. 1994). In cats a
switch from a Thl to Th2 response has also been suggested as playing a role in FIV
infection based the observation that asymptomatic cats produced high levels of IL-2
and low levels of IL-6. In contrast those in the advanced stages of infection produced
low levels of IL-2 and high levels of IL-6 (Lawrence et al. 1995). Looking at
constitutive cytokine mRNA expression in AM, blood monocytes and LNs of MVV
infected animals, there was no evidence to show a demarcation between Thl and
Th2 cytokine profiles. On the basis of this finding, it is hypothesed that both type of
cytokine response could occur concurrently during MVV. Thus, studies monitoring
changes in levels of Thl and Th2 cytokines during MVV infection are required
before a definite role of a shift from Thl to Th2 in the immunopathology of MVV
infection can be determined. Interestingly, increased levels of IL-6 mRNA were
observed in AM, blood monocytes and lymph node, but expression of IL-10 gene
was not detected in lymph nodes. This difference may reflect the level of cytokine
mRNA expression at the level of single cell type (such as AM) and may not reflect
cytokine synthesis in tissue. Whether or not a Thl/Th2 switch occurs, cytokines are
certainly critical in modulating the type and the effectiveness of the immune
response against lentiviral infection.
The results from this study suggest that the persistent expression of cytokine may
also occur because of direct up-regulation by virus or viral glycoproteins. However,
the results of this study indicate that the mechanism for the dysregulation of
cytokines found in animals with lentiviral infection is more complex. The suggestion
is supported by the facts that no expression of IL-6 and IL-10 was observed in
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MDMs in response to in vitro MVV infection. Apart from MVV, lack of cytokine
expression in macrophage in response to in vitro infection was also observed in two
other types of lentiviruses. A lack of TNF-a expression in response to in vitro
infection with both HIV (Molina et al. 1990) and CAEV (Lechner et al. 1996) These
findings suggest that this failure may be common feature in lentivirus infection. The
mechanism for this behaviour is not yet clear. The results shown in this study
suggest two possible mechanisms: (i) Failure to induce IL-10 expression by MVV
may be linked to cell differentiation. The results of this study show that IL-10
mRNA was detected in freshly isolated monocytes but not in cultured macrophages
in response to MVV infection, provides support for this theory, (ii) A cytokine may
have a role in overproduction of another. In this study, GM-CSF was found to
stimulate IL-6 expression in sheep MDMs
With regard to MVV infection, the level of GM-CSF expression has been shown to
correlate with the severity of lung lesions. GM-CSF was elevated in MVV-infected
sheep. Thus it is important to determine the cytokine directly influences the
expression of MVV in infected macrophages. Examination of the effects of GM-
CSF on MVV replication showed that it was effective at promoting MVV replication
in infected MDMs. The enhancing effect of GM-CSF on MVV replication in MDMs
is in agreement with reports concerning GM-CSF-stimulated regulation of HIV
replication (Folks et al. 1987, Koyanagi et al. 1988, Perno et al. 1989). Collectively
these studies are at variance with others that showed the inhibitory effects of GM-
CSF on lentivirus expression. Matsuda et al. (1995) reported an inhibitory effect of
GM-CSF on the replication of HIV in human blood MDMs. Moreover, the studies of
Hammer et al. (1986) indicated that GM-CSF can suppress viral replication in a
promonocytic cell line chronically infected with HIV. This leads to the hypothesis
that the regulatory interplay between GM-CSF and lentivirus is complex and may
depend on a number of factors including the cytokine milieu and the stage of
monocyte differentiation. Nevertheless, the results in this study support the concept
that GM-CSF could be an important mediator for promoting MVV replication, thus
promoting virus spread.
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GM-CSF was observed to increase the total amount of MVV produced in infected
macrophages and in this, MVV resembles HIV (Agostini et al. 1992). In SIV
infection, Walsh et al. (1992) have demonstrated that GM-SCF promoted SIV gag
protein production. These data suggest that the enhancing effects of GM-CSF on
lentivirus replication in macrophages may occur through the stimulation of the
production of host-cell transcriptional factors. These might bind to the virus LTR,
resulting in transactivation and thus cause an increase in virus transcription. Further
experiments were required to clarify this point. Of note is the fact that the level of
GM-CSF mRNA was enhanced in MVV-infected macrophages (Chapter 4) and
MVV-infected lung (Woodall et al. 1997) suggesting that GM-CSF could potentially
play a role in enhancing MVV replication in macrophages in vivo.
In exploring the effects of TGF-(3 on MVV replication in macrophages, it was
observed that TGF-(3 inhibited MVV replication of acutely infected MDMs. Whether
the inhibitory effects of TGF-(3 on the replication of lentivirus is direct or indirect
mechanism action is still unclear. Many steps have been defined in MVV infection
and replication, such as binding to the cell surface, internalisation of the viral core
into the cytoplasm, uncoating of viral RNA, reverse transcription, integration of viral
DNA to cellular DNA, viral DNA transcription and translation, viral components
assembly and virus budding. Inhibition of MVV binding to target ccells by TGF-f)
seemed unlikely in view of the lack of effects on expression of MHC class II mRNA
on macrophages. Further study is required to investigate the specific mechanisms by
which TGF-(3 might inhibit NVV replication after virus binding. Another possible
explanation worth investigating could be that TGF-(3 may exerts its negative effects
on the expression of critical cellular proteins involved in the replication of MVV,
such as enzymes of the cell signalling pathway that impact on nuclear translocation
or other cellular factors which might down-regulate other surface molecules needed
for virus binding or inhibit cellular components involved in virus fusion, uncoating
or transcription.
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The inhibitory effects of TGF-p on MVV replication, together with the observation
that the level of TGF-P mRNA was enhanced in MVV-infected macrophages,
implies that TGF-P may provide a possible mechanisms for suppression of MVV
replication within macrophages and inhibition of the spread of infection. Finally,
since others cytokines capable of inducing increased expression of MVV, such as
GM-CSF have been found be increased in AM (Chapter 4) or lung tissue (Woodall
et al. 1997), a delicate balance between stimulatory and inhibitory cytokines is likely
to determine the net rate of MVV replication and expression and subsequently in the
clinical progression of MVV infection.
Aside from the name, IFN-a, and IFN-y have little in common. IFN-a is produced
by macrophages and B cells and IFN-y is produced by T cells. There is no-cross
reactivity at receptor level. Despite there clear differences, both IFN-a and -y induce
potent antiviral activity against a wide range of retrovirus. However, the role of IFN-
a, P, and -y in the pathogenesis of MVV infection is largely unknown. Previous
studies showed the presence of an IFN with biochemical characteristics of both IFN-
a and IFN-y from lung leukocytes from experimentally MVV-infected lambs. As in
the in vitro study of with 'leukocyte-derived IFN in CAEV-infected monocytes (Zink
and Narayan 1989), bovine recombinant IFN-a has a substantially inhibitory effect
on MVV replication in macrophages (Ellis et al. 1994). In this study, it was not
possible to demonstrate any apparent enhanced or inhibitory effects of IFN-y on
MVV replication in MDMs. The reasons for this are not unknown, but may relate to
the activation of the infected macrophage at the time of exposure to IFN and the
differentiation stage of macrophages on the time of virus infection. In vitro culture
of blood monocytes results in a time-dependent differentiation into macrophages
characterised by an increased expression of certain surface markers (such as
CD11/CD18 and CD 14 antigens) (Lee et al. 1997, Gessani et al. 1993). This
differentiation process can result in marked change in cell behaviour such as an
increased susceptibility to MVV itself (Narayan et al. 1982), which may significantly
affect virus replication. The above data suggest that a direct effect of endogenous
INF-yon MVV replication or Ag production is unlikely. This may indirectly reflect
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the failure of activation of 2',5'A synthease or could be due to the absence in MVV
infected cells of other IFN inducible antiviral factors.
In in vitro culture systems cytokines have been identified to have profound affect on
MVV replication (Chapter 5), however, it is still not unclear whether cytokines have
similar regulatory roles in vivo. In support of this hypothesis are multiple
observations of increased expression of GM-CSF, IL-10, IL-6 and IL-8, and other
cytokines potentially capabling of regulating MVV (Woodall et al. 1997; Legastelois
et al. 1997; Chapter 4 and Chapter 5) and HIV (Pantaleo et al. 1993, Graziosi et al.
1994b, Poli etal. 1994).
In conclusion the level of MVV DNA and its replication status in AM from MVV
infected sheep and the relationship between virus burden/replication and histological
lesions in the lung were assessed. The sheep without histopathological evidence of
lesions in the lung, the load of MVV DNA in AM was low and viral RNA was
undetectable. Viral RNA became detectable following in vitro stimulation of AM
with phorbol esters. In contrast, sheep with histopathological lesions in the lung had
a significant increase of MVV DNA in AM and viral RNA was detected. These
results suggest that the infected AM have a key role in its pathogenesis of lung.
A dysregulation of cytokines was observed in macrophages, blood monocyte and
lymphoid tissue of naturally infected sheep. MVV infection changes the pattern of
expression of cytokines in macrophages. In vitro studies show the enhancing effect
of GM-CSF and inhibitory effects of TGF-P on MVV replication in MDM but no
effects of IFN-y, suggesting that cytokines could be an important mediator of
regulating the lentiviral replication, Because of the complex network of cytokine
interactions, it may be difficult to draw clear-cut conclusion on the role of specific
cytokines in MVV in macrophages. Despite these concerns, there is no doubt that
cytokines have remarkable potential for the regulation of MVV replication in vivo
and in vitro. A delicate balance between stimulatory and inhibitory cytokines is
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likely determining the net rate of MVV replication and expression and subsequently
in the clinical progression of MVV infection.
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APPENDIX
Appendix I: Bacterial culture and transformation of E.coli





Deionized H2O up to 1 litre
Autoclave
Cool to 55°C
Add 20mg of filter-sterilised ampcillin and 80mg of filter-sterilised methicillin. Pour
into petri dishes (25ml/100-mm plate)
LB/Amp/Meth/X-Gal plates
LB/Amp/Meth plates were made as above. 50 (4,1 of 20mg/ml X-Gal (made up in
dimethyl formamide) was spread directly onto LB/Amp/Meth/ plates with a glass
spreader 3 hours before use.
Transformation of competent cells
Supercompetent cells were thawed on ice and transferred into prechilled 15 ml
Falcon tube. After adding DNA, the tube was placed in ice for 30 minutes. Cells
were then heat-pulsed by putting the tube in a 42°C water bath for 45 seconds and
then cooled on ice for 2 minutes. 1 ml of pre-warmed LB/Amp/Meth was added into
each tube and incubated at 37°C for 60 minutes. lOOul of the cell culture was spread
on LB/Amp/Meth/X-Gal plates which were then incubated overnight at 37°C.
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Gacial acetic acid 57.1 ml
0.5M EDTA (pH 8.0) 100 ml
Made up to 1000 ml with deionised water.
Methods
Agarose was dissolved by boiling in 1 x TAE and then allowed to cool a little.
Ethidium Bromide was added to a concentration of 1 |lg/ml. The gel was poured and
left to set. 1 x TAE buffer was made up and added to the tank to just cover the gel.
0.2 volumes of loading buffer were mixed with each sample. Samples were loaded
and the gel was run. Nucleic acid in the gels was visualised on an UV
tansilluminator.
Alkaline Transfer of DNA
After electrophoresis to separate the DNA fragments, DNA in the gel was denatured
by soaking the gel in 0.4N NaOH for 30 minutes. Unnecessary parts of the gel was
removed and placed on the top of two pieces of 3MM papers acting as a wick to
draw up 0.4N NaOH from the trough below. A piece of membrane cut to exactly the
same size as the gel and equilibrated in 0.4N NaOH for 10-15 minutes was placed on
the gel. 10 pieces of 3MM papers were placed on the top of the membrane, followed
by a stack of dry paper towels. A glass plate and a weight were placed on the top.
The assembly was left overnight in a 0.4N NaOH transfer solution. The membrane
was washed in an excess of 2 X SSC for 1-2 minutes and air dried.
Hybridization buffer for ,2P-Iabelled probe
dH20 84.6 ml
Dextran Sulphate, Na salt (MW 500,000) 10 g
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10% SDS 10 ml
Heat at 65°C for 30 minutes, add 0.58 g of NaCl and then heat an additional 15
minutes. This buffer is stored at -20°C until use.
Recovery of DNA from agarose
DNA was recovered from low-melting agarose by binding to then elution from
silica. Geneclean reagents were used according to the manufacture's manual. Briefly,
DNA sample was run on 1.5% (m/v) low melting agarose gel, and then a slice of gel
containing the targeted DNA band was excised and weighed to estimate its volume.
2 volumes of Nal stock solution were added and the gel was melted by heating to
65°C. Glassmilk suspension was added (5pl for 5pg DNA) and placed on the ice for
5 minutes with mixing gently every 1-2 minutes, and then pelleted by centrifuging
for 5 seconds. The supernatant was removed and the pellet was washed three times
with "NEW WASH". After final washing as much supernatants possible was
removed. The DNA was eluted from grassmilk by resuspending the pellet in 10 pi of
disionized water and incubating at 50°C for three minutes, followed by centrifuging
for one minute(the elution was repeated once more). The eluted DNA concentration
was estimated by running a sample on a 2% agarose gel alongside markers.
Minipreps for the isolation of plasmid DNA
Plasmid mini-preps were prepared by using Qiagen Plasmid Spin kits (Qiagen)
according to manufacture's instruction. Briefly, Tansformants grown on selective
agarose plates were inoculated into LB/Amp./Meth. and grown up for 14 to 16 hours
at 37°C with shaking. 1 ml of cell culture was pelleted by 60s microcentrifugation
and resuspended in 250 pi of Buffer PI. After resuspension, cell clumps should not
be visible. 250 pi of Buffer P2 was added and gently mixed by inverting the tube
(dot not vortex), and then 350 pi of Buffer N3 was added and again, inverted
immediately but gently. After 10 min micro-centrifugation, the supernatants was
transferred to QIAprp column by pipetting. The column was centrifuged for 60s and
washed by adding 500 pi of Buffer PB and centrifuging 60s. The column was further
washed by adding 750 pi of Buffer PE and centrifuging 60s. After discarding the
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flow-throughs and further 1 min micro-centrifugation, the column was placed in
clean Eppendorf and 50 pi of H2O to the centre of the column, let stand for 1 minute
and centrifuge for 1 minute. Samples were run on a 1 % agarose gel alongside 1 Kb
DNA ladder and the appropriate control plasmid. Regents were prepared following
the manufacturer's protocol.
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Appendix HI: Sodium-Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis of
Proteins
Proteins were separated by discontinuous polyacrylamide gel electrophoresis with a
Tris glycine buffer containing SDS (0.1% SDS, 50mM Tris, 384 mM glycine)
(Laemmli, 1970). The resolving gels consisted of either 10 % acrylamide slab gel or
5%-20% linear gradient acrylamide gel (30% acrylamide +1.08% bis acrylamide) in
375mM Tris, pH 8.7 and 0.1% SDS. Stacking gels were 3% acrylamide, 0.15%
bisacrylamide in 125mM Tris, pH 6.8 and 0.1% SDS. Samples, mixed with an equal
volume of sample buffer, were boiled for 3min. 20ul of the mixture was loaded onto
a well (250 |il per large well). Gels were run at 180v for lhr.and then stained by
Coomassie Blue staining for 15 min at room temperature. Coomassie Brilliant Blue
G-250 was dissolved in 20% methanol, 5% acetic acid and filtered through
Whatman No.l filter paper. Gels were disdained in several changes of 20%
methanol and 5% acetic acid.
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Appendix IV: Detection of Antibodies Specific for MVV
Preparation of Total MVV Antigens for Western blotting
MVV antigens were prepared from fibroblast culture supernatant by centrifugation.
Briefly, the culture supernatant containing virus was harvested and clarified by
centrifugation (8500rpm, 4°C, 30min) to remove cell debris and then pelleted by
centrifugation (8500rpm, 4°C, overnight). The pellet was resuspended in a minimal
volume of PBS and stored in aliquots at -70°Cfor use in immunological experiments.
The antigen preparation was assessed by SDS-PAGE.
Western Blotting
The separated proteins on the gel were transferred to pre-wetted nitrocellulose
membranes (Hybond C, Amersham) at 120mA/30V for 2 hrs using a semi-dry
electroblotter (Ancos, Denmark). The buffer was 48 mM Tris, 39mM glycine and
20% methanol. After transfer, the nitrocellulose membranes were blocked using 5%
marvel, 0.05% Tween 20 in PBS at 4°C overnight and incubated with primary
antibodies, diluted in PBS/1% Marvel/0.05%Tween 20, at room temperature for
lhoure or at 4°C overnight. Blots were washed in PBS /1% Marvel /0.05% Tween
20 three times and then incubated 1 hour with alkaline phosphatase conjugated
secondary antibody of appropriate specificity, washed as before and further washed
twice in 0.1 M Tris-HCl (pH9.5), Blots were developed with the substrate solution
(0.2mg/ml nitro-blue tetrazolium and O.lmg/ml 5-bromo-4 chloro-3-indolyl
phoshpate in 0.1M Tris HC1, pH 9.5 and 0.02M MgCl2 for 10 min or more, as
appropriate. The reaction was stopped by washing in water and then dried.
Agar Gel Immunodiffusion Test
AGID test was conducted by a modification of the method of Cutlip et al (1979).
Briefly, a microhexagonal well pattern was used with alternating large (40|itl) and
small peripheral wells (25)0.1) and a small central well (25|il). Sera from sheep were
tested by filling the centre well with antigen (CVL, England) and the large peripheral
wells with test sera and the small wells with positive serum (CVL, England). The
183
plates were incubated overnight at room temperature in a moist chamber, and results
were recorded at 24 and 48 hrs.
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Appendix V: Liquid Phrase-blocking ELISA
96-well plates (Immuno) were coated with 20pg/ml recombinant MVVp25, diluted
with 0.05M bicarbonate buffer (pH9.5), overnight at 4°C. The plates were washed at
least three times with PBS/0.05% Tween-20 and blocked with 5 % BSA/PBS at
room temperature for 1 hour. Samples were incubated with equal volume of pre-
titrated monoclonal antibody to p25 overnight at 4°C and then added to each well,
incubated at room temperature for 2 hours. Plates were washed at least three times
with PBS/0.05% Tween-20. Alkaline phosphatase-conjugated antibody was diluted
in 1%BSA/ 0.05%Tween-20 /PBS according to the manufacturer's protocol. 50 pi
was added to each well and incubated at room temperature for 2 hours. Plates were
washed at least three times with PBS/0.05% Tween-20. 75pl of AP substrates
(according to the manufacturer's instruction, made up fresh each time) was added to
each well and allowed to develop in the dark at room temperature for 30- 45
minutes. 25 pi of 0.2M NaOH was added to stop the reaction. The optical density
was measured at 405nm.
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